



*Republic of Iraq
Ministry of Health
Iraqi Cancer Board*



CANCER REGISTRY OF IRAQ ANNUAL REPORT 2023





Republic of Iraq
Ministry of Health
Iraqi Cancer Board



CANCER
REGISTRY
REPORT
IRAQ
2023

Email: iqcboard@moh.gov.iq

Acknowledgments

We extend our gratitude to the personnel of hospitals, pathology laboratories, clinics, and Cancer Registry Units within each health directorate for their dedicated work in gathering and inputting data.

PREPARED BY

Dr. Hiba H. Salih

MBChB / FIBMS /CM / Director division of cancer research / Cancer board in Iraq / MOH

Miss. Athraa H. Hasan

Statistician

Mrs. Lamia M. Nasser

Statistician

Mrs. Khitam J. Selman

Statistician

Mrs. Menal H. Mola Mohamed

Statistician

Mrs. Joolan S. Mehidy

Manager

Mr. Ahmed F. Juad

Statistician

Mr. Kalid H. Hadi

Assistant Laboratory

Miss. Rania A. Hasoun

Medical Assistant

Miss. Triva Murad Khodadad

Senior Translator

Miss. Mais Munaim Obead

Chief medical assistant

Mr. Rasool Salem Jabar

Medical Assistant

Mr. Abas Mohammed Oraibi

Senior manager

Miss. Faten Hazem Mahammed

Medical assistant

Mrs. Redhab M. Sahib

Headprogrammer

REVIEWED BY

Dr. Tahseen Al-Rubai

Clinical Oncologist, MBChB DMTR / General Secretary of Cancer Board in Iraq / MOH

Dr. Sura Y. Abd

MBChB/ CABSFM/ Director division of cancer registration / Cancer board in Iraq/ MOH

Dr. Jawad Al- Diwan

Professor of Community Medicine, Baghdad Medical College

Dr. Ameer Dhahir Hameedi

MBChB, FICMS Pathology College of Medicine, University of Baghdad.

Dr. Najmuldeen Mohammed Rafeeq

Medical Oncologist/ FICMS / Director Division of Oncology Centers/ Cancer Board /MOH

Dr. Zainab Faisal Mohammed H.

MBChB, FICMS, Medical Oncology. Oncology Teaching Hospital, Baghdad Medical City

Dr. Saba M. Jasim

Medical oncologist / FICMS/ Medical City/ oncology teaching hospital

Dr. Sherin A. Hussein

Medical Oncologist/ FICMS /Al-Yarmouk teaching hospital

Dr. Mohammed Kamil Al Qayyim

MBChB., FIBMS, clinical hematology. hematology and transplant center/Medical city complex

Dr. Samar Muslim Al-Mehdi

Medical Oncologist / FICMS / Cancer Board /MOH

Dr. Sara Hamid Fadhil

MBChB. DMRT. / Cancer Board /MOH

Dr. Sarmad Qahtan Kshash

Medical Oncologist/ FICMS/National Al-Amal Oncology Hospital

Dr. Rand Qays Hadi

Medical Oncologist/ FICMS /Al-Yarmouk teaching hospital

Iraqi Cancer Registry Members

Dr. Tahseen Al-Rubai	Clinical Oncologist, MBChB DMTR / General Secretary of Cancer Board in Iraq /MOH.
Dr. Sura Y. Abd	MBChB/ CABSEFM/ Director division of cancer registration / Cancer Board in Iraq/ MOH
Dr. Hiba H. Salih	MBChB / FIBMS /CM / Director division of cancer research / Cancer Board in Iraq / MOH
Athraa H. Hasan	Statistician
Lamia M. Nasser	Statistician
Khitam J. Selman	Statistician
Menal H. Mola Mohamed	Statistician
Joolan S. Mehidy	Manager
Ahmed F. Juad	Statistician
Kalid H. Hadi	Assistant laboratory
Rania A. Hasoun	Medical assistant
Triva Murad Khodadad	Senior translator
Mais Munaim Obead	Chief medical assistant
Rasool Salem Jabar	Medical Assistant
Abas Mohammed Oraibi	Senior manager
Faten Hazem Mahammed	Medical assistant
Redhab M. Sahib	Headprogrammer
Malath K. Jabber	Manager
Ali H. Kamil	Researcher
Nadia A. Abo-Khdeef	Observer Assistant
Moshtaq T. Abdullah	Accountant Assistant

Contents	Page No.
Summary	1
Introduction	3
Scope on The Annual Report	5
Trend of cancer in Iraq 1976-2023	6
PART 1: DEMOGRAPHY OF IRAQ 2023	7
Geography	9
PART 2: CANCER INCIDENCE IN IRAQ 2023	13
Cancer Incidence in Iraq 2023	15
Distribution of Cancer Cases Among Iraqis by Governorates, Iraq 2023	18
Distribution of Cancer Cases by Gender and Primary Site	21
PART 3: INCIDENCE OF TOP TEN CANCERS	25
Most Common Cancers in Iraq	27
Female Breast cancer	31
Colorectal Cancer	33
Lung Cancer	35
Thyroid Cancer	37
Brain, Central Nervous System	39
Bladder	41
Leukemia	43
Prostate Cancer	45
Skin Cancer Including Non-Melanoma	47
Non-Hodgkin Lymphoma	49
PART 4: CANCER INCIDENCE IN GOVERNORATES	51
Distribution of Cancer Incidence in Governorates	53
4.1. Erbil Governorate	53
4.2. Karbala Governorate	55
4.3. Al-Najaf Governorate	57
4.4. Baghdad Governorate	59
4.5. Al-Sulaimaniyah Governorate	61
4.6. Al-Basrah Governorate	63
2.7. Babil Governorate	65
4.8. Diyala Governorate	67
4.9. Wasit Governorate	69
4.10. Al-Qadisiya Governorate	71
4.11. Misan Governorate	73
4.12. Al-Muthana Governorate	75

4.13. Duhok Governorate	77
4.14. Al-Anbar Governorate	79
4.15. Nineveh Governorate	81
4.16. Salah Al-Deen Governorate	83
4.17. ThiQar Governorate	85
4.18. Kirkuk Governorate	87
PART 5: CHILDHOOD CANCER	89
Child Cancers 0-14 Years in Iraq ,2023	91
Most Common Cancers Among Iraqi Children 0-14 year	93
Distribution of Most Common Cancers in Children 0-14 Years by Age Group, Iraq,2023	95
Distribution of The Most Common Cancers in Children by Governorates	97
Distribution of Cancer Cases Among Iraqi Children 0-14 year by Gender and Primary Sites	98
PART 6: CANCER MORTALITY	101
Cancer Mortality	103
Distribution of Cancer Mortality by Governorates, Iraq, 2023	105
Top Ten Cancer Mortality Among Iraqis ,2023	108
Top Ten Cancer Mortality Among Iraqis, Distributed by Genders ,2023	109
Mortality in Children	112
Top Ten Cancers Mortality Among Iraqi children 0-14 Year, by genders, 2023	113
PART 7: INCIDENCE TABLE	121
PART 8: CANCER AMONG NON-IRAQIS IN IRAQ	175
Cancer Among Non-Iraqis in Iraq, 2023	177
ملخص التقرير السنوي	184

List of Tables

Table No.	Title	Page No.
Table 1	Estimated Number and Percentage of Iraq Population by Gender and Age Group, 2023.	10
Table 2	Estimated Number of Iraq Population by Governorates and Gender, 2023.	12
Table 3	Distribution Of Cancer Cases Among Iraqis by Gender and Age Group, 2023.	15
Table 4	Distribution of Cancer Cases Among Iraqis by Governorates, Iraq 2023.	18
Table 5	Number of cases, Percentage and CIR Among Iraqis by Primary Site and Gender, 2023.	21
Table 6	Top Ten Cancers Among Iraqis,2023.	27
Table 7	Top Ten Cancers Among Iraqis by Gender, 2023.	28
Table 8	Morphological Distribution of Breast Cancer Among Females, Iraq, 2023.	31
Table 9	Morphological Distribution of Colorectal Cancer Among Iraqis, 2023.	33
Table 10	Morphological Distribution of Lung Cancer Among Iraqis, 2023.	35
Table 11	Morphological Distribution of Thyroid Cancer Among Iraqis, 2023.	37
Table 12	Morphological distribution of brain, CNS tumor among Iraqis, 2023.	39
Table 13	Morphological Distribution of bladder cancer Among Iraqis, 2023.	41
Table 14	Morphological distribution of Leukemia among Iraqis, 2023.	43
Table 15	Morphological Distribution of Prostate Cancer Among Iraqis, 2023.	45
Table 16	Morphological Distribution of Skin Cancer Among Iraqis, 2023.	47
Table 17	Morphological Distribution of Non-Hodgkin Lymphoma Among Iraqis, 2023.	49
Table 18	Top Ten Cancers at Erbil Governorate, Both Genders, Iraq, 2023.	53
Table 19	Top Ten Cancers at Erbil Governorate, By Gender, Iraq 2023.	53
Table 20	Top Ten Cancers at Karbala Governorate, Both Gender, Iraq, 2023.	55
Table 21	Top Ten Cancers at Karbala Governorate, By Gender 2023.	55
Table 22	Top Ten Cancers at Al-Najaf Governorate, both Genders, Iraq, 2023.	57
Table 23	Top Ten Cancers at Al-Najaf Governorate, By Gender 2023.	57
Table 24	Top Ten Cancers at Baghdad Governorate, Both Genders, Iraq, 2023.	59
Table 25	Top Ten Cancers at Baghdad Governorate, By Gender 2023.	59
Table 26	Top Ten Cancers at Al-Sulaimaniyah Governorate, Both Genders, Iraq, 2023.	61
Table 27	Top Ten Cancers at Al-Sulaimaniyah Governorate, By Gender 2023.	61
Table 28	Top Ten Cancers at Al-Basrah Governorate, Both Genders, Iraq, 2023.	63

Table No.	Title	Page No.
Table 29	Top Ten Cancers at Al-Basrah Governorate, By Gender, Iraq, 2023.	63
Table 30	Top Ten Cancers at Babil Governorate, Both Genders, Iraq, 2023.	65
Table 31	Top Ten Cancers at Babil Governorate, By Genders, Iraq, 2023.	65
Table 32	Top Ten Cancers at Diyala Governorate, Both Genders, Iraq, 2023.	67
Table 33	Top Ten Cancers at Diyala Governorate, By Gender, Iraq, 2023.	67
Table 34	Top Ten Cancers at Wasit Governorate, Both Genders, Iraq, 2023.	69
Table 35	Top Ten Cancers at Wasit Governorate, By Gender, Iraq, 2023.	69
Table 36	Top Ten Cancers at Al-Qadisiya Governorate, Both Genders, Iraq, 2023.	71
Table 37	Top Ten Cancers at Al-Qadisiya Governorate, By Gender Iraq, 2023.	71
Table 38	Top Ten Cancers at Misan Governorate, Both Genders, Iraq, 2023.	73
Table 39	Top Ten Cancers at Misan Governorate, By Gender, Iraq, 2023.	73
Table 40	Top Ten Cancers at Al-Muthana Governorate, Both Genders, Iraq, 2023.	75
Table 41	Top Ten Cancers at Al-Muthana Governorate, By Gender, Iraq, 2023.	75
Table 42	Top Ten Cancers at Duhok Governorate, Both Genders, Iraq, 2023.	77
Table 43	Top Ten Cancers at Duhok Governorate, By Gender, Iraq, 2023.	77
Table 44	Top Ten Cancers at Al-Anbar Governorate, Both Genders, Iraq, 2023.	79
Table 45	Top Ten Cancers at Al-Anbar Governorate, By Gender, Iraq, 2023.	79
Table 46	Top Ten Cancers at Nineveh Governorate, Both Genders, Iraq, 2023.	81
Table 47	Top Ten Cancers at Nineveh Governorate, By Gender, Iraq, 2023.	81
Table 48	Top Ten Cancers at Salah Al-Deen Governorate, Both Genders, Iraq, 2023.	83
Table 49	Top Ten Cancers at Salah Al-Deen Governorate, By Gender, Iraq, 2023.	83
Table 50	Top Ten Cancers at ThiQar Governorate, Both Genders, Iraq, 2023.	85
Table 51	Top Ten Cancers at ThiQar Governorate, By Gender, Iraq, 2023.	85
Table 52	Top Ten Cancers at Kirkuk Governorate, Both Genders, Iraq, 2023.	87
Table 53	Top Ten Cancers at Kirkuk Governorate, By Gender, Iraq, 2023.	87
Table 54	Number and Percentage of Top Ten Cancers in Children 0-14 Year, Iraq, 2023.	93
Table 55	Distribution of Top Ten Cancers in Children 0-14 Year by Genders, Iraq, 2023.	93
Table 56	Number of cases and Percentage of Top Ten Cancers in Children 0-14 Year by Age Group, Iraq, 2023	95
Table 57	Distribution of Top Ten Cancers in Children 0-14year By Governorates, Iraq, 2023.	97

Table No.	Title	Page No.
Table 58	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi children (per 100,000) by Primary Site and Genders, 2023.	98
Table 59	Distribution of Mortality Cases and ASMR/100,000 Among Iraqis, by Age Group, 2023.	103
Table 60	Distribution of Mortality Cases by Governorates, Iraq ,2023.	105
Table 61	Number And Percentage of Top Ten Cancers Mortality Among Iraqis, 2023.	108
Table 62	Number and Percentage of Top Ten Cancers Mortality Among Iraqis Distributed by Gender, 2023.	109
Table 63	Distribution of Top Ten Cancers Mortality by Age Group, Both Genders, Iraq, 2023.	111
Table 64	Number and Percentage of Top Ten Cancers Mortality Among Iraqi children 0-14 Year, 2023.	112
Table 65	Number and Percentage of Top Ten Cancers Mortality Among Iraqi children 0-14 Year, Distributed by Gender, 2023.	113
Table 66	Distribution of Top Ten Cancers Mortality Among Iraqi children by Governorate,2023.	115
Table 67	Number of Mortality Cases, Percentage and Crude Mortality Rate/100,000 Population by Primary Site and Gender, Iraq, 2023.	117
Table 68	Number of Cases Among Iraqi Males by Primary Site and Age Groups, 2023.	123
Table 69	Number of Cases Among Iraqi Females by Primary Site and Age Groups, 2023.	126
Table 70	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqis, Both Genders, (per 100,000) by Primary Site and Governorates,2023.	129
Table 71	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqis, Both Genders, (per 100,000) by Primary Site and Governorates,2023.	133
Table 72	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqis, Both Genders, (per 100,000) by Primary Site and Governorates,2023.	137
Table 73	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqis, Both Genders, (per 100,000) by Primary Site and Governorates,2023.	141
Table 74	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Males (per 100,000) by Primary Site and Governorates,2023.	145
Table 75	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Males (per 100,000) by Primary Site and Governorates,2023.	148
Table 76	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Males (per 100,000) by Primary Site and Governorates,2023.	151

Table No.	Title	Page No.
Table 77	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Males (per 100,000) by Primary Site and Governorates,2023.	154
Table 78	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Females (per 100,000) by Primary Site and Governorates,2023.	157
Table 79	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Females (per 100,000) by Primary Site and Governorates,2023.	161
Table 80	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Females (per 100,000) by Primary Site and Governorates,2023.	164
Table 81	Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Females (per 100,000) by Primary Site and Governorates,2023.	167
Table 82	Number and Percentage of Cancers in Both Gender by Age Group and Governorates, Iraq, 2023.	170
Table 83	Number and Percentage of Cancers in Male by Governorates and Age Group, Iraq, 2023.	171
Table 84	Number and Percentage of Cancers in Female by Governorates and Age Group, Iraq, 2023.	172
Table 85	Number and Percentage of Cancer Among Non-Iraqis by Primary Site and Gender, Iraq, 2023.	177
Table 86	Number and Percentage of Cancer Among Non-Iraqis by Age Group and Gender, Iraq, 2023.	179
Table 87	Number and Percentage of Cancer Among Non-Iraqi by Governorates and Gender, Iraq, 2023.	180
Table 88	Number and Percentage of Cancer Mortality Among Non-Iraqi by primary site and Gender, Iraq, 2023.	181
Table 89	Number and Percentage of Cancer Mortality Among Non-Iraqi by primary site and Governorates, Iraq, 2023.	182

List of Figures

Figure No.	Title	Page No.
Figure 1	Trend of The Crude Incidence Rate of Cancer in Iraq/100,000 Populations, 1976 – 2023.	6
Figure 2	Governorates of Iraq.	9
Figure 3	Pyramid of The Estimated Percentage of Iraq Population by Gender and Age Group, 2023.	11
Figure 4	Age-Specific Incidence Rate (Per 100,000) of All Cancers, Both Genders, Iraq ,2023.	16
Figure 5	Age-Specific Incidence Rate (Per 100,000) of All Cancers by Gender, Iraq ,2023.	17
Figure 6	Age Standardized Rate of All Cancer Sites in Both Genders Distributed by Governorate, Iraq,2023.	19
Figure 7	Age Standardized Rate of All Cancer Sites Distributed by Genders and Governorates, Iraq ,2023.	20
Figure 8	Crude Incidence Rate of Top Ten Cancers in Both Genders, Iraq, 2023.	29
Figure 9	Age Standardized Rate of Top Ten Cancers in Both Genders, Iraq, 2023.	29
Figure 10	Crude Incidence Rate and ASR (per 100,000) of Top Ten Cancers in Iraq by Gender,2023	30
Figure 11	Age-Specific Incidence Rate (ASIR) of Breast Cancer Among Females, Iraq, 2023	31
Figure 12	Distribution of Breast Cancer (ASR*) Among Females by Governorates, Iraq,2023	32
Figure 13	Age-Specific Incidence Rate (ASIR) of Colorectal Cancer Among Iraqis, 2023.	33
Figure 14	Distribution of Colorectal Cancer (ASR*) Among Iraqis by Governorates, 2023.	34
Figure 15	Age-Specific Incidence Rate (ASIR) of Lung Cancer Among Iraqis, 2023.	35
Figure 16	Distribution of Lung Cancer (ASR*) Among Iraqis by Governorates, 2023.	36
Figure 17	Age-Specific Incidence Rate (ASIR) of Thyroid Cancer Among Iraqis, 2023.	37
Figure 18	Distribution of Thyroid Cancer (ASR*) Among Iraqis by Governorates, 2023.	38
Figure 19	Age-Specific Incidence Rate (ASIR) of brain, CNS tumor among Iraqis, 2023.	39
Figure 20	Distribution of Brain, CNS tumor (ASR*) Among Iraqis by Governorates, 2023.	40
Figure 21	Age-Specific Incidence Rate (ASIR) of Bladder Cancer Among Iraqis, 2023	41
Figure 22	Distribution of Bladder Cancer (ASR*) Among Iraqi by Governorates, 2023	42

Figure No.	Title	Page No.
Figure 23	Age-Specific Incidence Rate (ASIR) of Leukemia Among Iraqis, 202	43
Figure 24	Distribution of Leukemia (ASR*) Among Iraqi by Governorates, 2023	44
Figure 25	Age-Specific Incidence Rate (ASIR) of Prostate Cancer Among Iraqis, 2023	45
Figure 26	Distribution of Prostate Cancer (ASR*) Among Iraqi by Governorates, 2023	46
Figure 27	Age-Specific Incidence Rate (AIR) of Skin Cancer Among Iraqis, 2023	47
Figure 28	Distribution of Cancer Skin (ASR*) Among Iraqi by Governorates, 2023	48
Figure 29	Age-Specific Incidence Rate (AIR) of Non-Hodgkin Lymphoma Cancer Among Iraqis Both Genders, 2023	49
Figure 30	Distribution of Non-Hodgkin Lymphoma (ASR*) Among Iraqis by governorates, 2023	50
Figure 31	Crude Incidence Rate of Top Ten Cancers at Erbil Governorate, Iraq, 2023	54
Figure 32	Crude Incidence Rate of Top Ten Cancers at Karbala Governorate, Iraq, 2023.	56
Figure 33	Crude Incidence Rate Top Ten Cancers at Al Najaf Governorate, Iraq, 2023.	58
Figure 34	Crude Incidence Rate of Top Ten Cancers at Baghdad Governorate, Iraq, 2023.	60
Figure 35	Crude Incidence Rate of Top Ten Cancers at Al-Sulaimaniyah Governorate, Iraq, 2023	62
Figure 36	Crude Incidence Rate of Top Ten Cancers at Al-Basrah Governorate, Iraq, 2023	64
Figure 37	Crude Incidence Rate of Top Ten Cancers at Babil Governorate, Iraq, 2023	66
Figure 38	Crude Incidence Rate of Top Ten Cancers at Diyala Governorate, Iraq, 2023	68
Figure 39	Crude Incidence Rate of Top Ten Cancers at Wasit Governorate, Iraq ,2023	70
Figure 40	Crude Incidence Rate of Top Ten Cancers at Al-Qadisiya Governorate, Iraq ,2023	72
Figure 41	Crude Incidence Rate of Top Ten Cancers at Misan Governorate, Iraq, 2023.	74
Figure 42	Crude Incidence Rate of Top Ten Cancers at Al-Muthana Governorate, Iraq, 2023.	76
Figure 43	Crude Incidence Rate of Top Ten Cancers at Duhok Governorate, Iraq,2023.	78

Figure No.	Title	Page No.
Figure 44	Crude Incidence Rate of Top Ten cancers at Al-Anbar Governorate, Iraq ,2023.	80
Figure 45	Crude Incidence Rate of Top Ten Cancers at Nineveh Governorate, Iraq ,2023.	82
Figure 46	Crude Incidence Rate of Top Ten Cancers at Salah Al- Deen Governorate, Iraq ,2023.	84
Figure 47	Crude Incidence Rate of Top Ten Cancers at ThiQar Governorate, Iraq ,2023.	86
Figure 48	Crude Incidence Rate of Top Ten Cancers at Kirkuk Governorate, Iraq ,2023.	88
Figure 49	Distribution of Cancer Cases Among Iraqi Children,2023.	91
Figure 50	Crude Incidence Rate of Cancers in Children 0-14 Year Distributed by Governorates, Iraq, 2023.	92
Figure 51	Crude Incidence Rate of Top Ten Cancers in Iraqi Children 0-14 Years,2023.	94
Figure 52	Crude Incidence Rate of All Cancer Sites in Children, by Age Group Iraq, 2023	96
Figure 53	Age -Specific Mortality Rates of All Cancers Sites, Iraq, 2023.	104
Figure 54	Age Standardized Mortality Rate by Governorates, Both Genders, Iraq ,2023.	106
Figure 55	Age Standardized Mortality Rate by Governorates and Genders, Iraq ,2023.	107
Figure 56	Crude Mortality Rate of Top Ten Cancers Mortality Among Iraqis, 2023.	108
Figure 57	Crude Mortality Rate of Top Ten Cancers Mortality Among Iraqi Males, 2023.	110
Figure 58	Crude Mortality Rate of Top Ten Cancers Mortality Among Iraqi Females, 2023.	110
Figure 59	Crude Mortality Rate of Top Ten Cancers Mortality Among Iraqi children /100, 000 Children Populations, 2023.	112
Figure 60	Crude Mortality Rate of Top Ten Cancers Mortality Among Male Children /100, 000 Children Populations, Iraq, 2023.	114
Figure 61	Crude Mortality Rate of Top Ten Cancers Mortality Among Female Children /100, 000 Children Populations, Iraq, 2023.	114
Figure 62	Crude Mortality Rate Among Iraqi Children Distributed by Governorate,2023.	116

List of Figures

P	population
ICB	Iraqi cancer board
ICR	Iraqi cancer registry
ICD-O	International classification of diseases for oncology
IR	Incidence rate
ASR	Age standardized rate
ASMR	Age standardized mortality rate
CNS	Central nervous system
NHL	Non- Hodgkin Lymphoma

Summary

The total number of new cases of cancer during the year 2023 was 43,062. The age standardized incidence rate was 171.6 /100,000P. Related to the governorates the highest crude incidence rate in Iraq was recorded in Erbil (143.8/100.000 P). it also recorded the highest crude incidence rate among males and females (128.4/100,000 MP and 159.4/100,000 FP) respectively. The lowest crude incidence rate in Iraq was recorded in Kirkuk (62.6/100.000 P).

The trend of the crude incidence rate of new cases of cancer increased from the year 1976 (31.5/100,000 P) to the year 2023 (99.4 /100,000 P).

The top ten cancers in both genders were breast (20.5%, 20.4/100,000P), colorectal (7.2%, 7.2/100,000 P), lung (7.0%, 7.0/100,000 P), Thyroid (6.6%, 6.5/100,000 P), brain, central nervous system tumor (CNS) (6.5%, 6.5/100,000 P), Bladder (4.7 %, 4.7 /100,000 P), Leukemia (4.4 %, 4.4 /100,000 P), prostate (3.8 %, 7.6 /100,000 MP), Skin, other (3.5 %, 3.5 /100,000 P) and Non-Hodgkin Lymphoma (3.3 %, 3.3 /100,000 P).

The top ten cancers in males were lung (11.8 %, 9.7 /100,000 MP), Prostate (9.2%, 7.6 /100,000 MP), Colorectal (8.9 %, 7.3 /100,000 MP), Bladder (8.9 %, 7.3 /100,000 MP), brain, central nervous system tumor (CNS) (7.4 %, 6.1 /100,000 MP), leukemia (5.6 %, 4.6 /100,000 MP), kidney (4.7 %, 3.9 /100,000 MP), Skin, other (4.6 %, 3.8 /100,000 MP), Non-Hodgkin Lymphoma (4.5 %, 3.7 /100,000 MP), and Pancreas (3.7 %, 3.0 /100,000 MP).

The top ten cancers in females were breast (34.8 %, 40.6 /100,000 FP), thyroid (9.1 %, 10.6 /100,000 FP), colorectal (6.0 %, 7.0 /100,000 FP), brain, central nervous system tumor (CNS) (6.0 %, 7.0 /100,000 FP), Ovary (4.1 %, 4.8 /100,000 FP), Lung (3.6 %, 4.2 /100,000 FP), leukemia (3.5 %, 4.1 /100,000FP), uterus unspecified (3.2 %, 3.7 /100,000 FP), Skin, other (2.8 %, 3.3 /100,000 FP), and Non-Hodgkin Lymphoma (2.5 %, 3.0 /100,000 FP).

The total number of cancers in children (0-14 years) was 1922 out of the 43,062 representing 4.5 % of total cases of cancer of all age groups, with crude incidence rate 11/100,000 children (0–14 year P). Related to the age group the lowest crude incidence rate was 5-9 years 9.9 /100,000. The highest crude incidence rate of cancer among children was leukemia (3.1 /100,000 children 0-14 years P).

Related to the governorates the highest crude incidence rate of cancers in children (0-14 years) was recorded in Al- Al-Muthana (17.1 /100,000 children 0-14 year Populations) and the lowest was in Babil (6.5 /100,000 children 0- 14 year P).

The total number of cancer mortality during the year 2023 was 12,982. The age standardized mortality rate of top ten cancer was 56 /100,000 P. The highest crude mortality rate of cancers, in general was lung cancer (15.7%, 4.7/100,000 P), among males the highest crude mortality rate of cancer was lung cancer (21.8 %, 6.3 /100,000 MP), while in females the highest crude mortality rate of cancer was breast cancer (24.2 %, 7.5 /100,000 FP). Related to the age group the highest crude mortality rate was among the age group 75-79 years. As to the governorates, the highest crude mortality rate of cancers was recorded in Al-Najaf governorate (45.4/100,000 P).

The total number of cases of cancer among non-Iraqis during the year 2023 was 227, the most affected age group in males was 55-59 years, while most affected age group in females was 60-64 year. The highest percentage of cancer in males was lung (19.1%) followed by prostate cancer (10.6%), while in females the highest percentage of cancer was breast cancer (43.6%) followed by Non-Hodgkin Lymphoma (5.3 %). The highest percentage of cases in both genders was reported in Erbil governorate (49.3 %). The total number of cancer mortality among non-Iraqis was 27(12 males and15 females). The highest percentage of mortality was reported in Duhok governorate (44.4 %).

Introduction

The annual report of the Iraqi cancer registry is a comprehensive document that provides detailed information about cancer in Iraq. It is based on data collected from the Iraqi Cancer Registry. It is a population-based cancer registry that collects data on all new cases of cancers diagnosed in Iraq.

Iraqi Cancer Board (ICB) was established in 1985 (law 63 in 1985). The Minister of Health assumed leadership of the ICB to streamline logistical support for the organization.

The first cancer registry report was published in 1987. It provided information of registry activities for the period 1976- 1985.

The annual report of ICB includes information on overall cancer incidence and mortality rates in Iraq, the most common types of cancer in Iraq, the age-specific and sex-specific incidence and mortality rates for each type of cancer, the trends in cancer incidence and mortality over time, the survival rates for different types of cancer, and the risk factors (likelihood of developing cancer based on various factors) for cancer in Iraq.

The annual report of ICB is an important resource for cancer researchers, policymakers, and public health officials. The report provides valuable data that can be used to develop and implement cancer prevention and control strategies in Iraq.

Surveillance, epidemiology, and end results (SEER) are reliable sources for the annual report of ICB in Iraq. SEER provides a trend over time.

Cancer statistics vary widely by region, country, and population demographics. In the last 10 years, Iraqi population grew at a rate of 2.97 percent annually. This growth rate is higher than that of middle-income countries and that of west Asia. It was estimated that the highest incidence of cancer within the next decades will be registered in the Eastern Mediterranean Region (EMR) for reasons attributed to population growth, aging, lifestyle modification, urbanization, and exposure to carcinogens.

In Iraq, Ministry of Health established Iraqi Cancer Registry (ICR). Several reports were published for the years 1976-1985, 1986-1988, 1989-1991, 1992-1994, 1995-1997, and 1998-1999, followed by successive reports, annually.

Trends can also change over time due to factors like improvements in screening methods, changes in diagnostic criteria, advancements in treatment, and public health initiatives.

The collected data from all governorates are registered by a trained staff, instructed on Cancer Registry Program 5 (Can Reg 5), who work at the cancer registry units. The completed forms are directed to the cancer registry section of the ICB, where they undergo a thorough review to ensure accuracy and completeness, then introduced in the Alphabetical Index into the system to prevent duplication.

ICB is usually headed by the Minister of Health by law, to enhance the logistic support for the activities of ICB. Since the establishment of ICB, six secretary generals have governed it. They were:

- Abdul Hadi Al-Khalili
- Hafidh Al-Khazrachi
- Ahmed Mubarek
- Mahdi Al-Saraji
- Haider Hamza
- Khudair Al-Rawaq
- Tahseen Al-Rubai

They were responsible mainly for the preparation of annual of Iraqi Cancer Registry

Scope on The Annual Report

Incidence rate of cancer is remarkably increased from 1976 (31.5/100,000) to (99.4/100,000) in 2023 (fig. 1). The obvious increase in crude incidence rate is in the line of increase incidence (crude and/or age specific rate) of cancer globally in the last century. The increasing trend was influenced by various factors e.g., lifestyle changes, environmental factors, and improved detection methods.

Over the last two decades, Iraq has experienced significant changes in various aspects of its lifestyle. The country has seen improvements in life expectancy and economic development. Iraq's life expectancy has increased to 70.4 years, and its GDP per capita has risen from \$855 in 2003 to \$4,686 in 2021. This indicates an improvement in living standards and economic conditions over the years. Increased prevalence of obesity, smoking, and low physical activity are risk factors for cancer.

The observed age standardized rate of cancer in 2023 was 171.6 per 100000 P. It is lower than that estimated global age-standardized cancer rate 196.8 cases per 100,000 people (GloboCan2023). This means that the cancer rate in Iraq is lower than the global average. Cancer rates can vary widely by region and country due to factors such as lifestyle, environmental conditions, access to healthcare, and genetic predisposition.

In general, although the age-standardized cancer rate in Iraq is below the global average, it is crucial to persist in monitoring and tackling the factors influencing cancer incidence in the country. This ensures the implementation of effective measures for prevention, early detection, and treatment

Trend of cancer in Iraq 1976-2023.




Figure 1: Trend of The Crude Incidence Rate of Cancer in Iraq/100,000 Populations, 1976– 2023.

Note: From 1995 till 2004 data excludes Kurdistan Region (Erbil, Duhuk, and Al-Slaimaniyah governorates.)

PART 1

DEMOGRAPHY OF

IRAQ

2023

Geography

The Republic of Iraq is located in the south-west of Asia, to the north-east of the Arab Homeland, bounded on the north by Turkey, on the east by Iran, on the south by Arab Gulf, Kuwait and Saudi Arabia, and on the west by Syria, Jordan and Saudi Arabia. The highest proportion of the length of Iraq's borders with neighboring countries is with Iran about (37.6%) followed by Saudi Arabia (23.5%).

Iraq has occupied an area of 435,052 square kilometers, the province of Anbar the highest area, reaching 31.7%, followed by Muthana province by 11.9% of the area of Iraq and Nineveh province reaching 8.6% of the area of Iraq.

The surface of Iraq is characterized by various landscapes, with deserts comprising approximately 38.7% of the region. The plains, incorporating marshes and lakes, account for around 30.5% of the area. Mountains occupy about 21.1% of the total surface, while terrain lands make up approximately 9.7% of Iraq's land area.



Figure 2: Governorates of Iraq.

Table 1: Estimated Number and Percentage of Iraq Population by Gender and Age Group, 2023.

Age Group	Male		Female		Total	
	No.	%	No.	%	No.	%
0-4	3,263,270	14.91	3,093,354	14.43	6,356,624	14.67
5-9	3,045,481	13.91	2,866,907	13.37	5,912,388	13.65
10-14	2,721,769	12.43	2,540,868	11.85	5,262,637	12.15
15-19	2,388,096	10.91	2,256,345	10.53	4,644,441	10.72
20-24	2,086,021	9.53	1,925,174	8.98	4,011,195	9.26
25-29	1,636,126	7.47	1,590,817	7.42	3,226,943	7.45
30-34	1,432,657	6.55	1,474,311	6.88	2,906,968	6.71
35-39	1,221,136	5.58	1,287,444	6.01	2,508,580	5.79
40-44	1,151,518	5.26	1,166,899	5.44	2,318,417	5.35
45-49	851,014	3.89	876,269	4.09	1,727,283	3.99
50-54	501,775	2.29	624,854	2.92	1,126,629	2.60
55-59	570,433	2.61	596,935	2.78	1,167,368	2.69
60-64	392,848	1.79	429,365	2.00	822,213	1.90
65-69	258,597	1.18	269,390	1.26	527,987	1.22
70-74	168,712	0.77	169,769	0.79	338,481	0.78
75-79	88,873	0.41	107,078	0.50	195,951	0.45
80+	110,012	0.50	159,901	0.75	269,913	0.62
Total	21,888,338	100%	21,435,680	100%	43,324,018	100%




Figure 2: Pyramid of The Estimated Percentage of Iraq Population by Gender and Age Group, 2023.

Table 2: Estimated Number of Iraq Population by Governorates and Gender, 2023.

Governorates	Male		Female		Total	
	No.	%	No.	%	No.	%
Baghdad	4,701,315	21.48	4,563,898	21.29	9,265,213	21.39
Nineveh	2,165,272	9.89	2,073,461	9.67	4,238,733	9.78
Al-Basrah	1,660,417	7.59	1,644,772	7.67	3,305,189	7.63
Al-Sulaimaniyah	1,229,205	5.62	1,227,984	5.73	2,457,189	5.67
ThiQar	1,195,067	5.46	1,185,876	5.53	2,380,943	5.50
Babil	1,185,748	5.42	1,160,948	5.42	2,346,696	5.42
Erbil	1,064,104	4.86	1,043,651	4.87	2,107,755	4.87
Al-Anbar	1,034,316	4.73	978,984	4.57	2,013,300	4.65
Diyala	924,594	4.22	905,909	4.23	1,830,503	4.23
Kirkuk	914,084	4.18	901,750	4.21	1,815,834	4.19
Salah Al-Deen	915,720	4.18	897,102	4.19	1,812,822	4.18
Al-Najaf	838,462	3.83	833,850	3.89	1,672,312	3.86
Wasit	790,969	3.61	775,820	3.62	1,566,789	3.62
Duhok	736,004	3.36	732,801	3.42	1,468,805	3.39
Al-Qadisiya	739,454	3.38	727,673	3.39	1,467,127	3.39
Karbala	698,647	3.19	686,294	3.20	1,384,941	3.20
Misan	629,919	2.88	634,508	2.96	1,264,427	2.92
Al-Muthana	465,041	2.12	460,399	2.15	925,440	2.14
Total	21,888,338	100%	21,435,680	100%	43,324,018	100%

PART 2

CANCER INCIDENCE

IN IRAQ

2023

Cancer Incidence in Iraq 2023.

There were 43,062 newly diagnosed cancer cases reported among Iraqi nationality in 2023, overall cancer among females were more than males; it affected 18,041 (41.9%) males and 25,021 (58.1%) females. The crude incidence rates (CIR) of all cancers founded to be 99.4/100,000. while overall age standardized rate (ASR) was 171.6/100,000. The crude incidence rates (CIR) among males were 82.4/100,000 and 116.7/100,000 among females. While age-standardized rate (ASR) was 156.4/100,000 among males and 186.8/100,000 among females.

Table 3: Distribution of Cancer Cases Among Iraqis by Gender and Age Group, 2023.

Age group	Male		Female		Total		
	No.	%	No.	%	No.	%	ASR
0-4	388	2.2	344	1.4	732	1.7	1.4
5-9	333	1.8	250	1.0	583	1.4	1.0
10-14	341	1.9	266	1.1	607	1.4	1.0
15-19	337	1.9	362	1.4	699	1.6	1.4
20-24	365	2.0	467	1.9	832	1.9	1.7
25-29	397	2.2	690	2.8	1,087	2.5	2.7
30-34	563	3.1	1,183	4.7	1,746	4.1	3.6
35-39	656	3.6	1,481	5.9	2,137	5.0	5.1
40-44	853	4.7	2,163	8.6	3,016	7.0	7.8
45-49	1139	6.3	2,565	10.3	3,704	8.6	12.9
50-54	1,634	9.1	2,953	11.8	4587	10.7	20.4
55-59	1,791	9.9	2,842	11.4	4,633	10.8	15.9
60-64	1,810	10.0	2,596	10.4	4,406	10.2	21.4
65-69	2,269	12.6	2,307	9.2	4,576	10.6	26.0
70-74	2,332	12.9	2,135	8.5	4,467	10.4	26.4
75-79	1,410	7.8	1,162	4.6	2,572	6.0	13.1
80+	1,423	7.9	1,255	5.0	2,678	6.2	9.9
Total	18,041	100%	25,021	100%	43,062	100%	171.6




Figure 4: Age-Specific Incidence Rate (Per 100,000) of All Cancers, Both Genders, Iraq ,2023.




Figure 5: Age -Specific Incidence Rate (Per 100,000) of All Cancers by Gender, Iraq,2023.

Distribution of Cancer Cases Among Iraqis by Governorates, Iraq 2023.

Erbil governorate reported the highest incidence rate 143.8/100,000 followed by Karbala 125.4/100,000 and Al-Najaf 120/100,000 while the lowest incidence rate was in Kirkuk (62.6/100,000). (Table 4)

The age standardized incidence rate was 237.1/100,000 in Erbil governorate followed by 230.6/100,000 in Karbala and 217.6/100,000 in Al-Najaf. (Figure 6)

Table 4: Distribution of Cancer Cases Among Iraqis by Governorates, Iraq, 2023.

Governorates	Male			Female			Total		
	No.	%	IR	No.	%	IR	No.	%	IR
Erbil	1,366	7.6	128.4	1,664	6.7	159.4	3,030	7.0	143.8
Karbala	698	3.9	99.9	1,039	4.2	151.4	1,737	4.0	125.4
Al-Najaf	869	4.8	103.6	1,138	4.5	136.5	2,007	4.7	120.0
Baghdad	4,264	23.6	90.7	6,807	27.2	149.1	11,071	25.7	119.5
Al-Sulaimaniyah	1305	7.2	106.2	1,491	6.0	121.4	2,796	6.5	113.8
Al-Basrah	1,504	8.3	90.6	1,991	8.0	121.1	3,495	8.1	105.7
Babil	891	4.9	75.1	1,254	5.0	108.0	2,145	5.0	91.4
Diyala	630	3.5	68.1	1,042	4.2	115.0	1,672	3.9	91.3
Wasit	597	3.3	75.5	826	3.3	106.5	1,423	3.3	90.8
Al-Qadisiya	596	3.3	80.6	724	2.9	99.5	1,320	3.1	90.0
Misan	497	2.8	78.9	591	2.4	93.1	1,088	2.5	86.0
Al-Muthana	368	2.0	79.1	415	1.7	90.1	783	1.8	84.6
Duhok	558	3.1	75.8	628	2.5	85.7	1,186	2.8	80.7
Al-Anbar	631	3.5	61.0	883	3.5	90.2	1,514	3.5	75.2
Nineveh	1,280	7.1	59.1	1,778	7.1	85.8	3,058	7.1	72.1
Salah Al-Deen	491	2.7	53.6	813	3.2	90.6	1,304	3.0	71.9
ThiQar	773	4.3	64.7	907	3.6	76.5	1,680	3.9	70.6
Kirkuk	459	2.5	50.2	677	2.7	75.1	1,136	2.6	62.6
Unknown	264	1.5	-----	353	1.4	-----	617	1.4	-----
Total	18,041	100	82.4	25,021	100	116.7	43,062	100	99.4




Figure 6: Age Standardized Rate of All Cancer Sites in Both Genders Distributed by Governorate, Iraq, 2023.

Karbala governorate reported the highest ASR among females 259.1/100,000 while Erbil governorates reported the highest ASR among male and 238.6/100,000 whereas, Kirkuk governorate reported the lowest ASR among females and males 111.9/100,000 and 89/100,000 respectively.




Figure 7: Age Standardized Rate of All Cancer Sites Distributed by Gender and Governorates, Iraq,2023.

Distribution of Cancer Cases by Gender and Primary Site.

Table (5): Number of cases, Percentage and CIR Among Iraqis by Primary Site and Gender, 2023.

ICDO/ Tumor	Male			Female			Total		
	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	16	0.09	0.07	10	0.04	0.05	26	0.06	0.06
C01 / Tongue, base	11	0.06	0.05	8	0.03	0.04	19	0.04	0.04
C02 / Tongue, other	69	0.38	0.32	80	0.32	0.37	149	0.35	0.34
C03 / Gum	4	0.02	0.02	4	0.02	0.02	8	0.02	0.02
C04 / Mouth - floor	15	0.08	0.07	8	0.03	0.04	23	0.05	0.05
C05 / Mouth - palate	13	0.07	0.06	12	0.05	0.06	25	0.06	0.06
C06 / Mouth - other	41	0.23	0.19	30	0.12	0.14	71	0.16	0.16
C07 / Parotid gland	39	0.22	0.18	28	0.11	0.13	67	0.16	0.15
C08 / Mouth glands	36	0.20	0.16	31	0.12	0.14	67	0.16	0.15
C09 / Tonsil	12	0.07	0.05	3	0.01	0.01	15	0.03	0.03
C10 / Oropharynx	11	0.06	0.05	5	0.02	0.02	16	0.04	0.04
C11 / Nasopharynx	150	0.83	0.69	68	0.27	0.32	218	0.51	0.50
C12 / Pyriform	3	0.02	0.01	3	0.01	0.01	6	0.01	0.01
C13 / Hypopharynx	6	0.03	0.03	14	0.06	0.07	20	0.05	0.05
C14 / Pharynx	7	0.04	0.03	14	0.06	0.07	21	0.05	0.05
C15 / Oesophagus	132	0.73	0.60	108	0.43	0.50	240	0.56	0.55
C16 / Stomach	602	3.34	2.75	589	2.35	2.75	1,191	2.77	2.75
C17 / Small intestine	89	0.49	0.41	85	0.34	0.40	174	0.40	0.40
C18 / Colon	1,057	5.86	4.83	1022	4.08	4.77	2,079	4.83	4.80
C19 / Recto sigmoid Junction	97	0.54	0.44	77	0.31	0.36	174	0.40	0.40
C20 / Rectum	452	2.51	2.07	403	1.61	1.88	855	1.99	1.97
C21 / Anus & anal canal	28	0.16	0.13	18	0.07	0.08	46	0.11	0.11
C22 / Liver & bile ducts	443	2.46	2.02	379	1.51	1.77	822	1.91	1.90
C23 / Gallbladder	101	0.56	0.46	153	0.61	0.71	254	0.59	0.59
C24 / Biliary tract, other	97	0.54	0.44	77	0.31	0.36	174	0.40	0.40
C25 / Pancreas	666	3.69	3.04	562	2.25	2.62	1,228	2.85	2.83
C26 / Other digestive organs	26	0.14	0.12	21	0.08	0.10	47	0.11	0.11
C30 / Nasal cavity	29	0.16	0.13	18	0.07	0.08	47	0.11	0.11
C31 / Accessory sinus	15	0.08	0.07	11	0.04	0.05	26	0.06	0.06
C32 / Larynx	387	2.15	1.77	88	0.35	0.41	475	1.10	1.10
C33 / Trachea	4	0.02	0.02	3	0.01	0.01	7	0.02	0.02
C34 / Bronchus & lung	2,129	11.80	9.73	891	3.56	4.16	3,020	7.01	6.97

ICDO/ Tumor		Male			Female			Total		
		No.	%	IR	No.	%	IR	No.	%	IR
C37 / Thymus		32	0.18	0.15	33	0.13	0.15	65	0.15	0.15
C38 / Heart, Mediastinum, pleura		56	0.31	0.26	43	0.17	0.20	99	0.23	0.23
C39 / Other respiratory & thoracic		3	0.02	0.01	3	0.01	0.01	6	0.01	0.01
C40 / Bone & cartilage, limbs		149	0.83	0.68	117	0.47	0.55	266	0.62	0.61
C41 / Bones & cartilage, other		147	0.81	0.67	94	0.38	0.44	241	0.56	0.56
C42/Reticulo endothelial& Hematopoietic System	Leukemia	1,014	5.62	4.63	873	3.49	4.07	1,887	4.38	4.36
	Chronic Myeloproliferative disorders	179	0.99	0.82	100	0.40	0.47	279	0.65	0.64
	Immunoproliferative diseases	3	0.02	0.01	1	0.00	0.00	4	0.01	0.01
	Mast cell tumor	2	0.01	0.01	1	0.00	0.00	3	0.01	0.01
	Plasma cell tumor	218	1.21	1.00	188	0.75	0.88	406	0.94	0.94
	Myelodys plastic syndromes	31	0.17	0.14	31	0.12	0.14	62	0.14	0.14
C44 /Skin, other		831	4.61	3.80	697	2.79	3.25	1,528	3.55	3.53
C47 /Nerves system		2	0.01	0.01	9	0.04	0.04	11	0.03	0.03
C48 / Peritoneum		28	0.16	0.13	43	0.17	0.20	71	0.16	0.16
C49 / soft tissues		297	1.65	1.36	253	1.01	1.18	550	1.28	1.27
C50 / Breast		141	0.78	0.64	8,708	34.80	40.62	8,849	20.55	20.43
C51 / Vulva		0	0.00	0.00	40	0.16	0.19	40	0.09	0.19
C52 / Vagina		0	0.00	0.00	15	0.06	0.07	15	0.03	0.07
C53 / Cervix uteri		0	0.00	0.00	320	1.28	1.49	320	0.74	1.49
C54 / Corpus uteri		0	0.00	0.00	513	2.05	2.39	513	1.19	2.39
C55 / Uterus unspecified		0	0.00	0.00	789	3.15	3.68	789	1.83	3.68
C56 / Ovary		0	0.00	0.00	1,036	4.14	4.83	1036	2.41	4.83
C57 / Female genital - other		0	0.00	0.00	6	0.02	0.03	6	0.01	0.03
C58 / Placenta		0	0.00	0.00	35	0.14	0.16	35	0.08	0.16
C60 / Penis		4	0.02	0.02	0	0.00	0.00	4	0.01	0.02
C61 / Prostate		1,656	9.18	7.57	0	0.00	0.00	1,656	3.85	7.57
C62 / Testis		275	1.52	1.26	0	0.00	0.00	275	0.64	1.26
C63 / Male genital - other		3	0.02	0.01	0	0.00	0.00	3	0.01	0.01
C64 / Kidney		853	4.73	3.90	508	2.03	2.37	1,361	3.16	3.14
C65 / Pelvis		30	0.17	0.14	18	0.07	0.08	48	0.11	0.11

ICDO/ Tumor		Male			Female			Total		
		No.	%	IR	No.	%	IR	No.	%	IR
C66 / Ureter		11	0.06	0.05	5	0.02	0.02	16	0.04	0.04
C67 / Urinary bladder		1,602	8.88	7.32	416	1.66	1.94	2,018	4.69	4.66
C68 / Urinary organs, other		8	0.04	0.04	0	0.00	0.00	8	0.02	0.02
C69 / Eye & adnexa		61	0.34	0.28	39	0.16	0.18	100	0.23	0.23
C70 / Meninges		126	0.70	0.58	348	1.39	1.62	474	1.10	1.09
C71 / Brain		1,085	6.01	4.96	988	3.95	4.61	2,073	4.81	4.78
C72 / Nervous system, other		40	0.22	0.18	49	0.20	0.23	89	0.21	0.21
C73 / Thyroid gland		558	3.09	2.55	2,265	9.05	10.57	2,823	6.56	6.52
C74 / Adrenal gland		72	0.40	0.33	77	0.31	0.36	149	0.35	0.34
C75 / Endocrine gland, other		82	0.45	0.37	116	0.46	0.54	198	0.46	0.46
C76 / Unspecified site		71	0.39	0.32	79	0.32	0.37	150	0.35	0.35
C77 / Lymph Nodes	Hodgkin Lymphoma	405	2.24	1.85	318	1.27	1.48	723	1.68	1.67
	Non-Hodgkin Lymphoma	807	4.47	3.69	635	2.54	2.96	1,442	3.35	3.33
C80 / Unknown primary site		372	2.06	1.70	389	1.55	1.81	761	1.77	1.76
Total		18,041	100%	82.4	25,021	100%	116.7	43,062	100%	99.4

Note:

- * From C51 to C58 the incidence rate was calculated from the female population.
- * From C60 to C63 the incidence rate was calculated from the male population.

PART 3

INCIDENCE OF TOP TEN CANCERS

Most Common Cancers in Iraq, 2023.

The total number of most common cancer sites in Iraq was 29149 accounting 67.7% from all newly diagnosed cancer cases in 2023. breast 8,849 (20.5%), colorectal 3,108 (7.2%), lung 3,020 (7%), thyroid 2,823 (6.6%), Brain, CNS 2,818 (6.5%) and Bladder cancer 2,018 (4.7%) these sixth cancers accounting more than half (52.6%) of all newly diagnosed cancer cases. Lung cancer was the most common cancer site among Iraqi males 2,129 (11.8%) followed by Prostate 1,656 (9.2%) and Colorectal 1,606 (8.9%) cases, while Breast cancer was the most common cancer site among females 8708 (34.8%) followed by thyroid cancer 2265 (9.1%) and Colorectal cancer 1502 (6.0%). (Table 6&7)

Table 6: Top Ten Cancers Among Iraqis, 2023.

Site	Male	Female	Total	%
Breast	141	8,708	8,849	20.5
Colorectal	1,606	1,502	3,108	7.2
Bronchus & Lung	2,129	891	3,020	7.0
Thyroid	558	2,265	2,823	6.6
Brain, CNS	1,327	1,491	2,818	6.5
Bladder	1,602	416	2,018	4.7
Leukemia	1,014	873	1,887	4.4
Prostate	1,656	----	1,656	3.8
Skin, other	831	697	1,528	3.5
Non-Hodgkin Lymphoma	807	635	1,442	3.3






Table 7: Top Ten Cancers Among Iraqis, by Gender, 2023.

Male			Female		
Site	NO	%	Site	NO	%
Bronchus & Lung	2,129	11.8	Breast	8,708	34.8
Prostate	1,656	9.2	Thyroid	2,265	9.1
Colorectal	1,606	8.9	Colorectal	1,502	6.0
Bladder	1,602	8.9	Brain, CNS	1491	6.0
Brain, CNS	1,327	7.4	Ovary	1,036	4.1
Leukemia	1,014	5.6	Bronchus & Lung	891	3.6
Kidney	853	4.7	Leukemia	873	3.5
Skin, other	831	4.6	Uterus Unspecified	789	3.2
Non-Hodgkin Lymphoma	807	4.5	Skin, other	697	2.8
Pancreas	666	3.7	Non-Hodgkin Lymphoma	635	2.5






Figure 8: Crude Incidence Rate (per 100,000) of Top Ten Cancers in Both Genders, Iraq, 2023.







Figure 9: Age standardized rate (per100,000) of Top Ten Cancers in Both Genders, Iraq,2023




IR/100,000 (Male)



IR/100,000 (Female)



ASR/100,000 (Male)



ASR/100,000 (Female)

Figure 10: Crude Incidence Rate and ASR (per 100,000) of Top Ten Cancers by Gender, Iraq, 2023.

Female Breast cancer

Breast cancer is the most common cancer among Iraqi females. There were 8,708 cases among females. Represented 34.8% of all cancer cases diagnosed among females. The ASR was 65.5/100,000 for the Iraqi female population. The five governorates with the highest ASR were Erbil 92.3 /100,000, followed by Baghdad with 83.8/100,000, then Karbala with 80 /100,000, Al-Najaf with 71.4/100,000 and Al-Basrah with 69/100,000. The mean age at diagnosis was 53.7 and the median was 53 years.

Figure 11: Age-Specific Incidence Rate (AIR) of Breast Cancer Among Females, Iraq ,2023.




Table 8: Morphological Distribution of Breast Cancer Among Females, Iraq, 2023.

Morphology	No.	%
Infiltrating duct carcinoma, NOS	8,030	92.2
Lobular carcinoma, NOS	467	5.4
Infiltrating duct and lobular carcinoma	110	1.3
Mucinous adenocarcinoma	26	0.3
Phyllodes tumor, malignant	20	0.2
Metaplastic carcinoma, NOS	16	0.2
others	39	0.4
Total	8,708	100%




Figure 12: Distribution of Breast Cancer (ASR*) Among Females by Governorates, Iraq, 2023.

Colorectal Cancer

Colorectal cancer was the second most common cancer after breast cancer in Iraq. There were 3,108 cases of colorectal cancer accounting for 7.2% of all newly diagnosed cases in the year 2023 among Iraqis. It affected 1,606 (51.7%) males and 1,502 (48.3%) females. The ASR was 14.3/100,000 for males and 12.0/100,000 for females. The five governorates with highest ASR were Erbil at 18.3/100000 followed by Karbala at 17.9/100000 then Al-Sulaimaniyah at 15.9/100000, at Al-Anbar 14.9/100000, and Al-Basrah at 14.6/100,000. The mean and the median at diagnosis was 58 years.

Figure 13: Age-Specific Incidence Rate (AIR) of Colorectal Cancer Among Iraqis, 2023.




Table 9: Morphological Distribution of Colorectal Cancer Among Iraqis, 2023

Morphology	Male	%	Female	%
Adenocarcinoma, NOS	1,584	98.6	1,474	98.1
Neuroendocrine carcinoma, NOS	8	0.5	13	0.9
Gastrointestinal stromal sarcoma	5	0.3	6	0.4
Others	9	0.6	9	0.6
Total	1,606	100%	1,502	100%




Figure 14: Distribution of Colorectal Cancer (ASR*) Among Iraqis by Governorates, 2023.

Lung Cancer

Lung cancer is the third most common cancer in Iraq and the first common cancer among males. There were 3,020 new cases reported in 2023. Lung cancer affected 2,129 cases among males accounting 70.5% of cases and 891 (29.5%) among females. Overall ASR was 14.4/100,000. The five governorates with the highest ASR were in Karbala 22.7 /100,000, followed by Al-Muthana at 22.2/100,000, then Al-Najaf at 21.9/100,000, Erbil at 20.8/100,000, and at Al-Qadisiya 19.2/100,000. the mean age at diagnosis was 66.9 and the median was 69 years.

Figure 15: Age-Specific Incidence Rate (AIR) of Lung Cancer Among Iraqis, 2023.




Table 10: Morphological Distribution of Lung Cancer Among Iraqis, 2023.

Morphology	Male	%	Female	%
Adenocarcinoma, NOS	995	46.7	500	56.1
Squamous cell carcinoma, NOS	757	35.6	262	29.4
Small cell carcinoma, NOS	287	13.5	72	8.1
Neuroendocrine carcinoma, NOS	41	1.9	29	3.3
Mesothelioma, malignant	20	0.9	12	1.3
Others	29	1.4	16	1.8
Total	2,129	100%	891	100%




Figure 16: Distribution Of Lung Cancer (ASR*) Among Iraqis by Governorates, 2023.

Thyroid Cancer

Thyroid cancer is the fourth most common cancer in Iraq. There were 2,823 new cases reported. Thyroid cancer affected 2,265 among females accounting (80.2%) and 558 (19.8%) among males. The overall ASR was 8.8/100,000. The five governorates with the highest ASR were Wasit governorate at 14.4/100,000, followed by Al-Anbar at 13.2/100,000, then Salah Al-Deen at 13.1/100,000, Karbala at 12.7/100,000 and Al-Najaf governorate at 12.5/100,000. The mean age at diagnosis was 42.9 and the median was 42 years.

Figure 17: Age-Specific Incidence Rate (AIR) of Thyroid Cancer Among Iraqis, 2023.




Table 11: Morphological Distribution of Thyroid Cancer Among Iraqis, 2023.

Morphology	Male	%	Female	%
Papillary adenocarcinoma, NOS	469	84.1	1,956	86.4
Follicular adenocarcinoma, NOS	53	9.5	247	10.9
Medullary carcinoma, NOS	21	3.8	27	1.2
Carcinoma, anaplastic, NOS	13	2.3	16	0.7
Others	2	0.4	19	0.8
Total	558	100%	2,265	100%




Figure 18: Distribution of Thyroid Cancer (ASR*) Among Iraqi by Governorates, 2023.

Brain, Central Nervous System

Brain, CNS is the fifth most common cancer in Iraq. There were 2,818 cases of brain, CNS accounting for 6.5% of all cancer cases diagnosed in Iraq in 2023. Brain, CNS affected 1,327 (47.1%) males and 1,491 (52.9%) females, The overall ASR was 9.4/100,000. The five governorates with the highest ASR were Karbala at 12.8/100,000 followed by Misan at 12.3/100,000 then Al-Basrah at 11.4/100,000, Al-Muthana at 11.3/100,000, and Baghdad at 10.6/100,000. The mean age at diagnosis was 42.7. and the median was 45 years.

Figure 19: Age-Specific Incidence Rate (AIR) of Brain, CNS Cancer Among Iraqis, 2023.




Table 12: Morphological Distribution of Brain Tumor, CNS Cancer Among Iraqis, 2023.

Morphology	Male	%	Female	%
Glioblastoma	425	32.0	351	23.5
Meningothelial meningioma	255	19.2	510	34.2
Astrocytoma, NOS	271	20.4	300	20.1
Pituitary neuroendocrine tumors	65	4.9	104	7.0
Medulloblastoma, NOS	89	6.7	51	3.4
Ependymoma, NOS	68	5.1	57	3.8
Oligodendroglioma, NOS	46	3.5	38	2.5
Craniopharyngioma	18	1.4	13	0.9
Germinoma	8	0.6	6	0.4
Chordoma, NOS	5	0.4	8	0.5
Pineoblastoma	6	0.5	3	0.2
others	71	5.4	50	3.4
Total	1,327	100%	1,491	100%




Figure 20: Distribution of Brain, CNS Cancer (ASR*) Among Iraqis by Governorates, 2023.

Bladder Cancer

Bladder is the sixth most common cancer in Iraq. There were 2,018 cases of Bladder cancer accounting for 4.7 % of all cancer cases diagnosed in Iraq in 2023. Bladder cancer affected 1,602 males accounting for (79.4 %) of cases and 416 of female 20.6 %. Overall ASR was 9.3 /100,000. The five governorates with the highest ASR were Karbala at 15.9 /100,000 followed by Al-Najaf at 15/100,000, then Misan at 13.7 /100,000, Al-Qadisiya at 12.6 /100,000, and Wasit at 12.5 /100,000. The mean age at diagnosis was 64.8 and the median 67 years.

Figure 21: Age-Specific Incidence Rate (AIR) of Bladder Cancer Among Iraqis, 2023.




Table 13: Morphological Distribution of Bladder Cancer Among Iraqis, 2023.

Morphology	Male	%	Female	%
Transitional cell carcinoma	1,451	90.6	366	88.0
Carcinoma, NOS	73	4.6	25	6.0
Adenocarcinoma, NOS	40	2.5	18	4.3
Squamous cell carcinoma, NOS	28	1.7	6	1.4
Others	10	0.6	1	0.2
Total	1,602	100%	416	100%




Figure 22: Distribution of Bladder Cancer (ASR*) Among Iraqis by Governorates, 2023.

Leukemia

Leukemia is the seventh most common cancer in Iraq. There were 1,887 cases accounting for 4.4 % of all cancer cases in Iraq. 1014 cases among males accounting for 53.7 % of all cases. and 873 (46.3 %) among females. Overall ASR was 6.0 /100,000. The five governorates with the highest ASR were Al-Najaf 13.1/100,000, followed by Karbala at 9.7/100,000, then Erbil at 8/100,000, Al-Qadisiya at 7.3/100,000 and Al-Muthana 7.3/100000. The mean and the median age at diagnosis was 38 years.

Figure 23: Age-Specific Incidence Rate (AIR) of Leukemia Cancer Among Iraqis, 2023.




Table 14: Morphological Distribution of Leukemia Among Iraqis, 2023.

Morphology	Male	%	Female	%
Acute myeloid leukaemia	421	41.5	416	47.7
Hairy cell leukemia	10	1.0	0	0.0
Chronic Lymphocytic leukemia	114	11.2	69	7.9
Myeloproliferative disorder	144	14.2	126	14.4
Precursor cell lymphoblastic leukemia	310	30.6	247	28.3
Others	15	1.5	15	1.7
Total	1,014	100%	873	100%




Figure 24: Distribution of Leukemia (ASR*) Among Iraqis by Governorates, 2023.

Prostate Cancer

Prostate cancer is second most common cancer among Iraqi males. There were 1656 cases of prostate cancer accounting for 9.2% of all cancer cases diagnosed among males. The overall ASR was 17.6/100,000. The five governorates with the highest ASR were in Erbil at 31.2/100,000 followed by Al-Sulaimaniyah at 21.1 /100,000 then Al-Anbar at 20.9/100,000, Al-Qadisiya at 20.5 /100,000, and Karbala at 20.2 /100,000. The mean age at diagnosis was 71.9 and the median age 72 years.

Figure 25: Age-Specific Incidence Rate (AIR) of Prostate Cancer Among Iraqis, 2023.




Table 15: Morphological Distribution of Prostate Cancer Among Iraqis, 2023.

Morphology	No.	%
Adenocarcinoma, NOS	1,646	99.4
neuroendocrine carcinoma	3	0.2
Others	7	0.4
Total	1,656	100%




Figure 26: Distribution of Prostate Cancer (ASR*) Among Iraqi by Governorates, 2023.

Skin Cancer Including Non-Melanoma

Skin cancer is the ninth most common cancer in Iraq. There were 1528 cases accounting for 3.5% of all cancer cases diagnosed in Iraq in 2023. skin cancer affected 831 males accounting for (54.4%) of cases and 697 (45.6%). Overall ASR was 6.7/100,000. The five governorates with the highest ASR were Erbil 22.6 /100,000 followed by Duhok at 10.6 /100,000 then Wasit at 10.6/100,000, Al-Najaf at 9.6 /100,000 and Diyala at 8.3 /100,000. The mean age at diagnosis was 61.5 and the median was 63 years.

Figure 27: Age-Specific Incidence Rate (AIR) of Skin Cancer Among Iraqis, 2023.




Table 16: Morphological Distribution of Skin Cancer Among Iraqis, 2023.

Morphology	Male	%	Female	%
Basal cell carcinoma, NOS	406	48.9	373	53.5
Squamous cell carcinoma, NOS	281	33.8	190	27.3
Malignant melanoma, NOS	76	9.1	79	11.3
Sarcoma, NOS	21	2.5	17	2.4
Skin appendage carcinoma	12	1.4	16	2.3
Kaposi sarcoma	23	2.8	5	0.7
Others	12	1.4	17	2.4
Total	831	100%	697	100%




Figure 28: Distribution of Skin Cancer (ASR*) Among Iraqi by Governorates, 2023.
Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma (NHL) is tenth most common cancer in Iraq. There were 1442 cases accounting for 3.3% of all new cancer cases diagnosed in 2023. NHL affected 807 (56%) males, and 635 (44%) females. Overall ASR was 5.5/100,000. The five governorates with the highest ASR were Karbala 8.6/100,000 followed by Al-Najaf at 7.7/100,000, then Al-Basrah at 7.6/100,000, Erbil at 7.5 /100,000, and Babil at 6.6/100,000. The mean age was 51.3 years and the median 55 years.

Figure 29: Age-Specific Incidence Rate (AIR) of Non-Hodgkin Lymphoma Among Iraqis, 2023.




Table 17: Morphological Distribution of Non-Hodgkin Lymphoma Among Iraqis, 2023.

Morphology	Male	%	Female	%
Diffuse large B -cell Non-Hodgkin lymphoma	287	35.6	249	39.2
B-cell Non-Hodgkin lymphoma	274	34.0	254	40.0
Mature T-cell Non-Hodgkin lymphoma	134	16.6	56	8.8
Burkitt lymphoma, NOS	30	3.7	13	2.0
Marginal zone B-cell lymphoma, NOS	17	2.1	21	3.3
Composite Hodgkin and non-Hodgkin lymphoma	18	2.2	20	3.1
Precursor T-cell lymphoblastic lymphoma	28	3.5	9	1.4
Follicular Lymphoma	19	2.4	13	2.0
Total	807	100%	635	100%




Figure 30: Distribution of Non-Hodgkin Lymphoma (ASR*) Among Iraqis by Governorates, 2023.

PART 4

CANCER INCIDENCE

IN GOVERNORATES

Distribution of Cancer Incidence in Governorate

4.1. Erbil Governorate


Erbil governorate reported 3030 newly diagnosed cases of cancer, 1366 (45.1%) among males and 1664 (54.9%) among females. Breast cancer was the most common cancer 669 (22.1%), followed by skin 270 (8.9%), colorectal 227 (7.5%), lung 225 (7.4%) and Prostate 158 (5.2%). Lung cancer was the most common cancer among males 173 cases IR 16.3/100,000 and breast cancer was the most common cancer among female 650 cases IR 62.3/100,000.

Table 18: Top Ten Cancers at Erbil Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	669	22.1
Skin, other	270	8.9
Colorectal	227	7.5
Bronchus & Lung	225	7.4
Prostate	158	5.2
Leukemia	127	4.2
Thyroid	124	4.1
Bladder	121	4.0
Brain, CNS	115	3.8
Kidney	99	3.3
Total Top Ten	2135	70.5
Total Other Sites	895	29.5
Total All Sites	3030	100

Table 19: Top Ten Cancers at Erbil Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	173	12.7	Breast	650	39.1
Prostate	158	11.6	Skin, other	127	7.6
Skin, other	143	10.5	Colorectal	98	5.9
Colorectal	129	9.4	Thyroid	94	5.6
Bladder	104	7.6	Ovary	68	4.1
Leukemia	75	5.5	Brain, CNS	59	3.5
Non-Hodgkin Lymphoma	61	4.5	Bronchus & Lung	52	3.1
Brain, CNS	56	4.1	Leukemia	52	3.1
Kidney	55	4.0	Corpus Uteri	44	2.6
Stomach	54	4.0	Kidney	44	2.6
Total Top Ten	1008	73.8	Total Top Ten	1288	77.4
Total Other Sites	358	26.2	Total Other Sites	376	22.6
Total All Sites	1366	100%	Total All Sites	1664	100%



All (3030 Cases) Erbil Governorate



Male (1366 Cases) Erbil Governorate



Female (1664 Cases) Erbil Governorate

Figure 31: Crude Incidence Rate Top Ten Cancers at Erbil Governorate, Iraq, 2023.

4.2. Karbala Governorate


Karbala governorate reported 1737 newly diagnosed cases of cancer, 698 (40.2%) among males and 1039 (59.8%) among females. Breast cancer was the most common cancer 342 cases (19.7%) followed by lung 138 (7.9%) then thyroid 131 (7.5%), colorectal 127 (7.3%) and brain, CNS 113 (6.5%). Lung cancer was the most common cancer among males 93 cases IR 13.3/100,000 and breast cancer was the most common cancer among female 334 cases IR 48.7/100,000.

Table 20: Top Ten Cancers at Karbala Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	342	19.7
Bronchus & Lung	138	7.9
Thyroid	131	7.5
Colorectal	127	7.3
Brain, CNS	113	6.5
Bladder	99	5.7
Leukemia	85	4.9
Non-Hodgkin Lymphoma	65	3.7
Pancreas	64	3.7
Kidney	58	3.3
Total Top Ten	1222	70.4
Total Other Sites	515	29.6
Total All Sites	1737	100

Table 21: Top Ten Cancers at Karbala Governorate, By Gender, Iraq,2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	93	13.3	Breast	334	32.1
Bladder	71	10.2	Thyroid	104	10.0
Colorectal	62	8.9	Colorectal	65	6.3
Prostate	54	7.7	Brain, CNS	64	6.2
Brain, CNS	49	7.0	Uterus Unspecified	46	4.4
Leukemia	43	6.2	Bronchus & Lung	45	4.3
Non-Hodgkin Lymphoma	38	5.4	Leukemia	42	4.0
Kidney	36	5.2	Ovary	30	2.9
Pancreas	35	5.0	Skin, other	30	2.9
Thyroid	27	3.9	Pancreas	29	2.8
Total Top Ten	508	72.8	Total Top Ten	789	75.9
Total Other Sites	190	27.2	Total Other Sites	250	24.1
Total All Sites	698	100%	Total All Sites	1039	100%



All (1737 Cases) Karbala Governorate



Male (698 Cases) Karbala Governorate



Female (1039 Cases) Karbala Governorate

Figure 32: Crude Incidence Rate of Top Ten Cancers at Karbala Governorate, Iraq, 2023

4.3. Al-Najaf Governorate


Al-Najaf governorate reported 2007 newly diagnosed cases of cancer, 869 (43.3%) among males and 1138 (56.7%) among females. Breast cancer was the most common cancer 355 cases followed by lung 164 (8.2%) then thyroid 158 (7.9%), leukemia 134 (6.7%) and bladder 118 (5.9%). Lung cancer was the most common cancer among males 113 cases, IR 13.5/100,000 while breast cancer was the most common cancer among females 346 cases, IR 41.5/100,000.

Table 22: Top Ten Cancers at Al - Najaf Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	355	17.7
Bronchus & Lung	164	8.2
Thyroid	158	7.9
Leukemia	134	6.7
Bladder	118	5.9
Brain, CNS	117	5.8
Colorectal	105	5.2
Kidney	79	3.9
Skin, other	78	3.9
Non-Hodgkin Lymphoma	73	3.6
Total Top Ten	1381	68.8
Total Other Sites	626	31.2
Total All Sites	2007	100

Table 23: Top Ten Cancers at Al-Najaf Governorate, By Gender, Iraq, 2023.


Top ten	Male	%	Top ten	Female	%
Bronchus & Lung	113	13.0	Breast	346	30.4
Bladder	94	10.8	Thyroid	127	11.2
Leukemia	66	7.6	Leukemia	68	6.0
Prostate	61	7.0	Brain, CNS	57	5.0
Brain, CNS	60	6.9	Ovary	55	4.8
Colorectal	53	6.1	Colorectal	52	4.6
Skin, other	47	5.4	Bronchus & Lung	51	4.5
Kidney	46	5.3	Kidney	33	2.9
Non-Hodgkin Lymphoma	44	5.1	Pancreas	33	2.9
Pancreas	39	4.5	Skin, other	31	2.7
Total Top Ten	623	71.7	Total Top Ten	853	75.0
Total Other Sites	246	28.3	Total other Sites	285	25.0
Total All Sites	869	100%	Total all sites	1138	100%



All (2007 Cases) Al-Najaf Governorate



Male (869 Cases) Al-Najaf



Female (1138 Cases) Al-Najaf

Figure 33: Crude Incidence Rate of Top Ten Cancers at Al- Najaf Governorate, Iraq, 2023.

4.4. Baghdad Governorate


Baghdad governorate reported 11071 newly diagnosed cases of cancer, 4264 (38.5%) among males and 6807 (61.5%) among females. Breast cancer was the most common cancer 2709 cases (24.5%) followed by colorectal 830 (7.5%) then brain, CNS 761 (6.9%), thyroid 756 (6.8%) and lung 637 (5.8%). lung cancer was the most common cancer among males 432 cases IR 9.2/100,000 and breast cancer was the most common cancer among female 2675 cases IR 58.6/100,000.

Table 24: Top Ten Cancers at Baghdad Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	2709	24.5
Colorectal	830	7.5
Brain, CNS	761	6.9
Thyroid	756	6.8
Bronchus & Lung	637	5.8
Bladder	437	3.9
Prostate	408	3.7
Leukemia	353	3.2
Pancreas	335	3.0
Kidney	335	3.0
Total Top Ten	7561	68.3
Total other Sites	3510	31.7
Total all sites	11071	100

Table 25: Top Ten Cancers at Baghdad Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	432	10.1	Breast	2675	39.3
Colorectal	408	9.6	Thyroid	610	9.0
Prostate	408	9.6	Colorectal	422	6.2
Brain, CNS	342	8.0	Brain, CNS	419	6.2
Bladder	332	7.8	Ovary	271	4.0
Kidney	224	5.3	Corpus Uteri	233	3.4
Leukemia	206	4.8	Bronchus & Lung	205	3.0
Pancreas	186	4.4	Uterus Unspecified	202	3.0
Skin, other	185	4.3	Pancreas	149	2.2
Non-Hodgkin Lymphoma	165	3.9	Leukemia	147	2.2
Total Top Ten	2888	67.7	Total Top Ten	5333	78.3
Total other Sites	1376	32.3	Total other Sites	1474	21.7
Total all sites	4264	100%	Total all sites	6807	100%



All (11071 Cases) Baghdad Governorate



Male (4264 Cases) Baghdad Governorate



Female (6807 Cases) Baghdad Governorate

Figure 34: Crude Incidence Rate of Top Ten Cancers at Baghdad Governorate, Iraq, 2023.

4.5. Al-Sulaimaniyah Governorate


Al- Sulaimaniyah governorate reported 2796 newly diagnosed cases of cancer, 1305 (46.7%) among males and 1491 (53.3%) among females. Breast cancer was the most common cancer 533 cases (19.1%) followed by colorectal 266 (9.5%) then lung 172 (6.2%) and Chronic Myeloproliferative Disorders 168 (6%). Prostate cancer was the most common cancer among males 152 cases IR 12.4/100,000 and breast cancer was the most common cancer among female 528 cases IR 43/100,000.

Table 26: Top Ten Cancers at Al-Sulaimaniyah Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	533	19.1
Colorectal	266	9.5
Bronchus & Lung	172	6.2
Chronic Myeloproliferative Disorders	168	6.0
Prostate	152	5.4
Brain, CNS	136	4.9
Thyroid	125	4.5
Non-Hodgkin Lymphoma	111	4.0
Bladder	107	3.8
Leukemia	94	3.4
Total Top Ten	1864	66.7
Total other Sites	932	33.3
Total all sites	2796	100

Table 27: Top Ten Cancers at Al-Sulaimaniyah Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Prostate	152	11.6	Breast	528	35.4
Colorectal	144	11.0	Colorectal	122	8.2
Bronchus & Lung	128	9.8	Thyroid	89	6.0
Chronic Myeloproliferative Disorders	114	8.7	Ovary	66	4.4
Bladder	89	6.8	Brain, CNS	65	4.4
Brain, CNS	71	5.4	Chronic Myeloproliferative Disorders	54	3.6
Non-Hodgkin Lymphoma	67	5.1	Bronchus & Lung	44	3.0
Stomach	53	4.1	Leukemia	44	3.0
Leukemia	50	3.8	Non-Hodgkin Lymphoma	44	3.0
Kidney	41	3.1	Corpus Uteri	43	2.9
Total Top Ten	909	69.7	Total Top Ten	1099	73.7
Total other Sites	396	30.3	Total other Sites	392	26.3
Total all sites	1305	100%	Total all sites	1491	100%



All (2796 Cases) Al- Sulaimaniyah Governorate



Male (1305 Cases) Al- Sulaimaniyah Governorate



Female (1491 Cases) Al- Sulaimaniyah Governorate

Figure 35: Crude Incidence Rate of Top Ten Cancers at Al-Sulaimaniyah Governorate, Iraq, 2023.

4.6. Al-Basrah Governorate


Al-Basrah governorate reported 3495 newly diagnosed cases of cancer, 1504 (43 %) among males and 1991 (57%) among females. Breast cancer was the most common cancer 636 cases (18.2%) followed by colorectal 257 (7.4%) then brain, CNS 250 (7.2%), lung 195 (5.6%) and bladder 182 (5.2%). Bladder cancer was the most common cancer among males 157 cases IR 9.5/100,000 and breast cancer was the most common cancer among female 631 cases IR 38.4/100,000.

Table 28: Top Ten Cancers at Al-Basrah Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	636	18.2
Colorectal	257	7.4
Brain, CNS	250	7.2
Bronchus & Lung	195	5.6
Bladder	182	5.2
Thyroid	166	4.7
Leukemia	150	4.3
Non-Hodgkin Lymphoma	138	3.9
Prostate	130	3.7
Kidney	121	3.5
Total Top Ten	2225	63.7
Total other Sites	1270	36.3
Total all sites	3495	100

Table 29: Top Ten Cancers at Al-Basrah Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bladder	157	10.4	Breast	631	31.7
Bronchus & Lung	147	9.8	Thyroid	131	6.6
Colorectal	140	9.3	Brain, CNS	129	6.5
Prostate	130	8.6	Colorectal	117	5.9
Brain, CNS	121	8.0	Ovary	108	5.4
Leukemia	86	5.7	Uterus Unspecified	108	5.4
Non-Hodgkin Lymphoma	72	4.8	Non-Hodgkin Lymphoma	66	3.3
Kidney	72	4.8	Leukemia	64	3.2
Pancreas	67	4.5	Stomach	59	3.0
Skin, other	51	3.4	Kidney	49	2.5
Total Top Ten	1043	69.3	Total Top Ten	1462	73.4
Total other Sites	461	30.7	Total other Sites	529	26.6
Total all sites	1504	100%	Total all sites	1991	100%



All (3495 Cases) Al-Basrah Governorate



Male (1504 Cases) Al-Basrah Governorate



Female (1991 Cases) Al-Basrah Governorate

Figure 36: Crude Incidence Rate of Top Ten Cancers at Al-Basrah Governorate, Iraq, 2023.

4.7. Babil Governorate


Babil governorate reported 2145 newly diagnosed cases of cancer, 891 (41.5 %) among males and 1254 (58.5 %) among females. Breast cancer was the most common cancer 402 cases (18.7 %) followed by thyroid 181 (8.4%) then lung 166 (7.7%), brain, CNS 161 (7.5%) and Bladder 126 (5.9%). Lung cancer was the most common cancer among males 96 cases IR 8.1/100,000 and breast cancer was the most common cancer among female 392 cases IR 33.8/100,000.

Table 30: Top Ten Cancers at Babil Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	402	18.7
Thyroid	181	8.4
Bronchus & Lung	166	7.7
Brain, CNS	161	7.5
Bladder	126	5.9
Colorectal	108	5.0
Leukemia	93	4.3
Non-Hodgkin Lymphoma	83	3.9
Prostate	79	3.7
Kidney	68	3.2
Total Top Ten	1467	68.4
Total other Sites	678	31.6
Total all sites	2145	100

Table 31: Top Ten Cancers at Babil Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	96	10.8	Breast	392	31.3
Bladder	94	10.5	Thyroid	145	11.6
Prostate	79	8.9	Brain, CNS	93	7.4
Brain, CNS	68	7.6	Bronchus & Lung	70	5.6
Colorectal	61	6.8	Uterus Unspecified	56	4.5
Leukemia	53	5.9	Colorectal	47	3.7
Kidney	52	5.8	Ovary	46	3.7
Non-Hodgkin Lymphoma	46	5.2	Leukemia	40	3.2
Thyroid	36	4.0	Non-Hodgkin Lymphoma	37	3.0
Skin, other	36	4.0	Bladder	32	2.6
Total Top Ten	621	69.7	Total Top Ten	958	76.4
Total other Sites	270	30.3	Total other Sites	296	23.6
Total all sites	891	100%	Total all sites	1254	100%



All (2145 Cases) Babil Governorate



Male (891 Cases) Babil Governorate



Female (1254 Cases) Babil Governorate

Figure 37: Crude Incidence Rate of Top Ten Cancers at Babil Governorate, Iraq, 2023.

2.8. Diyala Governorate


Diyala governorate reported 1672 newly diagnosed cases of cancer, 630 (37.7%) among males and 1042 (62.3%) among females. Breast cancer was the most common cancer 369 cases (22.1%) followed by lung 124 (7.4%) then brain, CNS 117 (7%), colorectal 109 (6.5%) and thyroid 99 (5.9%). Lung cancer was the most common cancer among males 92 cases IR 10/100,000 and breast cancer was the most common cancer among female 366 cases IR 40.4/100,000.

Table 32: Top Ten Cancers at Diyala Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	369	22.1
Bronchus & Lung	124	7.4
Brain, CNS	117	7.0
Colorectal	109	6.5
Thyroid	99	5.9
Skin, other	80	4.8
Prostate	78	4.7
Leukemia	67	4.0
Stomach	62	3.7
Bladder	54	3.2
Total Top Ten	1159	69.3
Total Other Sites	513	30.7
Total All Sites	1672	100

Table 33: Top Ten Cancers at Diyala Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	92	14.6	Breast	366	35.1
Prostate	78	12.4	Thyroid	83	8.0
Colorectal	51	8.1	Brain, CNS	71	6.8
Brain, CNS	46	7.3	Colorectal	58	5.6
Bladder	42	6.7	Ovary	50	4.8
Skin, other	42	6.7	Skin, other	38	3.6
Leukemia	30	4.8	Stomach	38	3.6
Pancreas	28	4.4	Leukemia	37	3.6
Kidney	24	3.8	Bronchus & Lung	32	3.1
Stomach	24	3.8	Uterus Unspecified	31	3.0
Total Top Ten	457	72.5	Total Top Ten	804	77.2
Total Other Sites	173	27.5	Total Other Sites	238	22.8
Total All Sites	630	100%	Total All Sites	1042	100%



All (1672 Cases) Diyala Governorate



Male (630 Cases) Diyala Governorate



Female (1042 Cases) Diyala Governorate

Figure 38: Crude Incidence Rate of Top Ten Cancers at Diyala Governorate, Iraq, 2023.

4.9. Wasit Governorate


Wasit governorate reported 1423 newly diagnosed cases of cancer, 597 (42%) among males and 826 (58 %) among females. Breast cancer was the most common cancer 261 cases (18.3%) followed by thyroid 154 (10.8%) then lung 93 (6.5%), colorectal 92 (6.5%) and bladder 90 (6.3%). Bladder cancer was the most common cancer among males 69 cases IR 8.7/100,000 and breast cancer was the most common cancer among female 257 cases IR 33.1/100,000.

Table 34: Top Ten Cancers at Wasit Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	261	18.3
Thyroid	154	10.8
Bronchus & Lung	93	6.5
Colorectal	92	6.5
Bladder	90	6.3
Brain, CNS	86	6.0
Skin, other	80	5.6
Kidney	56	3.9
Leukemia	54	3.8
Non-Hodgkin Lymphoma	49	3.4
Total Top Ten	1015	71.3
Total Other Sites	408	28.7
Total All Sites	1423	100

Table 35: Top Ten Cancers at Wasit Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bladder	69	11.6	Breast	257	31.1
Bronchus & Lung	65	10.9	Thyroid	121	14.6
Colorectal	47	7.9	Brain, CNS	46	5.6
Prostate	45	7.5	Colorectal	45	5.4
Brain, CNS	40	6.7	Skin, other	43	5.2
Skin, other	37	6.2	Ovary	36	4.4
Thyroid	33	5.5	Leukemia	30	3.6
Kidney	32	5.4	Bronchus & Lung	28	3.4
Non-Hodgkin Lymphoma	32	5.4	Uterus Unspecified	28	3.4
Pancreas	26	4.4	Kidney	24	2.9
Total Top Ten	426	71.4	Total Top Ten	658	79.7
Total Other Sites	171	28.6	Total Other Sites	168	20.3
Total All Sites	597	100%	Total All Sites	826	100%



All (1423 Cases) Wasit Governorate



Male (597 Cases) Wasit Governorate



Female (826 Cases) Wasit Governorate

Figure 39: Crude Incidence Rate of Top Ten Cancers at Wasit Governorate, Iraq ,2023.

4.10. Al-Qadisiya Governorate


Al-Qadisiya governorate reported 1320 newly diagnosed cases of cancer, 596 (45.2%) among males and 724 (54.8%) among females. Breast cancer was the most common cancer 199 cases (15.1%) followed by lung 127 (9.6%) then thyroid 117 (8.9%), colorectal 89 (6.7%) and brain, CNS 88 (6.7%). Lung cancer was the most common cancer among males 82 cases IR 11.1/100,000 and breast cancer was the most common cancer among female 194 cases IR 26.7/100,000.

Table 36: Top Ten Cancers at Al-Qadisiya Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	199	15.1
Bronchus & Lung	127	9.6
Thyroid	117	8.9
Colorectal	89	6.7
Brain, CNS	88	6.7
Bladder	84	6.4
Leukemia	72	5.5
Prostate	57	4.3
Kidney	56	4.2
Non-Hodgkin Lymphoma	52	3.9
Total Top Ten	941	71.3
Total Other Sites	379	28.7
Total All Sites	1320	100

Table 37: Top Ten Cancers at Al-Qadisiya Governorate, By Genders, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	82	13.8	Breast	194	26.8
Bladder	71	11.9	Thyroid	100	13.8
Prostate	57	9.6	Brain, CNS	48	6.6
Leukemia	49	8.2	Bronchus & Lung	45	6.2
Colorectal	48	8.1	Colorectal	41	5.7
Brain, CNS	40	6.7	Uterus Unspecified	39	5.4
Kidney	33	5.5	Skin, other	26	3.6
Non-Hodgkin Lymphoma	27	4.5	Non-Hodgkin Lymphoma	25	3.5
Skin, other	19	3.2	Leukemia	23	3.2
Liver	18	3.0	Kidney	23	3.2
Total Top Ten	444	74.5	Total Top Ten	564	77.9
Total Other Sites	152	25.5	Total Other Sites	160	22.1
Total All Sites	596	100%	Total All Sites	724	100%



All (1320 Cases) Al-Qadisiya Governorate



Male (596 Cases) Al-Qadisiya Governorate



Female (724 Cases) Al-Qadisiya Governorate

Figure 40: Crude Incidence Rate of Top Ten Cancers at Al-Qadisiya Governorate, Iraq, 2023.

4.11. Misan Governorate


Misan governorate reported 1088 newly diagnosed cases of cancer, 497 (45.7%) among males and 591 (54.3%) among females. Breast cancer was the most common cancer 175 cases (16.1 %) followed by Brain, CNS 97 (8.9%) then bladder 82 (7.5%), thyroid 75 (6.9%) and colorectal 74 (6.8%). Bladder cancer was the most common cancer among males 68 cases IR 10.8/100,000 and breast cancer was the most common cancer among female 173 cases IR 27.3/100,000.

Table 38: Top Ten Cancers at Misan Governorate, Both Genders, Iraq, 2023.


Site	NO.	%
Breast	175	16.1
Brain, CNS	97	8.9
Bladder	82	7.5
Thyroid	75	6.9
Colorectal	74	6.8
Bronchus & Lung	73	6.7
Leukemia	55	5.1
Non-Hodgkin Lymphoma	38	3.5
Prostate	38	3.5
Stomach	37	3.4
Total Top Ten	744	68.4
Total Other Sites	344	31.6
Total All Sites	1088	100

Table 39: Top Ten Cancers at Misan Governorate, By Gender, Iraq, 2023.


Site	No.	%	Female	No.	%
Bladder	68	13.7	Breast	173	29.3
Bronchus & Lung	54	10.9	Thyroid	61	10.3
Brain, CNS	44	8.9	Brain, CNS	53	9.0
Colorectal	40	8.0	Colorectal	34	5.8
Prostate	38	7.6	Uterus Unspecified	28	4.7
Leukemia	30	6.0	Leukemia	25	4.2
Non-Hodgkin Lymphoma	19	3.8	Ovary	21	3.6
Stomach	19	3.8	Bronchus & Lung	19	3.2
Kidney	18	3.6	Non-Hodgkin Lymphoma	19	3.2
Pancreas	18	3.6	Stomach	18	3.0
Total Top Ten	348	70.0	Total Top Ten	451	76.3
Total Other Sites	149	30.0	Total Other Sites	140	23.7
Total All Sites	497	100%	Total	591	100%



All (1088 Cases) Misan Governorate



Male (497 Cases) Misan Governorate



Female (591 Cases) Misan Governorate

Figure 41: Crude Incidence Rate of Top Ten Cancers at Misan Governorate, Iraq, 2023.

4.12. Al-Muthana Governorate


Al-Muthana governorate reported 783 newly diagnosed cases of cancer, 368 (47 %) among males and 415 (53%) among females. Breast cancer was the most common cancer 108cases (13.8%) followed by lung 93 (11.9%) then brain, CNS 66 (8.4%), leukemia 48 (6.1%) and thyroid 47 (6%). Lung cancer was the most common cancer among males 59 cases IR 12.7/100,000 and breast cancer was the most common cancer among female 106 cases IR 23/100,000.

Table 40: Top Ten Cancers at Al-Muthana Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	108	13.8
Bronchus & Lung	93	11.9
Brain, CNS	66	8.4
Leukemia	48	6.1
Thyroid	47	6.0
Bladder	46	5.9
Colorectal	39	5.0
Pancreas	32	4.1
Non-Hodgkin Lymphoma	28	3.6
Stomach	26	3.3
Total Top Ten	533	68.1
Total Other Sites	250	31.9
Total All Sites	783	100

Table 41: Top Ten Cancers at Al-Muthana Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	59	16.0	Breast	106	25.5
Brain, CNS	39	10.6	Thyroid	35	8.4
Bladder	34	9.2	Bronchus & Lung	34	8.2
Colorectal	23	6.3	Brain, CNS	27	6.5
Leukemia	23	6.3	Leukemia	25	6.0
Prostate	22	6.0	Pancreas	19	4.6
Hodgkin Lymphomas	18	4.9	Colorectal	16	3.9
Non-Hodgkin Lymphoma	16	4.3	Ovary	15	3.6
Stomach	16	4.3	Liver	14	3.4
Skin, other	15	4.1	Kidney	12	2.9
Total Top Ten	265	72.0	Total Top Ten	303	73.0
Total Other Sites	103	28.0	Total Other Sites	112	27.0
Total All Sites	368	100%	Total All Sites	415	100%



All (783 Cases) Al-Muthana Governorate



Male (368 Cases) Al-Muthana Governorate



Female (415 Cases) Al-Muthana Governorate

Figure 42: Crude Incidence Rate of Top Ten Cancers at Al-Muthana Governorate, Iraq, 2023.

4.13. Duhok Governorate


Duhok governorate reported 1186 newly diagnosed cases of cancer, 558 (47%) among males and 628 (53%) among females. Breast cancer was the most common cancer 250 cases (21.1%) followed by lung 110 (9.3%) then colorectal 101 (8.5%), skin 75 (6.3%) and leukemia 66 (5.6%). Lung cancer was the most common cancer among males 98 cases IR 13.3/100,000 and breast cancer was the most common cancer among female 248 cases IR 33.8/100,000.

Table 42: Top Ten Cancers at Duhok Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	250	21.1
Bronchus & Lung	110	9.3
Colorectal	101	8.5
Skin, other	75	6.3
Leukemia	66	5.6
Prostate	53	4.5
Brain, CNS	51	4.3
Thyroid	50	4.2
Non-Hodgkin Lymphoma	48	4.0
Bladder	45	3.8
Total Top Ten	849	71.6
Total Other Sites	337	28.4
Total All Sites	1186	100

Table 43: Top Ten Cancers at Duhok Governorate, By Gender, Iraq, 2023.


Male	No	%	Female	No	%
Bronchus & Lung	98	17.6	Breast	248	39.5
Prostate	53	9.5	Colorectal	50	8.0
Colorectal	51	9.1	Thyroid	38	6.1
Skin, other	39	7.0	Leukemia	38	6.1
Bladder	39	7.0	Skin, other	36	5.7
Brain, CNS	31	5.6	Ovary	24	3.8
Non-Hodgkin Lymphoma	31	5.6	Brain, CNS	20	3.2
Leukemia	28	5.0	Non-Hodgkin Lymphoma	17	2.7
Stomach	21	3.8	Uterus Unspecified	17	2.7
Pancreas	17	3.0	Stomach	15	2.4
Total Top Ten	408	73.1	Total Top Ten	503	80.1
Total Other Sites	150	26.9	Total Other Sites	125	19.9
Total All Sites	558	100%	Total	628	100%



All (1186 Cases) Duhok Governorate



Male (558 Cases) Duhok Governorate



Female (628 Cases) Duhok Governorate

Figure 43: Crude Incidence Rate of Top Ten Cancers at Duhok Governorate, Iraq, 2023.

4.14. Al-Anbar Governorate


Al-Anbar governorate reported 1514 newly diagnosed cases of cancer, 631 (41.7%) among males and 883 (58.3%) among females. Breast cancer was the most common cancer 278 cases (18.4%) followed by thyroid 175 (11.6%) then colorectal 137(9%), brain, CNS 105 (6.9%) and lung 89 (5.9%). Colorectal cancer was the most common cancer among males 80 cases IR 7.7/100,000 and breast cancer was the most common cancer among female 274 cases IR 28/100,000.

Table 44: Top Ten Cancers at Al-Anbar Governorate, Both Genders, Iraq, 2023.


Top ten	NO	%
Breast	278	18.4
Thyroid	175	11.6
Colorectal	137	9.0
Brain, CNS	105	6.9
Bronchus & Lung	89	5.9
Prostate	68	4.5
Leukemia	61	4.0
Non-Hodgkin Lymphoma	57	3.8
Bladder	54	3.6
Stomach	47	3.1
Total Top Ten	1071	70.7
Total Other Sites	443	29.3
Total All Sites	1514	100

Table 45: Crude Top Ten Cancers at Al-Anbar Governorate, By Gender, Iraq, 2023.


Male	No	%	Female	No	%
Colorectal	80	12.7	Breast	274	31.0
Prostate	68	10.8	Thyroid	144	16.3
Bronchus & Lung	61	9.7	Colorectal	57	6.5
Brain, CNS	54	8.6	Brain, CNS	51	5.8
Bladder	40	6.3	Ovary	41	4.6
Thyroid	31	4.9	Leukemia	30	3.4
Leukemia	31	4.9	Non-Hodgkin Lymphoma	30	3.4
Stomach	28	4.4	Bronchus & Lung	28	3.2
Non-Hodgkin Lymphoma	27	4.3	Uterus Unspecified	21	2.4
Hodgkin Lymphomas	27	4.3	Stomach	19	2.2
Total Top Ten	447	70.8	Total Top Ten	695	78.7
Total Other Sites	184	29.2	Total Other Sites	188	21.3
Total All Sites	631	100%	Total	883	100%



All (1514 Cases) Al-Anbar Governorate



Male (631 Cases) Al-Anbar Governorate



Female (883 Cases) Al-Anbar Governorate

Figure 44: Crude Incidence Rate of Top Ten Cancers at Al-Anbar Governorate, Iraq ,2023.

4.15. Nineveh Governorate


Nineveh governorate reported 3,058 newly diagnosed cases of cancer, 1,280 (41.9 %) among males and 1,778 (58.1 %) among females. Breast cancer was the most common cancer 652 cases (21.3%) followed by colorectal 225 (7.4%) then lung 218 (7.1%), leukemia 189 (6.2%) and Brain, CNS 187 (6.1%). Lung cancer was the most common cancer among males 160 cases IR 7.4/100,000 and breast cancer was the most common cancer among female 644 cases IR 31.1/100,000

Table 46: Top Ten Cancers at Nineveh Governorate, Both Genders, Iraq, 2023.


Site	NO.	%
Breast	652	21.3
Colorectal	225	7.4
Bronchus & Lung	218	7.1
Leukemia	189	6.2
Brain, CNS	187	6.1
Thyroid	119	3.9
Prostate	118	3.9
Bladder	118	3.9
Non-Hodgkin Lymphoma	101	3.3
Kidney	101	3.3
Total Top Ten	2,028	66.3
Total Other Sites	1,030	33.7
Total All Sites	3,058	100

Table 47: Top Ten Cancers at Nineveh Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	160	12.5	Breast	644	36.2
Prostate	118	9.2	Colorectal	121	6.8
Colorectal	104	8.1	Brain, CNS	103	5.8
Leukemia	104	8.1	Thyroid	97	5.5
Bladder	98	7.7	Ovary	89	5.0
Brain, CNS	84	6.6	Leukemia	85	4.8
Kidney	64	5.0	Bronchus & Lung	58	3.3
Stomach	53	4.1	Uterus Unspecified	58	3.3
Non-Hodgkin Lymphoma	52	4.1	Non-Hodgkin Lymphoma	49	2.8
Skin, other	52	4.1	Stomach	44	2.5
Total Top Ten	889	69.5	Total Top Ten	1,348	75.8
Total Other Sites	391	30.5	Total Other Sites	430	24.2
Total All Sites	1,280	100%	Total All Sites	1,778	100%



All (3,058 Cases) Nineveh Governorate



Male (1280 Cases) Nineveh Governorate



Female (1778 Cases) Nineveh Governorate

Figure 45: Crude Incidence Rate of Top Ten Cancers at Nineveh Governorate, Iraq ,2023

4.16. Salah Al-Deen Governorate


Salah Al-Deen governorate reported 1,304 newly diagnosed cases of cancer, 491 (37.7%) among males and 813 (62.3%) among females. Breast cancer was the most common cancer 271 cases (20.8%) followed by thyroid 156 (12%) then lung 95 (7.3%), brain, CNS 90 (6.9%) and colorectal 81 (6.2%). Lung cancer was the most common cancer among males 61 cases IR 6.7/100,000 and breast cancer was the most common cancer among female 269 cases IR 30/100,000.

Table 48: Top Ten Cancers at Salah Al-Deen Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	271	20.8
Thyroid	156	12.0
Bronchus & Lung	95	7.3
Brain, CNS	90	6.9
Colorectal	81	6.2
Bladder	52	4.0
Leukemia	50	3.8
Prostate	48	3.7
Skin, other	43	3.3
Kidney	39	3.0
Total Top Ten	925	70.9
Total Other Sites	379	29.1
Total All Sites	1,304	100

Table 49: Top Ten Cancers at Salah Al-Deen Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	61	12.4	Breast	269	33.1
Prostate	48	9.8	Thyroid	133	16.4
Colorectal	41	8.4	Brain, CNS	53	6.5
Bladder	39	7.9	Colorectal	40	4.9
Brain, CNS	37	7.5	Bronchus & Lung	34	4.2
Kidney	28	5.7	Leukemia	30	3.7
Skin, other	25	5.1	Uterus Unspecified	28	3.4
Non-Hodgkin Lymphoma	24	4.9	Ovary	25	3.1
Thyroid	23	4.7	Pancreas	21	2.6
Leukemia	20	4.1	Skin, other	18	2.2
Total Top Ten	346	70.5	Total Top Ten	651	80.1
Total Other Sites	145	29.5	Total Other Sites	162	19.9
Total All Sites	491	100%	Total All Sites	813	100%



All (1304 Cases) Salah Al-Deen Governorate



Male (491 Cases) Salah Al-Deen Governorate



Female (813 Cases) Salah Al-Deen Governorate

Figure 46: Crude Incidence Rate of Top Ten Cancers at Salah Al-Deen Governorate, Iraq ,2023.

4.17. ThiQar Governorate


Thi Qar governorate reported 1,680 newly diagnosed cases of cancer, 773(46%) among males and 907 (54 %) among females. Breast cancer was the most common cancer 260 cases (15.5%) followed by lung 171 (10.2%) then brain, CNS 155(9.2%), bladder 114 (6.8%) and Thyroid 101(6 %). Lung cancer was the most common cancer among males 122 cases IR 10.2/100,000 and breast cancer was the most common cancer among female 248 cases IR 20.9/100,000.

Table 50: Top Ten Cancers at ThiQar Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	260	15.5
Bronchus & Lung	171	10.2
Brain, CNS	155	9.2
Bladder	114	6.8
Thyroid	101	6.0
Leukemia	100	6.0
Colorectal	95	5.7
Non-Hodgkin Lymphoma	68	4.0
Pancreas	67	4.0
Kidney	57	3.4
Total Top Ten	1,188	70.7
Total Other Sites	492	29.3
Total All Sites	1,680	100

Table 51: Top Ten Cancers at ThiQar Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	122	15.8	Breast	248	27.3
Bladder	89	11.5	Thyroid	79	8.7
Brain, CNS	79	10.2	Brain, CNS	76	8.4
Leukemia	50	6.5	Leukemia	50	5.5
Colorectal	47	6.1	Bronchus & Lung	49	5.4
Pancreas	40	5.2	Colorectal	48	5.3
Non-Hodgkin Lymphoma	34	4.4	Uterus Unspecified	36	4.0
Prostate	32	4.1	Non-Hodgkin Lymphoma	34	3.7
Kidney	32	4.1	Pancreas	27	3.0
Liver	25	3.2	Liver	26	2.9
Total Top Ten	550	71.2	Total Top Ten	673	74.2
Total Other Sites	223	28.8	Total Other Sites	234	25.8
Total All Sites	773	100%	Total All Sites	907	100%



All (1680 Cases) ThiQar Governorate



Male (773 Cases) ThiQar Governorate



Female (907 Cases) ThiQar Governorate

Figure 47: Crude Incidence Rate of Top Ten Cancers at ThiQar Governorate, Iraq ,2023.

4.18. Kirkuk Governorate


Kirkuk governorate reported 1136 newly diagnosed cases of cancer, 459 (40.4%) among males and 677 (59.6%) among females. Breast cancer was the most common cancer 309 cases (27.2%) followed by colorectal 112 (9.9%) then lung 101 (8.9%), Brain, CNS 60 (5.3%) and Leukemia 55 (4.8%). lung cancer was the most common cancer among males 71 cases IR 7.8/100,000 and breast cancer was the most common cancer among female 304 cases IR 33.7/100,000.

Table 52: Top Ten Cancers at Kirkuk Governorate, Both Genders, Iraq, 2023.


Site	No.	%
Breast	309	27.2
Colorectal	112	9.9
Bronchus & Lung	101	8.9
Brain, CNS	60	5.3
Leukemia	55	4.8
Bladder	50	4.4
Prostate	41	3.6
Stomach	40	3.5
Kidney	37	3.3
Thyroid	36	3.2
Total Top Ten	841	74.0
Total Other Sites	295	26.0
Total All Sites	1136	100

Table 53: Top Ten Cancers at Kirkuk Governorate, By Gender, Iraq, 2023.


Male	No.	%	Female	No.	%
Bronchus & Lung	71	15.5	Breast	304	44.9
Colorectal	59	12.9	Colorectal	53	7.8
Bladder	42	9.2	Bronchus & Lung	30	4.4
Prostate	41	8.9	Ovary	29	4.3
Brain, CNS	36	7.8	Thyroid	26	3.8
Leukemia	32	7.0	Stomach	25	3.7
Kidney	26	5.7	Brain, CNS	24	3.5
Skin, other	18	3.9	Leukemia	23	3.4
Non-Hodgkin Lymphoma	17	3.7	Liver	17	2.5
Stomach	15	3.3	Pancreas	15	2.2
Total Top Ten	357	77.8	Total Top Ten	546	80.6
Total Other Sites	102	22.2	Total Other Sites	131	19.4
Total All Sites	459	100%	Total All Sites	677	100%



All (1136 Cases) Kirkuk Governorate



Male (459 Cases) Kirkuk Governorate



Female (677 Cases) Kirkuk Governorate

Figure 48: Crude Incidence Rate of Top Ten Cancers at Kirkuk Governorate, Iraq, 2023.

PART 5

CHILDHOOD CANCER

Child Cancers 0-14 Years in Iraq ,2023

A total of 1922 cancer cases were diagnosed among children aged between 0 and 14 accounting for 4.5% of the total number of cancers reported to the Iraqi cancer registry in 2023. The crude incidence rate was 11/100,000, The reported incidents show that cancer was more common among boys than girls, 1062 (55.3%) cases were reported among boys, with crude incidence rate 11.8/100,000 and 860 (44.7%) cases were reported among girls, with crude incidence rate 10.1 /100,000. Al-Muthana governorate reported the highest incidence rate of cancers in children 17.1/100,000 followed by Al-Sulaimaniyah 14.7/100,000 and Erbil 13/100,000 while Babil reported the lowest incidence rate 6.5/100,000. (Figure 50)




Figure 49: Distribution of Cancer Cases Among Iraqi Children,2023.




Figure 50: Crude Incidence Rate of Cancers in Children 0-14 Year Distributed by Governorates, Iraq, 2023.

Most Common Cancers Among Iraqi Children 0-14 year


leukemia was the most common cancer among children 551 (28.7%), followed by Brain, CNS 405 (21.1%), then Hodgkin's lymphoma 145 (7.5%), Bone cancer 131 (6.8%) and Non-Hodgkin's lymphoma 127 (6.6%)

Table 54: Number and Percentage of Top Ten Cancers in Children 0-14 Year, Iraq, 2023.


Site	No.	%
Leukemia	551	28.7
Brain, CNS	405	21.1
Hodgkin Lymphomas	145	7.5
Bone & cartilage, limbs, Other	131	6.8
Non-Hodgkin Lymphoma	127	6.6
Kidney	109	5.7
Adrenal Gland	72	3.7
Soft Tissues	66	3.4
Eye & Adnexa	64	3.3
Liver	34	1.8
Total Top Ten	1,704	88.7
Total Other Sites	218	11.3
Total All Sites	1,922	100

Table 55: Distribution of Top Ten Cancers in Children 0-14 Year by Genders, Iraq, 2023.


Male	No.	%	Female	No.	%
Leukemia	300	28.2	Leukemia	251	29.2
Brain, CNS	232	21.8	Brain, CNS	173	20.1
Hodgkin Lymphomas	98	9.2	Kidney	64	7.4
Non-Hodgkin Lymphoma	85	8	Bone & cartilage, limbs, Other	63	7.3
Bone & cartilage, limbs, Other	68	6.4	Hodgkin Lymphomas	47	5.5
Kidney	45	4.2	Non-Hodgkin Lymphoma	42	4.9
Soft Tissues	42	4	Adrenal Gland	37	4.3
Eye & Adnexa	38	3.6	Eye & Adnexa	26	3
Adrenal Gland	35	3.3	Soft Tissues	24	2.8
Unspecified Site	20	1.9	Ovary	21	2.4
Total Top Ten	963	90.7	Total Top Ten	748	87
Total Other Sites	99	9.3	Total Other Sites	112	13
Total All Sites	1,062	100%	Total All Sites	860	100%



Both genders



Male



Female

Figure 51: Crude Incidence Rate of Top Ten Cancers Among Iraqi Children 0-14 Years,2023.

Distribution of Most Common Cancers in Children 0-14 Years by Age Group, Iraq, 2023.

The highest number of cancer cases was reported in the age group 0 - 4 years, While the lowest crude incidence rate/100,000 children 0–14 year population were reported in the age group 5-9 years and the lowest among the age group 5-9 years. Table No.; (56), Figure No.; (52)

Table 56: Number of Cases and Percentage of Top Ten Cancers in Children 0-14 Year by Age Group, Iraq, 2023.

Sites	0-4		5-9		10-14		Total	
	No.	%	No.	%	No.	%	No.	%
Leukemia	233	31.8	172	29.5	146	24.1	551	28.7
Brain, CNS	102	13.9	159	27.3	144	23.7	405	21.1
Hodgkin Lymphomas	24	3.3	55	9.4	66	10.9	145	7.5
Bone & cartilage, limbs, Other	21	2.9	26	4.5	84	13.8	131	6.8
Non-Hodgkin Lymphoma	38	5.2	50	8.6	39	6.4	127	6.6
Kidney	76	10.4	28	4.8	5	0.8	109	5.7
Adrenal Gland	51	7.0	14	2.4	7	1.2	72	3.7
soft tissues	24	3.3	18	3.1	24	4.0	66	3.4
Eye & Adnexa	50	6.8	10	1.7	4	0.7	64	3.3
Liver	26	3.6	4	0.7	4	0.7	34	1.8
Total Top Ten	645	88.1	536	91.9	523	86.2	1,704	88.7
Total Other Sites	87	11.9	47	8.1	84	13.8	218	11.3
Total All Sites	732	100	583	100	607	100	1,922	100




Figure 52: Crude Incidence Rate of All Cancer Sites in Children, by Age Group, Iraq, 2023.

Distribution of The Most Common Cancers in Children by Governorates

Majority of cancer cases among Iraqi children were reported in Baghdad governorate followed by Nineveh and Al-Basrah while the lowest number of cases were in Misan.

Table 57: Distribution of Top Ten Cancers in Children 0-14 year by Governorates, Iraq, 2023.

Top ten	Baghdad	Nineveh	Al-Basrah	Al-Sulaimaniyah	Erbil	Thi Qar	Al-Najaf	Al-Anbar	Karbala	Al-Muthana	Diyala	Babil	Kirkuk	Salah Al-Deen	Al-Qadisiya	Wasit	Duhok	Misan	Unknown	Total
Leukemia	129	70	52	25	38	26	24	19	18	16	21	13	18	15	14	22	18	13	0	551
Brain, CNS	110	35	32	20	11	27	22	12	14	12	13	21	7	11	14	12	11	13	8	405
Hodgkin Lymphomas	23	13	15	8	10	12	7	5	5	7	5	5	6	7	4	1	7	4	1	145
Bone & cartilage, limbs, Other	32	11	11	7	4	6	2	6	10	6	1	8	5	5	2	5	5	4	1	131
Non-Hodgkin Lymphoma	28	13	10	8	6	3	3	6	2	5	2	6	5	8	3	4	6	7	2	127
Kidney	27	8	8	5	4	7	4	4	3	5	6	2	6	3	7	4	3	2	1	109
Adrenal Gland	12	9	7	6	4	5	2	2	3	3	2	4	2	6	3	2	0	0	0	72
soft tissues	12	12	2	3	8	2	1	0	4	3	5	0	0	3	2	0	4	2	3	66
Eye & Adnexa	16	5	7	3	4	3	2	4	1	1	4	1	6	2	2	0	0	2	1	64
Liver	8	0	3	5	1	1	2	3	1	0	1	0	2	0	3	3	0	1	0	34
Total Top Ten	397	176	147	90	90	92	69	61	61	58	60	60	57	60	54	53	54	48	17	1704
Total all sites	437	189	171	121	104	102	76	75	69	68	68	64	63	62	62	61	59	52	19	1922
Percentage	22.7	9.8	8.9	6.3	5.4	5.3	4.0	3.9	3.6	3.5	3.5	3.3	3.3	3.2	3.2	3.2	3.1	2.7	1.0	100%

Distribution of Cancer Cases Among Iraqi Children 0-14 year by Gender and Primary Sites

Table 58: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi children (per 100,000) by Primary Site and Genders, 2023.

ICD-O/Site		Male			Female			Both Genders		
		No.	%	IR	No.	%	IR	No.	%	IR
C02 / Tongue, other		1	0.09	0.01	0	0.00	0.00	1	0.05	0.01
C04 / Mouth - floor		1	0.09	0.01	1	0.12	0.01	2	0.10	0.01
C05 / Mouth - palate		0	0.00	0.00	2	0.23	0.02	2	0.10	0.01
C06 / Mouth - other		1	0.09	0.01	1	0.12	0.01	2	0.10	0.01
C07 / Parotid gland		2	0.19	0.02	1	0.12	0.01	3	0.16	0.02
C08 / Mouth glands		0	0.00	0.00	1	0.12	0.01	1	0.05	0.01
C11 / Nasopharynx		7	0.66	0.08	2	0.23	0.02	9	0.47	0.05
C14 / Pharynx		0	0.00	0.00	2	0.23	0.02	2	0.10	0.01
C16 / Stomach		0	0.00	0.00	1	0.12	0.01	1	0.05	0.01
C17 / Small intestine		0	0.00	0.00	1	0.12	0.01	1	0.05	0.01
C18 / Colon		3	0.28	0.03	0	0.00	0.00	3	0.16	0.02
C20 / Rectum		0	0.00	0.00	1	0.12	0.01	1	0.05	0.01
C22 / Liver & bile ducts		16	1.51	0.18	18	2.09	0.21	34	1.77	0.19
C25 / Pancreas		2	0.19	0.02	3	0.35	0.04	5	0.26	0.03
C30 / Nasal cavity		1	0.09	0.01	0	0.00	0.00	1	0.05	0.01
C31 / Accessory sinus		0	0.00	0.00	1	0.12	0.01	1	0.05	0.01
C34 / Bronchus & lung		3	0.28	0.03	1	0.12	0.01	4	0.21	0.02
C37 / Thymus		3	0.28	0.03	1	0.12	0.01	4	0.21	0.02
C38 / Heart, Mediastinum, pleura		2	0.19	0.02	3	0.35	0.04	5	0.26	0.03
C40 / Bone & cartilage, limbs		38	3.58	0.42	40	4.65	0.47	78	4.06	0.44
C41 / Bones & cartilage, other		30	2.82	0.33	23	2.67	0.27	53	2.76	0.30
C42/Reticulo endothelial& Hematopoietic System	Leukemia	300	28.25	3.32	251	29.19	2.95	551	28.67	3.14
	Chronic Myeloproliferative disorders	5	0.47	0.06	4	0.47	0.05	9	0.47	0.05
	Myelodysplastic syndromes	0	0.00	0.00	2	0.23	0.02	2	0.10	0.01
C44 / Skin, other		7	0.66	0.08	7	0.81	0.08	14	0.73	0.08
C47 /Nerves system		0	0.00	0.00	5	0.58	0.06	5	0.26	0.03
C48 / Peritoneum		5	0.47	0.06	7	0.81	0.08	12	0.62	0.07
C49 / soft tissues		42	3.95	0.47	24	2.79	0.28	66	3.43	0.38
C52 / Vagina		0	0.00	0.00	1	0.12	0.01	1	0.05	0.01
C55 / Uterus unspecified		0	0.00	0.00	1	0.12	0.01	1	0.05	0.01

ICD-O/Site		Male			Female			Both Genders		
		No.	%	IR	No.	%	IR	No.	%	IR
C56 / Ovary		0	0.00	0.00	21	2.44	0.25	21	1.09	0.25
C62 / Testis		18	1.69	0.20	0	0.00	0.00	18	0.94	0.20
C64 / Kidney		45	4.24	0.50	64	7.44	0.75	109	5.67	0.62
C65 / Pelvis		5	0.47	0.06	1	0.12	0.01	6	0.31	0.03
C67 / Urinary bladder		3	0.28	0.03	0	0.00	0.00	3	0.16	0.02
C69 / Eye & adnexa		38	3.58	0.42	26	3.02	0.31	64	3.33	0.37
C70 / Meninges		4	0.38	0.04	4	0.47	0.05	8	0.42	0.05
C71 / Brain		210	19.77	2.33	149	17.33	1.75	359	18.68	2.05
C72 / Nervous system, other		9	0.85	0.10	11	1.28	0.13	20	1.04	0.11
C73 / Thyroid gland		4	0.38	0.04	20	2.33	0.24	24	1.25	0.14
C74 / Adrenal gland		35	3.30	0.39	37	4.30	0.44	72	3.75	0.41
C75 / Endocrine gland, other		9	0.85	0.10	9	1.05	0.11	18	0.94	0.10
C76 / Unspecified site		20	1.88	0.22	13	1.51	0.15	33	1.72	0.19
C77/ Lymph Node	Hodgkin Lymphoma	98	9.23	1.09	47	5.47	0.55	145	7.54	0.83
	Non-Hodgkin Lymphoma	85	8.00	0.94	42	4.88	0.49	127	6.61	0.72
C80 / Unknown primary site		10	0.94	0.11	11	1.28	0.13	21	1.09	0.12
Total All Site		1062	100%	11.8	860	100%	10.1	1922	100%	11.0

Note:

* From C51 to C58 the incidence rate was calculated from the female population.

*From C60 to C63 the incidence rate was calculated from the male population

PART 6

CANCER MORTALITY

Cancer Mortality

During the year 2023 there were 12,982 deaths among Iraqi cancer patients, 6,340 (48.8%) of death cases among males and 6,642 (51.2%) among female. out of total deaths there were 448 cancer deaths in children, 260 deaths among boys and 188 deaths among girls.

Overall standardized mortality rate was 56/100,000 while the crude mortality rate was 30/100,000.

The age standardized mortality rate among males were 58.7/100,000 while among females were 53.9/100,000

Table 59: Distribution of Mortality Cases and ASMR /100,000 Among Iraqis, by Age Group, 2023.

Age group	Male		Female		Both Genders		
	NO.	%	NO.	%	No.	%	ASMR
0-4	84	1.3	61	0.9	145	1.1	0.3
5-9	85	1.3	58	0.9	143	1.1	0.2
10-14	91	1.4	69	1	160	1.2	0.3
15-19	84	1.3	78	1.2	162	1.2	0.3
20-24	93	1.5	80	1.2	173	1.3	0.3
25-29	84	1.3	102	1.5	186	1.4	0.5
30-34	102	1.6	134	2	236	1.8	0.5
35-39	126	2	219	3.3	345	2.7	0.8
40-44	176	2.8	318	4.8	494	3.8	1.3
45-49	324	5.1	427	6.4	751	5.8	2.6
50-54	494	7.8	639	9.6	1,133	8.7	5.0
55-59	644	10.2	738	11.1	1,382	10.6	4.7
60-64	607	9.6	722	10.9	1,329	10.2	6.5
65-69	932	14.7	762	11.5	1,694	13	9.6
70-74	937	14.8	902	13.6	1,839	14.2	10.9
75-79	704	11.1	566	8.5	1,270	9.8	6.5
80+	773	12.2	767	11.5	1,540	11.9	5.7
All Ages	6,340	100%	6,642	100%	12,982	100%	56.0

The rate of death started to increase markedly in the older age groups, in general after the age of 40 years. The highest mortality rate was observed in the age group 75-79 years. 648.1/100,000 population.




Figure 53: Age -Specific Mortality Rates of All Cancers Sites, Iraq, 2023.

Distribution of Cancer Mortality by Governorates, Iraq, 2023.

Baghdad governorate reported the highest number of cancer death cases 3,833 (29.5%) followed by Al-Basrah 1,199 (9.2%), then Ninevah 1,046 (8.1%), ThiQar 772 (5.9%) and Al-Najaf 759 (5.8%).

The highest mortality rate was in Al-Najaf governorate 45.4/100,000 while the lowest mortality rate was in Erbil 0.9/100,000.

Table 60: Distribution of Mortality Cases by Governorates, Iraq ,2023.

Governorates	Male			Female			Total		
	No.	%	MR	No.	%	MR	No.	%	MR
Al-Najaf	372	5.9	44.4	387	5.8	46.4	759	5.8	45.4
Kerbala	290	4.6	41.5	304	4.6	44.3	594	4.6	42.9
Baghdad	1,811	28.6	38.5	2,022	30.4	44.3	3,833	29.5	41.4
Al-Muthana	186	2.9	40.0	154	2.3	33.4	340	2.6	36.7
Al-Basrah	571	9.0	34.4	628	9.5	38.2	1,199	9.2	36.3
Diyala	308	4.9	33.3	337	5.1	37.2	645	5.0	35.2
Wasit	275	4.3	34.8	249	3.7	32.1	524	4.0	33.4
Misan	216	3.4	34.3	204	3.1	32.2	420	3.2	33.2
ThiQar	392	6.2	32.8	380	5.7	32	772	5.9	32.4
Babil	335	5.3	28.3	364	5.5	31.4	699	5.4	29.8
Al-Qadisiya	185	2.9	25.0	210	3.2	28.9	395	3.0	26.9
Nineveh	521	8.2	24.1	525	7.9	25.3	1,046	8.1	24.7
Al-Sulaimaniyah	279	4.4	22.7	233	3.5	19	512	3.9	20.8
Salah Al-Deen	163	2.6	17.8	207	3.1	23.1	370	2.9	20.4
Al-Anbar	197	3.1	19.0	194	2.9	19.8	391	3.0	19.4
Kirkuk	110	1.7	12.0	143	2.2	15.9	253	1.9	13.9
Duhok	108	1.7	14.7	87	1.3	11.9	195	1.5	13.3
Erbil	12	0.2	1.1	7	0.1	0.7	19	0.1	0.9
Unknown	9	0.1	----	7	0.1	----	16	0.1	----
Total	6,340	100	29	6,642	100	31	12,982	100	30




Figure 54: Age Standardized Mortality Rate by Governorates, Both Genders, Iraq ,2023.




Figure 55: Age Standardized Mortality Rate by Governorates and Genders, Iraq ,2023.

Top Ten Cancer Mortality Among Iraqis ,2023.

Lung cancer was the most common cancer leading to death among Iraqis followed by breast, brain, CNS, colorectal cancer and leukemia. These five cancer sites together represented more than half (50.4%) of all deaths from cancer.

Table 61: Number And Percentage of Top Ten Cancers Mortality Among Iraqis, 2023.

Site	No.	%
Bronchus & Lung	2,039	15.7
Breast	1,642	12.6
Brain, CNS	1,021	7.9
Colorectal	960	7.4
Leukemia	881	6.8
Pancreas	824	6.3
Liver	633	4.9
Stomach	630	4.9
Non-Hodgkin Lymphoma	503	3.9
Bladder	487	3.8
Total Top Ten	9,620	74.1%
Total Other Sites	3,362	25.9%
Total All Sites	12,982	100%




Figure 56: Crude Mortality Rate of Top Ten Cancers Mortality Among Iraqis, 2023.

Top Ten Cancer Mortality Among Iraqis, Distributed by Genders ,2023.

Mortality from lung cancer was the highest among Iraqi males 1,384 (21.8%) followed by Brain, CNS 540 (8.5%) then Colorectal 492 (7.8%), Leukemia 465 (7.3%) and Pancreas 449 (7.1%). These five cancers accounting 52.5% of all deaths from cancer among males, while breast cancer was the highest number of cancer deaths 1,608 (24.2%) Among females followed by Lung cancer 655 (9.9%) then brain, CNS 481 (7.2%), Colorectal 468 (7%) and Leukemia 416 (6.3%). Together these five cancer types accounting 54.6% of all deaths from cancer among females.

Table 62: Number and Percentage of Top Ten Cancers Mortality Among Iraqis Distributed by Gender, 2023.

Male	No.	%	Female	No.	%
Bronchus &Lung	1,384	21.8	Breast	1,608	24.2
Brain, CNS	540	8.5	Bronchus & Lung	655	9.9
Colorectal	492	7.8	Brain, CNS	481	7.2
Leukemia	465	7.3	Colorectal	468	7.0
Pancreas	449	7.1	Leukemia	416	6.3
Prostate	425	6.7	Pancreas	375	5.6
Bladder	361	5.7	Stomach	303	4.6
Liver	349	5.5	Uterus Unspecified	298	4.5
Stomach	327	5.2	Liver	284	4.3
Non-Hodgkin Lymphoma	255	4.0	Ovary	262	3.9
Total Top Ten	5,047	79.6%	Total Top Ten	5,150	77.5%
Total Other Sites	1,293	20.4%	Total Other Sites	1,492	22.5%
Total All Sites Death	6,340	100%	Total All Sites Death	6,642	100%




Figure 57: Crude Mortality Rate of Top Ten Cancers Mortality Among Iraqi Males, 2023.




Figure 58: Crude Mortality Rate of Top Ten Cancers Mortality Among Iraqi Females, 2023.

Table 63: Distribution of Top Ten Cancers Mortality by Age Group, Both Genders, Iraq, 2023.

Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total	%
Bronchus & Lung	1	0	1	2	6	7	10	22	31	71	133	219	225	331	408	289	283	2,039	15.7
Breast	0	0	0	0	1	11	34	78	107	148	239	252	193	181	158	101	139	1,642	12.6
Brain, CNS	31	55	54	28	26	31	29	49	42	74	93	101	91	108	95	45	69	1,021	7.9
Colorectal	0	0	1	8	9	15	23	28	41	63	109	123	88	133	125	95	99	960	7.4
Leukemia	51	43	45	50	45	32	37	20	32	46	58	71	59	75	81	66	70	881	6.8
Pancreas	0	0	0	1	3	4	5	8	20	36	69	98	113	128	147	100	92	824	6.3
Liver	4	2	1	1	3	6	10	11	14	34	46	69	71	94	98	68	101	633	4.9
Stomach	0	0	0	0	5	12	18	30	33	51	78	66	58	70	84	54	71	630	4.9
Non-Hodgkin Lymphoma	8	7	8	15	16	13	17	18	26	23	41	58	48	55	61	42	47	503	3.9
Bladder	0	0	1	1	0	2	0	4	8	11	9	34	35	71	93	81	137	487	3.8
Total Top Ten	95	107	111	106	114	133	183	268	354	557	875	1091	981	1246	1350	941	1,108	9,620	74.1%
Total Other Sites	50	36	49	56	59	53	53	77	140	194	258	291	348	448	489	329	432	3,362	25.9%
Total All Cancer	145	143	160	162	173	186	236	345	494	751	1,133	1,382	1,329	1,694	1,839	1,270	1,540	12,982	100%

Mortality in Children

Brain, CNS tumor was the most common cancer leading to death in children 140 deaths followed by Leukemia 139 deaths these two cancers represented 62.3% of all deaths from cancer among Iraqi children.

Table 64: Number and Percentage of Top Ten Cancers Mortality Among Iraqi Children 0-14 Year, 2023.

Sites	No.	%
Brain, CNS	140	31.3
Leukemia	139	31.0
Bone & cartilage, limbs, Other	33	7.3
Kidney	25	5.6
Non-Hodgkin Lymphoma	23	5.1
Adrenal Gland	18	4.0
Soft Tissues	12	2.7
Liver	7	1.6
Hodgkin Lymphomas	6	1.3
Eye & Adnexa	6	1.3
Total Top Ten	409	91.2%
Total Other Sites	39	8.8%
Total All Sites Death	448	100%




Figure 59: Crude Mortality Rate of Top Ten Cancers Mortality Among Iraqi children /100,000 Children Populations, 2023.

Distribution of Most Common Cancers in Children 0-14 Years by Age Group, Iraq, 2023.

Brain, CNS and Leukemia these two sites were the most common cancer leading to death among boys and girls.

Table 65: Number and Percentage of Top Ten Cancers Mortality Among Iraqi children 0-14 Year, Distributed by Gender, 2023.

Male	No.	%	Female	No.	%
Brain, CNS	88	33.8	Leukemia	54	28.7
Leukemia	85	32.7	Brain, CNS	52	27.7
Non-Hodgkin Lymphoma	15	5.8	Bones & Cartilage, Limbs, Other	19	10.1
Bone & Cartilage, Limbs, Other	14	5.4	Kidney	13	6.9
Adrenal Gland	13	5.0	Non-Hodgkin Lymphoma	8	4.3
Kidney	12	4.6	Soft Tissues	8	4.3
Eye & Adnexa	4	1.5	Adrenal Gland	5	2.7
Soft Tissues	4	1.5	Hodgkin Lymphomas	4	2.1
Unknown Primary Site	4	1.5	Liver	4	2.1
Liver	3	1.2	Chronic Myeloproliferative Disorders	3	1.6
Total Top Ten	242	93%	Total Top Ten	170	90.5%
Total Other Sites	18	7%	Total Other Sites	18	9.5%
Total All Sites Death	260	100%	Total All Sites Death	188	100%




Figure 60: Crude Mortality Rate of Top Ten Cancers Mortality Among Male Children /100,000 Children Populations, Iraq, 2023.




Figure 61: Crude Mortality Rate of Top Ten Cancers Mortality Among Female Children /100,000 Children Populations, Iraq, 2023.

Table 66: Distribution of Top Ten Cancers Mortality Among Iraqi children by Governorate,2023.

Top ten	Baghdad	Al-Basrah	Nineveh	ThiQar	Babil	Al-Najaf	Wasit	Al-Qadisiya	Al-Sulaimaniyah	Salah Al-Deen	Al-Anbar	Misan	Diyala	Kirkuk	Karbala	Al-Muthana	Erbil	Duhok	Total
Brain, CNS	31	16	18	13	9	14	8	5	4	6	0	3	6	2	3	2	0	0	140
Leukemia	35	23	14	9	10	4	9	3	2	5	8	6	1	4	0	6	0	0	139
Kidney	8	3	4	1	1	0	1	1	1	2	1	0	1	0	0	1	0	0	25
Non-Hodgkin Lymphoma	5	0	1	3	0	2	1	1	1	1	1	2	1	1	1	0	1	1	23
Adrenal Gland	3	2	1	1	3	2	0	2	0	0	1	0	0	0	3	0	0	0	18
Bone & cartilage, limbs, Other	7	2	6	5	2	1	3	0	1	2	2	0	1	1	0	0	0	0	33
Soft Tissues	2	0	2	1	1	1	0	1	1	0	0	0	0	1	2	0	0	0	12
Liver	3	0	1	1	0	0	1	0	0	0	0	0	0	0	1	0	0	0	7
Hodgkin Lymphomas	3	1	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	6
Eye & Adnexa	3	0	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	6
Total Top Ten	100	47	48	34	26	24	23	13	12	16	14	11	10	10	10	9	1	1	409
Total Other Sites	6	5	0	2	3	2	1	4	5	0	1	3	2	1	0	1	2	1	39
Total All Site	106	52	48	36	29	26	24	17	17	16	15	14	12	11	10	10	3	2	448
Percentage	23.7	11.6	10.7	8.0	6.5	5.8	5.4	3.8	3.8	3.6	3.3	3.1	2.7	2.5	2.2	2.2	0.7	0.4	100%




Figure 62: Crude Mortality Rate Among Iraqi Children Distributed by Governorate, 2023.

Table 67: Number of Mortality Cases, Percentage and Crude Mortality Rate/100,000 Population by Primary Site and Gender, Iraq, 2023.

ICD-O/ Site		Male			Female			Both Genders		
		No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip		2	0.03	0.01	1	0.02	0.00	3	0.02	0.01
C01 / Tongue, base		12	0.19	0.05	6	0.09	0.03	18	0.14	0.04
C02 / Tongue, other		22	0.35	0.10	22	0.33	0.10	44	0.34	0.10
C03 / Gum		2	0.03	0.01	0	0.00	0.00	2	0.02	0.00
C04 / Mouth - floor		6	0.09	0.03	5	0.08	0.02	11	0.08	0.03
C05 / Mouth - palate		3	0.05	0.01	1	0.02	0.00	4	0.03	0.01
C06 / Mouth - other		2	0.03	0.01	4	0.06	0.02	6	0.05	0.01
C07 / Parotid gland		6	0.09	0.03	4	0.06	0.02	10	0.08	0.02
C08 / Mouth glands		6	0.09	0.03	6	0.09	0.03	12	0.09	0.03
C09 / Tonsil		2	0.03	0.01	0	0.00	0.00	2	0.02	0.00
C10 / Oropharynx		9	0.14	0.04	4	0.06	0.02	13	0.10	0.03
C11 / Nasopharynx		17	0.27	0.08	11	0.17	0.05	28	0.22	0.06
C13 / Hypopharynx		4	0.06	0.02	5	0.08	0.02	9	0.07	0.02
C14 / Pharynx		8	0.13	0.04	6	0.09	0.03	14	0.11	0.03
C15 / Oesophagus		67	1.06	0.31	41	0.62	0.19	108	0.83	0.25
C16 / Stomach		327	5.16	1.49	303	4.56	1.41	630	4.85	1.45
C17 / Small intestine		37	0.58	0.17	48	0.72	0.22	85	0.65	0.20
C18 / Colon		403	6.36	1.84	388	5.84	1.81	791	6.09	1.83
C19 / Recto sigmoid Junction		4	0.06	0.02	4	0.06	0.02	8	0.06	0.02
C20 / Rectum		85	1.34	0.39	76	1.14	0.35	161	1.24	0.37
C21 / Anus & anal canal		2	0.03	0.01	2	0.03	0.01	4	0.03	0.01
C22 / Liver & bile ducts		349	5.50	1.59	284	4.28	1.32	633	4.88	1.46
C23 / Gallbladder		57	0.90	0.26	78	1.17	0.36	135	1.04	0.31
C24 / Biliary tract, other		45	0.71	0.21	43	0.65	0.20	88	0.68	0.20
C25 / Pancreas		449	7.08	2.05	375	5.65	1.75	824	6.35	1.90
C26 / Other digestive organs		15	0.24	0.07	20	0.30	0.09	35	0.27	0.08
C30 / Nasal cavity		3	0.05	0.01	4	0.06	0.02	7	0.05	0.02
C31 / Accessory sinus		6	0.09	0.03	5	0.08	0.02	11	0.08	0.03
C32 / Larynx		138	2.18	0.63	35	0.53	0.16	173	1.33	0.40
C33 / Trachea		2	0.03	0.01	0	0.00	0.00	2	0.02	0.00
C34 / Bronchus & lung		1,384	21.83	6.32	655	9.86	3.06	2039	15.71	4.71
C37 / Thymus		7	0.11	0.03	2	0.03	0.01	9	0.07	0.02
C38 / Heart, Mediastinum, pleura		9	0.14	0.04	8	0.12	0.04	17	0.13	0.04
C39 / Other respiratory & thoracic		2	0.03	0.01	1	0.02	0.00	3	0.02	0.01
C40 / Bone & cartilage, limbs		47	0.74	0.21	39	0.59	0.18	86	0.66	0.20
C41 / Bones & cartilage, other		94	1.48	0.43	76	1.14	0.35	170	1.31	0.39
C42/Reticulo endothelial& Hematopoietic System	Myelodysplastic syndromes	5	0.08	0.02	3	0.05	0.01	8	0.06	0.02
	Chronic Myeloproliferative disorders	9	0.14	0.04	12	0.18	0.06	21	0.16	0.05
	Leukemia	465	7.33	2.12	416	6.26	1.94	881	6.79	2.03
	Plasma cell tumor	32	0.50	0.15	41	0.62	0.19	73	0.56	0.17
C44 / Skin, other		62	0.98	0.28	52	0.78	0.24	114	0.88	0.26

ICD-O/ Site		Male			Female			Both Genders		
		No.	%	IR	No.	%	IR	No.	%	IR
C47 /Nerves system		3	0.05	0.01	2	0.03	0.01	5	0.04	0.01
C48 / Peritoneum		10	0.16	0.05	7	0.11	0.03	17	0.13	0.04
C49 / soft tissues		45	0.71	0.21	39	0.59	0.18	84	0.65	0.19
C50 / Breast		34	0.54	0.16	1608	24.21	7.50	1642	12.65	3.79
C51 / Vulva		0	0.00	0.00	4	0.06	0.02	4	0.03	0.02
C52 / Vagina		0	0.00	0.00	7	0.11	0.03	7	0.05	0.03
C53 / Cervix uteri		0	0.00	0.00	62	0.93	0.29	62	0.48	0.29
C54 / Corpus uteri		0	0.00	0.00	72	1.08	0.34	72	0.55	0.34
C55 / Uterus unspecified		0	0.00	0.00	298	4.49	1.39	298	2.30	1.39
C56 / Ovary		0	0.00	0.00	262	3.94	1.22	262	2.02	1.22
C58 / Placenta		0	0.00	0.00	1	0.02	0.00	1	0.01	0.00
C61 / Prostate		425	6.70	1.94	0	0.00	0.00	425	3.27	1.94
C62 / Testis		18	0.28	0.08	0	0.00	0.00	18	0.14	0.08
C64 / Kidney		195	3.08	0.89	96	1.45	0.45	291	2.24	0.67
C65 / Pelvis		3	0.05	0.01	1	0.02	0.00	4	0.03	0.01
C66 / Ureter		2	0.03	0.01	1	0.02	0.00	3	0.02	0.01
C67 / Urinary bladder		361	5.69	1.65	126	1.90	0.59	487	3.75	1.12
C68 / Urinary organs, other		1	0.02	0.00	0	0.00	0.00	1	0.01	0.00
C69 / Eye & adnexa		4	0.06	0.02	3	0.05	0.01	7	0.05	0.02
C70 / Meninges		1	0.02	0.00	2	0.03	0.01	3	0.02	0.01
C71 / Brain		523	8.25	2.39	460	6.93	2.15	983	7.57	2.27
C72 / Nervous system, other		13	0.21	0.06	14	0.21	0.07	27	0.21	0.06
C73 / Thyroid gland		45	0.71	0.21	73	1.10	0.34	118	0.91	0.27
C74 / Adrenal gland		27	0.43	0.12	13	0.20	0.06	40	0.31	0.09
C75 / Endocrine gland, other		6	0.09	0.03	5	0.08	0.02	11	0.08	0.03
C76 / Unspecified site		15	0.24	0.07	13	0.20	0.06	28	0.22	0.06
C77/ Lymph node	Hodgkin Lymphoma	18	0.28	0.08	23	0.35	0.11	41	0.32	0.09
	Non-Hodgkin Lymphoma	255	4.02	1.17	248	3.73	1.16	503	3.87	1.16
C80 / Unknown primary site		130	2.05	0.59	116	1.75	0.54	246	1.89	0.57
All sites Total		6,340	100%	29.0	6,642	100%	31.0	12,982	100%	30.0

Note:

- * From C51 to C58 the incidence rate was calculated from the female population.
- * From C60 to C63 the incidence rate was calculated from the male population.

PART 7

INCIDENCE TABLE

Table 68: Number of Cases Among Iraqi Males by Primary Site and Age Groups, 2023.

ICDO/ Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total
C00 / lip	0	0	0	0	0	0	0	0	1	2	2	0	2	0	3	4	2	16
C01 / Tongue, base	0	0	0	0	1	0	0	1	1	0	1	1	3	0	2	1	0	11
C02 / Tongue, other	0	0	1	0	0	1	5	3	5	2	7	14	7	10	8	2	4	69
C03 / Gum	0	0	0	0	0	0	0	0	1	0	1	0	0	2	0	0	0	4
C04 / Mouth - floor	1	0	0	0	0	0	0	0	1	2	2	0	2	4	2	0	1	15
C05 / Mouth - palate	0	0	0	0	0	0	2	0	0	1	1	2	0	4	3	0	0	13
C06 / Mouth - other	1	0	0	0	0	1	0	0	6	4	4	3	10	4	4	3	1	41
C07 / Parotid gland	0	0	2	1	2	0	2	2	3	5	5	2	3	2	5	3	2	39
C08 / Mouth glands	0	0	0	0	1	1	2	2	2	6	3	6	2	6	1	0	4	36
C09 / Tonsil	0	0	0	0	0	0	0	0	1	0	2	2	1	3	0	3	0	12
C10 / Oropharynx	0	0	0	0	0	0	0	0	0	1	3	2	2	1	0	2	0	11
C11 / Nasopharynx	1	0	6	11	12	7	7	10	11	26	24	11	8	7	4	3	2	150
C12 / Pyriform	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	3
C13 / Hypopharynx	0	0	0	0	0	1	1	0	1	1	1	0	0	0	1	0	0	6
C14 / Pharynx	0	0	0	0	1	0	0	0	0	2	1	0	0	0	2	1	0	7
C15 / Oesophagus	0	0	0	0	0	0	3	6	3	8	12	10	16	20	23	11	20	132
C16 / Stomach	0	0	0	0	2	9	17	19	40	52	63	73	73	84	84	46	40	602
C17 / Small intestine	0	0	0	0	0	0	1	1	8	14	15	13	11	9	7	4	6	89
C18 / Colon	0	0	3	4	7	22	41	46	53	79	140	150	129	123	133	80	47	1057
C19 / Recto sigmoid Junction	0	0	0	0	2	1	4	4	3	8	13	5	18	15	11	7	6	97
C20 / Rectum	0	0	0	0	4	13	20	22	29	49	59	64	57	52	34	20	29	452
C21 / Anus & anal canal	0	0	0	0	0	1	0	0	1	4	6	7	2	2	2	3	0	28
C22 / Liver & bile ducts	12	2	2	1	1	3	9	7	5	14	39	40	52	85	68	50	53	443
C23 / Gallbladder	0	0	0	0	1	0	3	1	6	4	16	13	12	14	17	7	7	101
C24 / Biliary tract, other	0	0	0	1	0	1	0	0	3	4	13	12	24	13	12	8	6	97
C25 / Pancreas	1	0	1	1	0	3	5	11	19	46	72	75	84	113	117	56	62	666
C26 / Other digestive organs	0	0	0	0	0	0	1	1	0	1	3	2	2	5	7	2	2	26

ICDO/ Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total
C30 / Nasal cavity	0	1	0	0	0	1	1	3	1	2	3	0	6	4	2	0	5	29
C31 / Accessory sinus	0	0	0	1	0	2	0	0	1	2	1	2	1	2	2	0	1	15
C32 / Larynx	0	0	0	0	2	1	3	8	9	29	32	53	55	70	58	29	38	387
C33 / Trachea	0	0	0	0	0	0	2	0	0	0	0	1	0	1	0	0	0	4
C34 / Bronchus & lung	3	0	0	0	5	4	11	20	37	75	140	246	268	382	443	261	234	2129
C37 / Thymus	0	2	1	0	0	4	3	2	4	3	3	2	2	4	1	0	1	32
C38 / Heart, Mediastinum, pleura	1	1	0	1	0	2	0	3	2	3	7	5	7	7	9	3	5	56
C39 / Other respiratory & thoracic	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	3
C40 / Bone & cartilage, limbs	5	6	27	31	19	9	7	4	4	4	7	5	7	2	6	3	3	149
C41 / Bones & cartilage, other	7	8	15	26	11	6	4	3	8	8	7	11	5	8	7	9	4	147
Leukemia	111	94	95	54	51	29	38	39	45	57	69	73	58	61	63	43	34	1014
Chronic Myeloproliferative disorders	2	2	1	9	13	12	9	19	14	14	21	17	16	11	13	2	4	179
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	3
mast cell tumor	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2
Plasma cell tumor	0	0	0	1	2	0	2	3	15	18	30	38	23	32	38	9	7	218
Myelodysplastic syndromes	0	0	0	2	3	0	1	1	0	4	4	2	6	2	2	2	2	31
C44 / Skin, other	4	0	3	3	7	19	19	28	40	41	93	70	97	94	128	90	95	831
C47 /Nerves system	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	2
C48 / Peritoneum	3	0	2	0	0	0	3	0	1	3	5	2	3	0	3	2	1	28
C49 / soft tissues	13	14	15	22	22	15	14	15	27	24	27	23	17	15	17	11	6	297
C50 / Breast	0	0	0	1	1	3	5	1	10	17	17	17	17	16	14	10	12	141
C60 / Penis	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	4
C61 / Prostate	0	0	0	0	0	0	0	0	2	6	46	100	156	327	392	291	336	1656
C62 / Testis	11	2	5	14	42	44	35	41	38	23	6	2	3	3	3	0	3	275

ICDO/ Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total
C63 / Male genital - other	0	0	0	0	1	0	0	1	0	1	0	0	0	0	0	0	0	3
C64 / Kidney	35	8	2	2	6	8	15	41	57	81	124	109	112	100	81	39	33	853
C65 / Pelvis	3	1	1	1	0	0	0	1	0	2	4	3	3	2	5	1	3	30
C66 / Ureter	0	0	0	0	0	0	0	0	0	2	0	3	1	2	3	0	0	11
C67 / Urinary bladder	1	0	2	2	12	6	17	29	42	85	161	200	191	236	267	170	181	1602
C68 / Urinary organs, other	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	4	0	8
C69 / Eye & adnexa	28	7	3	0	0	0	0	2	5	1	3	2	1	3	4	1	1	61
C70 / Meninges	0	3	1	2	0	5	10	11	12	11	16	13	11	15	10	4	2	126
C71 / Brain	56	84	70	57	36	56	69	87	67	84	83	85	74	83	46	29	19	1085
C72 / Nervous system, other	5	2	2	3	1	5	4	1	5	3	3	2	1	2	0	1	0	40
C73 / Thyroid gland	0	0	4	4	22	30	73	68	85	78	53	45	22	30	22	11	11	558
C74 / Adrenal gland	27	5	3	0	0	1	4	1	4	6	8	2	4	5	2	0	0	72
C75 / Endocrine gland, other	2	3	4	6	5	2	11	8	13	8	5	4	7	4	0	0	0	82
C76 / Unspecified site	8	11	1	1	1	1	2	3	5	1	9	4	3	9	4	3	5	71
C77/ Lymph node	16	40	42	42	42	40	36	25	21	25	17	23	14	9	7	3	3	405
C80 / Unknown primary site	24	35	26	29	24	26	36	45	55	56	85	75	59	80	73	37	42	807
All Sites Total	388	333	341	337	365	397	563	656	853	1139	1634	1791	1810	2269	2332	1410	1423	18041
Percentage	2.2	1.8	1.9	1.9	2.0	2.2	3.1	3.6	4.7	6.3	9.1	9.9	10.0	12.6	12.9	7.8	7.9	100%

Table 69: Number of Cases Among Iraqi Females by Primary Site and Age Groups, 2023.

ICDO/ Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total
C00 / lip	0	0	0	0	0	0	0	0	0	0	3	2	1	0	2	2	0	10
C01 / Tongue, base	0	0	0	0	1	0	0	0	0	1	1	0	0	0	2	2	1	8
C02 / Tongue, other	0	0	0	0	1	0	1	3	7	5	6	14	8	12	13	4	6	80
C03 / Gum	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0	1	4
C04 / Mouth - floor	1	0	0	0	0	0	0	0	1	0	1	1	1	2	1	0	0	8
C05 / Mouth - palate	0	1	1	0	0	1	0	0	0	0	0	1	1	2	2	2	1	12
C06 / Mouth - other	0	1	0	1	0	0	1	1	2	1	6	2	3	2	5	3	2	30
C07 / Parotid gland	1	0	0	1	0	0	2	2	1	2	5	1	2	3	4	1	3	28
C08 / Mouth glands	1	0	0	1	1	1	4	2	0	2	3	3	2	4	3	1	3	31
C09 / Tonsil	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	3
C10 / Oropharynx	0	0	0	0	0	0	1	0	1	0	0	1	0	0	1	0	1	5
C11 / Nasopharynx	0	0	2	8	5	4	7	6	7	6	8	6	2	2	4	0	1	68
C12 / Pyriform	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	3
C13 / Hypopharynx	0	0	0	0	0	0	1	2	1	2	1	0	2	1	2	1	1	14
C14 / Pharynx	0	1	1	2	1	1	0	0	0	0	2	2	0	0	2	2	0	14
C15 / Oesophagus	0	0	0	0	1	1	1	2	6	11	11	7	8	11	14	10	25	108
C16 / Stomach	0	0	1	2	8	18	22	32	50	50	69	70	44	61	68	45	49	589
C17 / Small intestine	0	1	0	1	1	6	0	6	2	4	9	9	12	13	13	3	5	85
C18 / Colon	0	0	0	5	11	9	37	42	76	71	133	117	102	146	105	87	81	1022
C19 / Recto sigmoid Junction	0	0	0	0	0	1	2	7	6	7	12	8	10	7	6	6	5	77
C20 / Rectum	0	0	1	4	3	17	16	16	33	40	51	53	50	43	33	17	26	403
C21 / Anus & anal canal	0	0	0	0	1	0	0	0	2	0	1	3	5	2	2	0	2	18
C22 / Liver & bile ducts	14	2	2	1	2	3	4	5	13	12	28	42	45	32	74	38	62	379
C23 / Gallbladder	0	0	0	0	0	0	4	0	3	7	11	17	20	25	36	13	17	153

ICDO / Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total
C24 / Biliary tract, other	0	0	0	0	0	1	0	0	1	6	7	11	13	12	15	5	6	77
C25 / Pancreas	0	1	2	3	6	4	6	8	18	30	55	55	79	78	97	63	57	562
C26 / Other digestive organs	0	0	0	1	0	0	0	2	1	1	1	3	2	5	4	0	1	21
C30 / Nasal cavity	0	0	0	1	1	0	1	1	2	1	1	1	3	1	3	0	2	18
C31 / Accessory sinus	0	0	1	0	0	1	0	1	1	1	1	0	1	2	1	1	0	11
C32 / Larynx	0	0	0	0	1	1	4	1	5	3	3	11	9	16	18	10	6	88
C33 / Trachea	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0	0	3
C34 / Bronchus & lung	0	1	0	0	3	4	4	11	18	28	63	88	100	128	189	117	137	891
C37 / Thymus	0	0	1	1	3	2	4	4	2	3	4	1	3	1	2	1	1	33
C38 / Heart, Mediastinum, pleura	2	1	0	1	1	3	2	0	1	2	4	5	6	1	5	5	4	43
C39 / Other respiratory & thoracic	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	3
C40 / Bone & cartilage, limbs	4	7	29	18	7	7	2	4	6	4	10	2	2	4	5	2	4	117
C41 / Bones & cartilage, other	5	5	13	13	7	4	2	3	4	3	6	5	7	6	3	6	2	94
Leukemia	122	78	51	45	39	36	41	25	44	40	54	49	48	64	54	39	44	873
Chronic Myeloproliferative disorders	0	2	2	4	2	2	5	4	5	10	15	14	4	12	8	6	5	100
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
mast cell tumor	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1
Plasma cell tumor	0	0	0	0	0	0	1	2	5	12	19	25	29	28	39	12	16	188
Myelodysplastic syndromes	1	1	0	0	0	1	2	0	0	0	1	3	4	2	5	6	5	31
C44 / Skin, other	3	1	3	7	7	10	20	16	39	36	67	67	89	80	99	60	93	697
C47 /Nerves system	3	2	0	0	0	1	0	1	0	0	1	1	0	0	0	0	0	9
C48 / Peritoneum	5	2	0	1	0	1	3	4	3	2	5	3	8	3	2	1	0	43
C49 / soft tissues	11	4	9	17	19	19	17	15	17	29	21	20	16	14	12	6	7	253

ICDO/ Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total
C50 / Breast	0	0	0	1	19	123	352	598	1050	1257	1332	1200	996	758	535	260	227	8708
C51 / Vulva	0	0	0	2	0	0	1	3	3	6	2	3	5	6	4	3	2	40
C52 / Vagina	1	0	0	0	0	0	3	0	0	1	2	0	2	4	0	1	1	15
C53 / Cervix uteri	0	0	0	0	3	4	9	16	31	42	55	41	43	32	24	11	9	320
C54 / Corpus uteri	0	0	0	0	2	2	9	6	24	38	64	110	82	90	57	12	17	513
C55 / Uterus unspecified	0	0	1	1	3	9	15	36	44	59	87	150	149	98	78	34	25	789
C56 / Ovary	5	2	14	26	39	28	54	58	81	123	119	107	115	107	79	41	38	1036
C57 / Female genital - other	0	0	0	0	0	0	2	0	0	0	3	0	0	0	0	1	0	6
C58 / Placenta	0	0	0	4	5	9	5	7	2	3	0	0	0	0	0	0	0	35
C64 / Kidney	41	20	3	3	9	13	24	24	35	52	47	58	59	37	39	19	25	508
C65 / Pelvis	1	0	0	1	0	1	0	4	0	2	3	1	2	0	2	0	1	18
C66 / Ureter	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	0	5
C67 / Urinary bladder	0	0	0	5	3	3	5	5	6	11	23	29	41	61	97	60	67	416
C69 / Eye & adnexa	22	3	1	0	0	1	1	0	0	1	1	2	3	1	2	0	1	39
C70 / Meninges	1	0	3	2	6	2	15	26	38	46	47	39	43	35	26	13	6	348
C71 / Brain	32	60	57	47	47	32	68	65	70	95	95	80	72	56	52	21	39	988
C72 / Nervous system, other	4	4	3	4	5	2	3	4	5	3	2	3	3	1	0	0	3	49
C73 / Thyroid gland	1	4	15	50	107	222	327	308	318	284	232	137	100	72	39	24	25	2265
C74 / Adrenal gland	24	9	4	0	2	0	3	8	4	5	5	4	4	3	2	0	0	77
C75 / Endocrine gland, other	2	3	4	7	11	17	15	8	3	13	12	8	4	5	1	2	1	116
C76 / Unspecified site	9	0	4	2	0	0	1	5	3	9	7	9	10	9	5	4	2	79
C77/ Lymph node	Hodgkin Lymphoma																	
	8	15	24	47	52	41	28	16	11	18	13	14	15	2	7	4	3	318
Non-Hodgkin Lymphoma																		
Non-Hodgkin Lymphoma																		
C80 / Unknown primary site	6	4	1	3	5	7	8	23	22	27	39	40	54	40	51	31	28	389
All Sites Total	344	250	266	362	467	690	1183	1481	2163	2565	2953	2842	2596	2307	2135	1162	1255	25021
Percentage	1.4	1.0	1.1	1.4	1.9	2.8	4.7	5.9	8.6	10.3	11.8	11.4	10.4	9.2	8.5	4.6	5.0	100%

Table 70: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqis, Both Genders, (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	1	0.08	0.07	2	0.07	0.08	3	0.10	0.14	1	0.03	0.02	0	0.00	0.00
C01 / Tongue, base	1	0.08	0.07	1	0.04	0.04	0	0.00	0.00	0	0.00	0.00	1	0.09	0.06
C02 / Tongue, other	7	0.59	0.48	4	0.14	0.16	9	0.30	0.43	12	0.39	0.28	5	0.44	0.28
C03 / Gum	0	0.00	0.00	1	0.04	0.04	2	0.07	0.09	1	0.03	0.02	1	0.09	0.06
C04 / Mouth - floor	0	0.00	0.00	0	0.00	0.00	4	0.13	0.19	1	0.03	0.02	0	0.00	0.00
C05 / Mouth - palate	1	0.08	0.07	4	0.14	0.16	3	0.10	0.14	1	0.03	0.02	1	0.09	0.06
C06 / Mouth - other	0	0.00	0.00	3	0.11	0.12	3	0.10	0.14	6	0.20	0.14	1	0.09	0.06
C07 / Parotid gland	1	0.08	0.07	1	0.04	0.04	7	0.23	0.33	7	0.23	0.17	1	0.09	0.06
C08 / Mouth glands	3	0.25	0.20	4	0.14	0.16	2	0.07	0.09	3	0.10	0.07	2	0.18	0.11
C09 / Tonsil	0	0.00	0.00	1	0.04	0.04	1	0.03	0.05	2	0.07	0.05	0	0.00	0.00
C10 / Oropharynx	1	0.08	0.07	2	0.07	0.08	0	0.00	0.00	0	0.00	0.00	1	0.09	0.06
C11 / Nasopharynx	2	0.17	0.14	5	0.18	0.20	14	0.46	0.66	16	0.52	0.38	7	0.62	0.39
C12 / Pyriform	0	0.00	0.00	1	0.04	0.04	0	0.00	0.00	1	0.03	0.02	0	0.00	0.00
C13 / Hypopharynx	0	0.00	0.00	1	0.04	0.04	2	0.07	0.09	1	0.03	0.02	2	0.18	0.11
C14 / Pharynx	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	2	0.07	0.05	0	0.00	0.00
C15 / Oesophagus	12	1.01	0.82	26	0.93	1.06	22	0.73	1.04	14	0.46	0.33	9	0.79	0.50
C16 / Stomach	36	3.04	2.45	91	3.25	3.70	90	2.97	4.27	97	3.17	2.29	40	3.52	2.20
C17 / Small intestine	3	0.25	0.20	6	0.21	0.24	5	0.17	0.24	18	0.59	0.42	4	0.35	0.22
C18 / Colon	65	5.48	4.43	194	6.94	7.90	155	5.12	7.35	161	5.26	3.80	69	6.07	3.80
C19 / Recto sigmoid Junction	1	0.08	0.07	6	0.21	0.24	19	0.63	0.90	5	0.16	0.12	8	0.70	0.44
C20 / Rectum	35	2.95	2.38	66	2.36	2.69	53	1.75	2.51	59	1.93	1.39	35	3.08	1.93

ICDO/Site		Duhok		Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
		No.	%	IR	No.	%	IR	No.	%	IR	No.	%	No.	%	IR
C21 / Anus & anal canal		0	0.00	0.00	2	0.07	0.08	3	0.10	0.14	3	0.10	0.07	0	0.00
C22 / Liver & bile ducts		17	1.43	1.16	40	1.43	1.63	19	0.63	0.90	43	1.41	1.01	28	2.46
C23 / Gallbladder		11	0.93	0.75	33	1.18	1.34	22	0.73	1.04	12	0.39	0.28	14	1.23
C24 / Biliary tract, other		5	0.42	0.34	9	0.32	0.37	15	0.50	0.71	11	0.36	0.26	4	0.35
C25 / Pancreas		25	2.11	1.70	51	1.82	2.08	68	2.24	3.23	82	2.68	1.93	20	1.76
C26 / Other digestive organs		0	0.00	0.00	0	0.00	0.00	3	0.10	0.14	2	0.07	0.05	1	0.09
C30 / Nasal cavity		3	0.25	0.20	2	0.07	0.08	1	0.03	0.05	1	0.03	0.02	0	0.00
C31 / Accessory sinus		2	0.17	0.14	1	0.04	0.04	3	0.10	0.14	1	0.03	0.02	0	0.00
C32 / Larynx		12	1.01	0.82	16	0.57	0.65	43	1.42	2.04	59	1.93	1.39	9	0.79
C33 / Trachea		0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.09
C34 / Bronchus & lung		110	9.27	7.49	172	6.15	7.00	225	7.43	10.67	218	7.13	5.14	101	8.89
C37 / Thymus		1	0.08	0.07	2	0.07	0.08	4	0.13	0.19	6	0.20	0.14	0	0.00
C38 / Heart, Mediastinum, pleura		3	0.25	0.20	4	0.14	0.16	7	0.23	0.33	5	0.16	0.12	4	0.35
C39 / Other respiratory & thoracic		0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00
C40 / Bone & cartilage, limbs		11	0.93	0.75	13	0.46	0.53	12	0.40	0.57	16	0.52	0.38	8	0.70
C41 / Bones & cartilage, other		5	0.42	0.34	17	0.61	0.69	11	0.36	0.52	25	0.82	0.59	4	0.35
C42 / Reticulo endothelial& Hematopoietic System	Leukemia	66	5.56	4.49	94	3.36	3.83	127	4.19	6.03	189	6.18	4.46	55	4.84
	Chronic Myeloproliferative disorders	1	0.08	0.07	168	6.01	6.84	29	0.96	1.38	12	0.39	0.28	3	0.26
	Immunoproliferative diseases	0	0.00	0.00	0	0.00	0.00	1	0.03	0.05	0	0.00	0.00	0	0.00
mast cell tumor		0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00
Plasma cell tumor		12	1.01	0.82	68	2.43	2.77	42	1.39	1.99	21	0.69	0.50	5	0.44

ICDO/Site		Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
		No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
Myelodysplastic syndromes		2	0.17	0.14	19	0.68	0.77	6	0.20	0.28	0	0.00	0.00	0	0.00	0.00
	C44 / Skin, other	75	6.32	5.11	76	2.72	3.09	270	8.91	12.81	92	3.01	2.17	29	2.55	1.60
C47 /Nerves system		0	0.00	0.00	0	0.00	0.00	1	0.03	0.05	0	0.00	0.00	0	0.00	0.00
C48 / Peritoneum		2	0.17	0.14	6	0.21	0.24	9	0.30	0.43	2	0.07	0.05	1	0.09	0.06
C49 / soft tissues		9	0.76	0.61	24	0.86	0.98	33	1.09	1.57	50	1.64	1.18	7	0.62	0.39
C50 / Breast		250	21.08	17.02	533	19.06	21.69	669	22.08	31.74	652	21.32	15.38	309	27.20	17.02
C51 / Vulva		0	0.00	0.00	0	0.00	0.00	3	0.10	0.29	1	0.03	0.05	1	0.09	0.11
C52 / Vagina		0	0.00	0.00	2	0.07	0.16	2	0.07	0.19	2	0.07	0.10	1	0.09	0.11
C53 / Cervix uteri		8	0.67	1.09	13	0.46	1.06	24	0.79	2.30	19	0.62	0.92	5	0.44	0.55
C54 / Corpus uteri		7	0.59	0.96	43	1.54	3.50	44	1.45	4.22	40	1.31	1.93	6	0.53	0.67
C55 / Uterus unspecified		17	1.43	2.32	7	0.25	0.57	38	1.25	3.64	58	1.90	2.80	15	1.32	1.66
C56 / Ovary		24	2.02	3.28	66	2.36	5.37	68	2.24	6.52	89	2.91	4.29	29	2.55	3.22
C57 / Female genital - other		1	0.08	0.14	1	0.04	0.08	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C58 / Placenta		2	0.17	0.27	1	0.04	0.08	4	0.13	0.38	2	0.07	0.10	0	0.00	0.00
C60 / Penis		0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C61 / Prostate		53	4.47	7.20	152	5.44	12.37	158	5.21	14.85	118	3.86	5.45	41	3.61	4.49
C62 / Testis		13	1.10	1.77	24	0.86	1.95	24	0.79	2.26	27	0.88	1.25	6	0.53	0.66
C63 / Male genital - other		0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C64 / Kidney		29	2.45	1.97	60	2.15	2.44	99	3.27	4.70	101	3.30	2.38	37	3.26	2.04
C65 / Pelvis		3	0.25	0.20	23	0.82	0.94	2	0.07	0.09	0	0.00	0.00	0	0.00	0.00
C66 / Ureter		0	0.00	0.00	1	0.04	0.04	3	0.10	0.14	1	0.03	0.02	0	0.00	0.00
C67 / Urinary bladder		45	3.79	3.06	107	3.83	4.35	121	3.99	5.74	118	3.86	2.78	50	4.40	2.75

ICDO/Site	Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk			
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	
C68 / Urinary organs, other	0	0.00	0.00	1	0.04	0.04	0	0.00	0.00	0	0.00	0.00	1	0.09	0.06	
C69 / Eye & adnexa	1	0.08	0.07	4	0.14	0.16	10	0.33	0.47	7	0.23	0.17	6	0.53	0.33	
C70 / Meninges	4	0.34	0.27	13	0.46	0.53	5	0.17	0.24	16	0.52	0.38	14	1.23	0.77	
C71 / Brain	43	3.63	2.93	114	4.08	4.64	94	3.10	4.46	156	5.10	3.68	36	3.17	1.98	
C72 / Nervous system, other	1	0.08	0.07	6	0.21	0.24	7	0.23	0.33	8	0.26	0.19	2	0.18	0.11	
C73 / Thyroid gland	50	4.22	3.40	125	4.47	5.09	124	4.09	5.88	119	3.89	2.81	36	3.17	1.98	
C74 / Adrenal gland	3	0.25	0.20	13	0.46	0.53	8	0.26	0.38	10	0.33	0.24	6	0.53	0.33	
C75 / Endocrine gland, other	4	0.34	0.27	9	0.32	0.37	9	0.30	0.43	9	0.29	0.21	9	0.79	0.50	
C76 / Unspecified site	2	0.17	0.14	8	0.29	0.33	4	0.13	0.19	2	0.07	0.05	2	0.18	0.11	
C77/ Lymph node	Hodgkin Lymphoma	24	2.02	1.63	49	1.75	1.99	36	1.19	1.71	59	1.93	1.39	10	0.88	0.55
	Non-Hodgkin Lymphoma	48	4.05	3.27	111	3.97	4.52	97	3.20	4.60	101	3.30	2.38	25	2.20	1.38
C80 / Unknown primary site	13	1.10	0.89	74	2.65	3.01	29	0.96	1.38	85	2.78	2.01	8	0.70	0.44	
Total All Sites	1186	100%	80.7	2796	100%	113.8	3030.0	100%	143.8	3058	100%	72.1	113	100%	62.6	

Note:

*From C51 to C58 the incidence rate was calculated from the female population.

*From C60 to C63 the incidence rate was calculated from the male population.

Table 71: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqis, Both Genders, (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	8	0.07	0.09	0	0.00	0.00	1	0.08	0.06	1	0.07	0.05
C01 / Tongue, base	8	0.07	0.09	0	0.00	0.00	2	0.15	0.11	0	0.00	0.00
C02 / Tongue, other	37	0.33	0.40	4	0.24	0.22	4	0.31	0.22	8	0.53	0.40
C03 / Gum	1	0.01	0.01	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C04 / Mouth - floor	9	0.08	0.10	1	0.06	0.05	0	0.00	0.00	0	0.00	0.00
C05 / Mouth - palate	3	0.03	0.03	1	0.06	0.05	0	0.00	0.00	0	0.00	0.00
C06 / Mouth - other	19	0.17	0.21	2	0.12	0.11	2	0.15	0.11	1	0.07	0.05
C07 / Parotid gland	20	0.18	0.22	1	0.06	0.05	1	0.08	0.06	3	0.20	0.15
C08 / Mouth glands	20	0.18	0.22	3	0.18	0.16	2	0.15	0.11	3	0.20	0.15
C09 / Tonsil	5	0.05	0.05	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C10 / Oropharynx	4	0.04	0.04	0	0.00	0.00	1	0.08	0.06	0	0.00	0.00
C11 / Nasopharynx	53	0.48	0.57	2	0.12	0.11	8	0.61	0.44	10	0.66	0.50
C12 / Pyriform	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	3	0.03	0.03	1	0.06	0.05	2	0.15	0.11	0	0.00	0.00
C14 / Pharynx	5	0.05	0.05	0	0.00	0.00	1	0.08	0.06	1	0.07	0.05
C15 / Oesophagus	52	0.47	0.56	6	0.36	0.33	6	0.46	0.33	7	0.46	0.35
C16 / Stomach	268	2.42	2.89	62	3.71	3.39	33	2.53	1.82	47	3.10	2.33
C17 / Small intestine	41	0.37	0.44	14	0.84	0.76	5	0.38	0.28	3	0.20	0.15
C18 / Colon	523	4.72	5.64	74	4.43	4.04	58	4.45	3.20	81	5.35	4.02
C19 / Recto sigmoid Junction	52	0.47	0.56	8	0.48	0.44	5	0.38	0.28	12	0.79	0.60
C20 / Rectum	255	2.30	2.75	27	1.61	1.48	18	1.38	0.99	44	2.91	2.19

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C21 / Anus & anal canal	11	0.10	0.12	1	0.06	0.05	1	0.08	0.06	0	0.00	0.00
C22 / Liver & bile ducts	240	2.17	2.59	32	1.91	1.75	31	2.38	1.71	41	2.71	2.04
C23 / Gallbladder	58	0.52	0.63	3	0.18	0.16	8	0.61	0.44	6	0.40	0.30
C24 / Biliary tract, other	50	0.45	0.54	8	0.48	0.44	2	0.15	0.11	1	0.07	0.05
C25 / Pancreas	335	3.03	3.62	53	3.17	2.90	36	2.76	1.99	38	2.51	1.89
C26 / Other digestive organs	16	0.14	0.17	1	0.06	0.05	2	0.15	0.11	7	0.46	0.35
C30 / Nasal cavity	22	0.20	0.24	3	0.18	0.16	1	0.08	0.06	2	0.13	0.10
C31 / Accessory sinus	8	0.07	0.09	1	0.06	0.05	1	0.08	0.06	1	0.07	0.05
C32 / Larynx	106	0.96	1.14	20	1.20	1.09	15	1.15	0.83	10	0.66	0.50
C33 / Trachea	1	0.01	0.01	0	0.00	0.00	1	0.08	0.06	0	0.00	0.00
C34 / Bronchus & lung	637	5.75	6.88	124	7.42	6.77	95	7.29	5.24	89	5.88	4.42
C37 / Thymus	22	0.20	0.24	2	0.12	0.11	2	0.15	0.11	0	0.00	0.00
C38 / Heart, Mediastinum, pleura	28	0.25	0.30	5	0.30	0.27	2	0.15	0.11	5	0.33	0.25
C39 / Other respiratory & thoracic	2	0.02	0.02	0	0.00	0.00	1	0.08	0.06	1	0.07	0.05
C40 / Bone & cartilage, limbs	65	0.59	0.70	10	0.60	0.55	9	0.69	0.50	19	1.25	0.94
C41 / Bones & cartilage, other	66	0.60	0.71	6	0.36	0.33	7	0.54	0.39	9	0.59	0.45
Leukemia	353	3.19	3.81	67	4.01	3.66	50	3.83	2.76	61	4.03	3.03
Chronic Myeloproliferative disorders	5	0.05	0.05	4	0.24	0.22	0	0.00	0.00	2	0.13	0.10
C42 / Reticulo endothelial& Hematopoietic System	1	0.01	0.01	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
Immunoproliferative diseases	1	0.01	0.01	0	0.00	0.00	0	0.00	0.00	1	0.07	0.05
mast cell tumor	61	0.55	0.66	7	0.42	0.38	5	0.38	0.28	20	1.32	0.99
Plasma cell tumor	5	0.05	0.05	0	0.00	0.00	0	0.00	0.00	1	0.07	0.05
Myelodysplastic syndromes												

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C44 / Skin, other	319	2.88	3.44	80	4.78	4.37	43	3.30	2.37	19	1.25	0.94
C47 /Nerves system	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C48 / Peritoneum	17	0.15	0.18	1	0.06	0.05	1	0.08	0.06	5	0.33	0.25
C49 / soft tissues	181	1.63	1.95	29	1.73	1.58	16	1.23	0.88	9	0.59	0.45
C50 / Breast	2709	24.47	29.24	369	22.07	20.16	271	20.78	14.95	278	18.36	13.81
C51 / Vulva	11	0.10	0.24	3	0.18	0.33	1	0.08	0.11	1	0.07	0.10
C52 / Vagina	2	0.02	0.04	0	0.00	0.00	1	0.08	0.11	1	0.07	0.10
C53 / Cervix uteri	89	0.80	1.95	12	0.72	1.32	10	0.77	1.11	16	1.06	1.63
C54 / Corpus uteri	233	2.10	5.11	19	1.14	2.10	3	0.23	0.33	15	0.99	1.53
C55 / Uterus unspecified	202	1.82	4.43	31	1.85	3.42	28	2.15	3.12	21	1.39	2.15
C56 / Ovary	271	2.45	5.94	50	2.99	5.52	25	1.92	2.79	41	2.71	4.19
C57 / Female genital - other	3	0.03	0.07	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C58 / Placenta	9	0.08	0.20	0	0.00	0.00	3	0.23	0.33	0	0.00	0.00
C60 / Penis	1	0.01	0.02	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C61 / Prostate	408	3.69	8.68	78	4.67	8.44	48	3.68	5.24	68	4.49	6.57
C62 / Testis	55	0.50	1.17	18	1.08	1.95	3	0.23	0.33	6	0.40	0.58
C63 / Male genital - other	1	0.01	0.02	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C64 / Kidney	335	3.03	3.62	46	2.75	2.51	39	2.99	2.15	32	2.11	1.59
C65 / Pelvis	1	0.01	0.01	3	0.18	0.16	4	0.31	0.22	1	0.07	0.05
C66 / Ureter	5	0.05	0.05	0	0.00	0.00	2	0.15	0.11	0	0.00	0.00
C67 / Urinary bladder	437	3.95	4.72	54	3.23	2.95	52	3.99	2.87	54	3.57	2.68
C68 / Urinary organs, other	4	0.04	0.04	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C69 / Eye & adnexa	26	0.23	0.28	6	0.36	0.33	5	0.38	0.28	5	0.33	0.25
C70 / Meninges	202	1.82	2.18	24	1.44	1.31	13	1.00	0.72	15	0.99	0.75

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C71 / Brain	487	4.40	5.26	83	4.96	4.53	71	5.44	3.92	85	5.61	4.22
C72 / Nervous system, other	14	0.13	0.15	3	0.18	0.16	1	0.08	0.06	0	0.00	0.00
C73 / Thyroid gland	756	6.83	8.16	99	5.92	5.41	156	11.96	8.61	175	11.56	8.69
C74 / Adrenal gland	35	0.32	0.38	3	0.18	0.16	9	0.69	0.50	4	0.26	0.20
C75 / Endocrine gland, other	60	0.54	0.65	8	0.48	0.44	5	0.38	0.28	5	0.33	0.25
C76 / Unspecified site	59	0.53	0.64	4	0.24	0.22	3	0.23	0.17	5	0.33	0.25
C77/ Lymph node	125	1.13	1.35	20	1.20	1.09	24	1.84	1.32	42	2.77	2.09
C80 / Unknown primary site	236	2.13	2.55	35	2.09	1.91	12	0.92	0.66	19	1.25	0.94
All Sites Total	1107	100%	119.5	1672	100%	91.3	1304	100%	71.9	1514	100%	75.2

Note:

* From C51 to C58 the incidence rate was calculated from the female population.

* From C60 to C63 the incidence rate was calculated from the male population.

Table 72: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqis, Both Genders, (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	1	0.05	0.06	1	0.06	0.07	2	0.09	0.09	1	0.07	0.06	1	0.08	0.07
C01 / Tongue, base	0	0.00	0.00	0	0.00	0.00	5	0.23	0.21	0	0.00	0.00	0	0.00	0.00
C02 / Tongue, other	9	0.45	0.54	10	0.58	0.72	2	0.09	0.09	5	0.35	0.32	3	0.23	0.20
C03 / Gum	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.07	0.06	0	0.00	0.00
C04 / Mouth - floor	0	0.00	0.00	0	0.00	0.00	1	0.05	0.04	0	0.00	0.00	0	0.00	0.00
C05 / Mouth - palate	1	0.05	0.06	0	0.00	0.00	3	0.14	0.13	0	0.00	0.00	1	0.08	0.07
C06 / Mouth - other	3	0.15	0.18	5	0.29	0.36	4	0.19	0.17	2	0.14	0.13	3	0.23	0.20
C07 / Parotid gland	6	0.30	0.36	3	0.17	0.22	1	0.05	0.04	1	0.07	0.06	3	0.23	0.20
C08 / Mouth glands	4	0.20	0.24	3	0.17	0.22	3	0.14	0.13	3	0.21	0.19	3	0.23	0.20
C09 / Tonsil	0	0.00	0.00	0	0.00	0.00	1	0.05	0.04	1	0.07	0.06	0	0.00	0.00
C10 / Oropharynx	0	0.00	0.00	1	0.06	0.07	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C11 / Nasopharynx	10	0.50	0.60	13	0.75	0.94	11	0.51	0.47	7	0.49	0.45	4	0.30	0.27
C12 / Pyriform	1	0.05	0.06	1	0.06	0.07	1	0.05	0.04	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	1	0.05	0.06	0	0.00	0.00	1	0.05	0.04	0	0.00	0.00	0	0.00	0.00
C14 / Pharynx	0	0.00	0.00	1	0.06	0.07	1	0.05	0.04	1	0.07	0.06	1	0.08	0.07
C15 / Oesophagus	5	0.25	0.30	3	0.17	0.22	22	1.03	0.94	5	0.35	0.32	6	0.45	0.41
C16 / Stomach	56	2.79	3.35	40	2.30	2.89	47	2.19	2.00	32	2.25	2.04	30	2.27	2.04
C17 / Small intestine	5	0.25	0.30	11	0.63	0.79	11	0.51	0.47	6	0.42	0.38	5	0.38	0.34
C18 / Colon	75	3.74	4.48	107	6.16	7.73	82	3.82	3.49	67	4.71	4.28	61	4.62	4.16
C19 / Recto sigmoid Junction	9	0.45	0.54	2	0.12	0.14	1	0.05	0.04	5	0.35	0.32	7	0.53	0.48
C20 / Rectum	21	1.05	1.26	18	1.04	1.30	25	1.17	1.07	20	1.41	1.28	21	1.59	1.43

ICDO/Site		Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
		No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C42 / Reticulo endothelial & Hematopoi etic System	C21 / Anus & anal canal	5	0.25	0.30	4	0.23	0.29	3	0.14	0.13	1	0.07	0.06	1	0.08	0.07
	C22 / Liver & bile ducts	46	2.29	2.75	34	1.96	2.45	49	2.28	2.09	39	2.74	2.49	32	2.42	2.18
	C23 / Gallbladder	7	0.35	0.42	10	0.58	0.72	8	0.37	0.34	8	0.56	0.51	5	0.38	0.34
	C24 / Biliary tract, other	3	0.15	0.18	4	0.23	0.29	3	0.14	0.13	6	0.42	0.38	14	1.06	0.95
	C25 / Pancreas	72	3.59	4.31	64	3.68	4.62	60	2.80	2.56	43	3.02	2.74	31	2.35	2.11
	C26 / Other digestive organs	6	0.30	0.36	0	0.00	0.00	2	0.09	0.09	1	0.07	0.06	3	0.23	0.20
	C30 / Nasal cavity	1	0.05	0.06	0	0.00	0.00	2	0.09	0.09	1	0.07	0.06	1	0.08	0.07
	C31 / Accessory sinus	0	0.00	0.00	0	0.00	0.00	1	0.05	0.04	0	0.00	0.00	0	0.00	0.00
	C32 / Larynx	25	1.25	1.49	17	0.98	1.23	30	1.40	1.28	17	1.19	1.09	13	0.98	0.89
	C33 / Trachea	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.07	0.06	0	0.00	0.00
	C34 / Bronchus & lung	164	8.17	9.81	138	7.94	9.96	166	7.74	7.07	93	6.54	5.94	127	9.62	8.66
	C37 / Thymus	3	0.15	0.18	2	0.12	0.14	0	0.00	0.00	1	0.07	0.06	3	0.23	0.20
	C38 / Heart, Mediastinum, pleura	8	0.40	0.48	2	0.12	0.14	3	0.14	0.13	1	0.07	0.06	2	0.15	0.14
	C39 / Other respiratory & thoracic	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
	C40 / Bone & cartilage, limbs	7	0.35	0.42	14	0.81	1.01	15	0.70	0.64	8	0.56	0.51	8	0.61	0.55
	C41 / Bones & cartilage, other	11	0.55	0.66	15	0.86	1.08	8	0.37	0.34	12	0.84	0.77	12	0.91	0.82
C42 / Reticulo endothelial & Hematopoi etic System	Leukemia	134	6.68	8.01	85	4.89	6.14	93	4.34	3.96	54	3.79	3.45	72	5.45	4.91
	Chronic Myeloproliferative disorders	0	0.00	0.00	3	0.17	0.22	3	0.14	0.13	2	0.14	0.13	1	0.08	0.07
	Immunoproliferative diseases	0	0.00	0.00	1	0.06	0.07	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
	mast cell tumor	0	0.00	0.00	1	0.06	0.07	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
	Plasma cell tumor	12	0.60	0.72	10	0.58	0.72	31	1.45	1.32	6	0.42	0.38	12	0.91	0.82
	Myelodysplastic syndromes	0	0.00	0.00	3	0.17	0.22	2	0.09	0.09	0	0.00	0.00	1	0.08	0.07

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C44 / Skin, other	78	3.89	4.66	54	3.11	3.90	54	2.52	2.30	80	5.62	5.11	45	3.41	3.07
C47 /Nerves system	1	0.05	0.06	1	0.06	0.07	1	0.05	0.04	0	0.00	0.00	1	0.08	0.07
C48 / Peritoneum	2	0.10	0.12	3	0.17	0.22	3	0.14	0.13	0	0.00	0.00	0	0.00	0.00
C49 / soft tissues	23	1.15	1.38	20	1.15	1.44	28	1.31	1.19	10	0.70	0.64	9	0.68	0.61
C50 / Breast	355	17.69	21.23	342	19.69	24.69	402	18.74	17.13	261	18.34	16.66	199	15.08	13.56
C51 / Vulva	2	0.10	0.24	2	0.12	0.29	1	0.05	0.09	1	0.07	0.13	1	0.08	0.14
C52 / Vagina	1	0.05	0.12	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.08	0.14
C53 / Cervix uteri	13	0.65	1.56	23	1.32	3.35	13	0.61	1.12	7	0.49	0.90	6	0.45	0.82
C54 / Corpus uteri	25	1.25	3.00	4	0.23	0.58	7	0.33	0.60	1	0.07	0.13	6	0.45	0.82
C55 / Uterus unspecified	24	1.20	2.88	46	2.65	6.70	56	2.61	4.82	28	1.97	3.61	39	2.95	5.36
C56 / Ovary	55	2.74	6.60	30	1.73	4.37	46	2.14	3.96	36	2.53	4.64	19	1.44	2.61
C57 / Female genital - other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.07	0.13	0	0.00	0.00
C58 / Placenta	3	0.15	0.36	3	0.17	0.44	1	0.05	0.09	0	0.00	0.00	0	0.00	0.00
C60 / Penis	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	2	0.15	0.27
C61 / Prostate	61	3.04	7.28	54	3.11	7.73	79	3.68	6.66	45	3.16	5.69	57	4.32	7.71
C62 / Testis	12	0.60	1.43	10	0.58	1.43	13	0.61	1.10	17	1.19	2.15	8	0.61	1.08
C63 / Male genital - other	0	0.00	0.00	2	0.12	0.29	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C64 / Kidney	79	3.94	4.72	58	3.34	4.19	68	3.17	2.90	56	3.94	3.57	56	4.24	3.82
C65 / Pelvis	1	0.05	0.06	1	0.06	0.07	1	0.05	0.04	1	0.07	0.06	0	0.00	0.00
C66 / Ureter	0	0.00	0.00	1	0.06	0.07	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C67 / Urinary bladder	118	5.88	7.06	99	5.70	7.15	126	5.87	5.37	90	6.32	5.74	84	6.36	5.73
C68 / Urinary organs, other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.07	0.06	0	0.00	0.00
C69 / Eye & adnexa	6	0.30	0.36	1	0.06	0.07	2	0.09	0.09	2	0.14	0.13	3	0.23	0.20
C70 / Meninges	12	0.60	0.72	23	1.32	1.66	30	1.40	1.28	19	1.34	1.21	9	0.68	0.61

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C71 / Brain	95	4.73	5.68	77	4.43	5.56	120	5.59	5.11	58	4.08	3.70	71	5.38	4.84
C72 / Nervous system, other	4	0.20	0.24	3	0.17	0.22	6	0.28	0.26	1	0.07	0.06	2	0.15	0.14
C73 / Thyroid gland	158	7.87	9.45	131	7.54	9.46	181	8.44	7.71	154	10.82	9.83	117	8.86	7.97
C74 / Adrenal gland	2	0.10	0.12	6	0.35	0.43	8	0.37	0.34	3	0.21	0.19	9	0.68	0.61
C75 / Endocrine gland, other	8	0.40	0.48	10	0.58	0.72	6	0.28	0.26	8	0.56	0.51	6	0.45	0.41
C76 / Unspecified site	19	0.95	1.14	1	0.06	0.07	3	0.14	0.13	4	0.28	0.26	13	0.98	0.89
C77/ Lymph node	49	2.44	2.93	36	2.07	2.60	43	2.00	1.83	22	1.55	1.40	12	0.91	0.82
	73	3.64	4.37	65	3.74	4.69	83	3.87	3.54	49	3.44	3.13	52	3.94	3.54
C80 / Unknown primary site	17	0.85	1.02	5	0.29	0.36	61	2.84	2.60	17	1.19	1.09	6	0.45	0.41
All Sites Total	2007	100%	120.0	1737	100%	125.4	2145	100%	91.4	1423	100%	90.8	1320	100%	90.0

Note:

* From C51 to C58 the incidence rate was calculated from the female population.

* From C60 to C63 the incidence rate was calculated from the male population.

Table 73: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqis, Both Genders, (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	0	0.00	0.00	1	0.06	0.04	1	0.09	0.08	1	0.03	0.03
C01 / Tongue, base	1	0.13	0.11	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C02 / Tongue, other	1	0.13	0.11	3	0.18	0.13	3	0.28	0.24	19	0.54	0.57
C03 / Gum	0	0.00	0.00	1	0.06	0.04	0	0.00	0.00	0	0.00	0.00
C04 / Mouth - floor	2	0.26	0.22	2	0.12	0.08	0	0.00	0.00	2	0.06	0.06
C05 / Mouth - palate	1	0.13	0.11	4	0.24	0.17	0	0.00	0.00	1	0.03	0.03
C06 / Mouth - other	1	0.13	0.11	4	0.24	0.17	1	0.09	0.08	10	0.29	0.30
C07 / Parotid gland	1	0.13	0.11	2	0.12	0.08	2	0.18	0.16	5	0.14	0.15
C08 / Mouth glands	0	0.00	0.00	0	0.00	0.00	2	0.18	0.16	3	0.09	0.09
C09 / Tonsil	0	0.00	0.00	2	0.12	0.08	1	0.09	0.08	1	0.03	0.03
C10 / Oropharynx	1	0.13	0.11	1	0.06	0.04	2	0.18	0.16	2	0.06	0.06
C11 / Nasopharynx	4	0.51	0.43	21	1.25	0.88	4	0.37	0.32	22	0.63	0.67
C12 / Pyriform	1	0.13	0.11	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	3	0.38	0.32	1	0.06	0.04	2	0.18	0.16	0	0.00	0.00
C14 / Pharynx	2	0.26	0.22	2	0.12	0.08	1	0.09	0.08	3	0.09	0.09
C15 / Oesophagus	8	1.02	0.86	6	0.36	0.25	10	0.92	0.79	20	0.57	0.61
C16 / Stomach	26	3.32	2.81	37	2.20	1.55	37	3.40	2.93	107	3.06	3.24
C17 / Small intestine	5	0.64	0.54	11	0.65	0.46	7	0.64	0.55	14	0.40	0.42
C18 / Colon	22	2.81	2.38	62	3.69	2.60	47	4.32	3.72	155	4.43	4.69
C19 / Recto sigmoid Junction	3	0.38	0.32	3	0.18	0.13	8	0.74	0.63	16	0.46	0.48
C20 / Rectum	14	1.79	1.51	30	1.79	1.26	19	1.75	1.50	86	2.46	2.60

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C21 / Anus & anal canal	3	0.38	0.32	3	0.18	0.13	0	0.00	0.00	5	0.14	0.15
C22 / Liver & bile ducts	21	2.68	2.27	51	3.04	2.14	19	1.75	1.50	38	1.09	1.15
C23 / Gallbladder	4	0.51	0.43	8	0.48	0.34	5	0.46	0.40	27	0.77	0.82
C24 / Biliary tract, other	2	0.26	0.22	10	0.60	0.42	3	0.28	0.24	21	0.60	0.64
C25 / Pancreas	32	4.09	3.46	67	3.99	2.81	31	2.85	2.45	115	3.29	3.48
C26 / Other digestive organs	1	0.13	0.11	0	0.00	0.00	1	0.09	0.08	1	0.03	0.03
C30 / Nasal cavity	0	0.00	0.00	1	0.06	0.04	1	0.09	0.08	5	0.14	0.15
C31 / Accessory sinus	1	0.13	0.11	2	0.12	0.08	0	0.00	0.00	4	0.11	0.12
C32 / Larynx	10	1.28	1.08	18	1.07	0.76	12	1.10	0.95	41	1.17	1.24
C33 / Trachea	0	0.00	0.00	1	0.06	0.04	1	0.09	0.08	1	0.03	0.03
C34 / Bronchus & lung	93	11.88	10.05	171	10.18	7.18	73	6.71	5.77	195	5.58	5.90
C37 / Thymus	0	0.00	0.00	1	0.06	0.04	2	0.18	0.16	13	0.37	0.39
C38 / Heart, Mediastinum, pleura	4	0.51	0.43	4	0.24	0.17	5	0.46	0.40	5	0.14	0.15
C39 / Other respiratory & thoracic	1	0.13	0.11	1	0.06	0.04	0	0.00	0.00	0	0.00	0.00
C40 / Bone & cartilage, limbs	5	0.64	0.54	13	0.77	0.55	9	0.83	0.71	21	0.60	0.64
C41 / Bones & cartilage, other	8	1.02	0.86	9	0.54	0.38	5	0.46	0.40	10	0.29	0.30
C42 / Reticulo endothelial& Hematopoietic System	48	6.13	5.19	100	5.95	4.20	55	5.06	4.35	150	4.29	4.54
	Leukemia											
	Chronic											
	1	0.13	0.11	2	0.12	0.08	8	0.74	0.63	35	1.00	1.06
	Myeloproliferative disorders											
	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.03	0.03
C42 / Reticulo endothelial& Hematopoietic System	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
	mast cell tumor											
	8	1.02	0.86	20	1.19	0.84	17	1.56	1.34	46	1.32	1.39
C42 / Reticulo endothelial& Hematopoietic System	Plasma cell tumor											
	1	0.13	0.11	0	0.00	0.00	5	0.46	0.40	17	0.49	0.51
Myelodysplastic syndromes												

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C44 / Skin, other	20	2.55	2.16	31	1.85	1.30	18	1.65	1.42	97	2.78	2.93
C47 /Nerves system	2	0.26	0.22	1	0.06	0.04	1	0.09	0.08	2	0.06	0.06
C48 / Peritoneum	3	0.38	0.32	3	0.18	0.13	1	0.09	0.08	12	0.34	0.36
C49 / soft tissues	7	0.89	0.76	26	1.55	1.09	13	1.19	1.03	37	1.06	1.12
C50 / Breast	108	13.79	11.67	260	15.48	10.92	175	16.08	13.84	636	18.20	19.24
C51 / Vulva	0	0.00	0.00	1	0.06	0.08	2	0.18	0.32	8	0.23	0.49
C52 / Vagina	1	0.13	0.22	1	0.06	0.08	0	0.00	0.00	0	0.00	0.00
C53 / Cervix uteri	3	0.38	0.65	11	0.65	0.93	3	0.28	0.47	42	1.20	2.55
C54 / Corpus uteri	9	1.15	1.95	3	0.18	0.25	1	0.09	0.16	25	0.72	1.52
C55 / Uterus unspecified	3	0.38	0.65	36	2.14	3.04	28	2.57	4.41	108	3.09	6.57
C56 / Ovary	15	1.92	3.26	25	1.49	2.11	21	1.93	3.31	108	3.09	6.57
C57 / Female genital - other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C58 / Placenta	1	0.13	0.22	0	0.00	0.00	1	0.09	0.16	5	0.14	0.30
C60 / Penis	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.03	0.06
C61 / Prostate	22	2.81	4.73	32	1.90	2.68	38	3.49	6.03	130	3.72	7.83
C62 / Testis	1	0.13	0.22	8	0.48	0.67	6	0.55	0.95	21	0.60	1.26
C63 / Male genital - other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C64 / Kidney	25	3.19	2.70	57	3.39	2.39	32	2.94	2.53	121	3.46	3.66
C65 / Pelvis	1	0.13	0.11	1	0.06	0.04	2	0.18	0.16	3	0.09	0.09
C66 / Ureter	0	0.00	0.00	0	0.00	0.00	2	0.18	0.16	1	0.03	0.03
C67 / Urinary bladder	46	5.87	4.97	114	6.79	4.79	82	7.54	6.49	182	5.21	5.51
C68 / Urinary organs, other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.03	0.03
C69 / Eye & adnexa	1	0.13	0.11	3	0.18	0.13	4	0.37	0.32	7	0.20	0.21
C70 / Meninges	10	1.28	1.08	14	0.83	0.59	18	1.65	1.42	8	0.23	0.24

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C71 / Brain	51	6.51	5.51	127	7.56	5.33	71	6.53	5.62	203	5.81	6.14
C72 / Nervous system, other	2	0.26	0.22	7	0.42	0.29	4	0.37	0.32	18	0.52	0.54
C73 / Thyroid gland	47	6.00	5.08	101	6.01	4.24	75	6.89	5.93	166	4.75	5.02
C74 / Adrenal gland	3	0.38	0.32	12	0.71	0.50	2	0.18	0.16	12	0.34	0.36
C75 / Endocrine gland, other	3	0.38	0.32	7	0.42	0.29	4	0.37	0.32	21	0.60	0.64
C76 / Unspecified site	1	0.13	0.11	4	0.24	0.17	3	0.28	0.24	12	0.34	0.36
C77/ Lymph node	Hodgkin Lymphoma			26	1.55	1.09	25	2.30	1.98	85	2.43	2.57
	Non-Hodgkin Lymphoma			68	4.05	2.86	38	3.49	3.01	138	3.95	4.18
C80 / Unknown primary site	6	0.77	0.65	26	1.55	1.09	19	1.75	1.50	67	1.92	2.03
All Sites Total	783	100%	84.6	1680	100%	70.6	1088	100%	86.0	3495	100%	105.7

Note:

* From C51 to C58 the incidence rate was calculated from the female population.

* From C60 to C63 the incidence rate was calculated from the male population.

Table 74: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Males (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	0	0.00	0.00	1	0.08	0.08	2	0.15	0.19	1	0.08	0.05	0	0.00	0.00
C01 / Tongue, base	1	0.18	0.14	1	0.08	0.08	0	0.00	0.00	0	0.00	0.00	1	0.22	0.11
C02 / Tongue, other	2	0.36	0.27	3	0.23	0.24	3	0.22	0.28	4	0.31	0.18	4	0.87	0.44
C03 / Gum	0	0.00	0.00	1	0.08	0.08	0	0.00	0.00	1	0.08	0.05	1	0.22	0.11
C04 / Mouth - floor	0	0.00	0.00	0	0.00	0.00	4	0.29	0.38	1	0.08	0.05	0	0.00	0.00
C05 / Mouth - palate	1	0.18	0.14	2	0.15	0.16	1	0.07	0.09	1	0.08	0.05	0	0.00	0.00
C06 / Mouth - other	0	0.00	0.00	2	0.15	0.16	2	0.15	0.19	5	0.39	0.23	0	0.00	0.00
C07 / Parotid gland	1	0.18	0.14	1	0.08	0.08	4	0.29	0.38	3	0.23	0.14	1	0.22	0.11
C08 / Mouth glands	1	0.18	0.14	3	0.23	0.24	1	0.07	0.09	2	0.16	0.09	1	0.22	0.11
C09 / Tonsil	0	0.00	0.00	1	0.08	0.08	1	0.07	0.09	2	0.16	0.09	0	0.00	0.00
C10 / Oropharynx	1	0.18	0.14	2	0.15	0.16	0	0.00	0.00	0	0.00	0.00	1	0.22	0.11
C11 / Nasopharynx	2	0.36	0.27	4	0.31	0.33	10	0.73	0.94	10	0.78	0.46	6	1.31	0.66
C12 / Pyriform	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	0	0.00	0.00	0	0.00	0.00	1	0.07	0.09	0	0.00	0.00	1	0.22	0.11
C14 / Pharynx	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C15 / Oesophagus	8	1.43	1.09	9	0.69	0.73	13	0.95	1.22	7	0.55	0.32	2	0.44	0.22
C16 / Stomach	21	3.76	2.85	53	4.06	4.31	54	3.95	5.07	53	4.14	2.45	15	3.27	1.64
C17 / Small intestine	1	0.18	0.14	6	0.46	0.49	1	0.07	0.09	11	0.86	0.51	1	0.22	0.11
C18 / Colon	35	6.27	4.76	102	7.82	8.30	91	6.66	8.55	79	6.17	3.65	37	8.06	4.05
C19 / Recto sigmoid Junction	0	0.00	0.00	2	0.15	0.16	9	0.66	0.85	1	0.08	0.05	5	1.09	0.55
C20 / Rectum	16	2.87	2.17	40	3.07	3.25	29	2.12	2.73	24	1.88	1.11	17	3.70	1.86
C21 / Anus & anal canal	0	0.00	0.00	2	0.15	0.16	1	0.07	0.09	2	0.16	0.09	0	0.00	0.00
C22 / Liver & bile ducts	9	1.61	1.22	24	1.84	1.95	11	0.81	1.03	28	2.19	1.29	11	2.40	1.20
C23 / Gallbladder	2	0.36	0.27	15	1.15	1.22	10	0.73	0.94	5	0.39	0.23	5	1.09	0.55
C24 / Biliary tract, other	3	0.54	0.41	5	0.38	0.41	10	0.73	0.94	8	0.63	0.37	2	0.44	0.22
C25 / Pancreas	17	3.05	2.31	26	1.99	2.12	39	2.86	3.67	42	3.28	1.94	5	1.09	0.55

ICDO/Site	Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C26 / Other digestive organs	0	0.00	0.00	0	0.00	0.00	2	0.15	0.19	1	0.08	0.05	0	0.00	0.00
C30 / Nasal cavity	2	0.36	0.27	2	0.15	0.16	1	0.07	0.09	0	0.00	0.00	0	0.00	0.00
C31 / Accessory sinus	2	0.36	0.27	1	0.08	0.08	1	0.07	0.09	1	0.08	0.05	0	0.00	0.00
C32 / Larynx	12	2.15	1.63	16	1.23	1.30	35	2.56	3.29	48	3.75	2.22	6	1.31	0.66
C33 / Trachea	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.22	0.11
C34 / Bronchus & lung	98	17.56	13.32	128	9.81	10.41	173	12.66	16.26	160	12.50	7.39	71	15.47	7.77
C37 / Thymus	0	0.00	0.00	2	0.15	0.16	2	0.15	0.19	4	0.31	0.18	0	0.00	0.00
C38 / Heart, Mediastinum, pleura	2	0.36	0.27	2	0.15	0.16	4	0.29	0.38	2	0.16	0.09	2	0.44	0.22
C39 / Other respiratory & thoracic	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C40 / Bone & cartilage, limbs	7	1.25	0.95	2	0.15	0.16	7	0.51	0.66	7	0.55	0.32	3	0.65	0.33
C41 / Bones & cartilage, other	2	0.36	0.27	10	0.77	0.81	8	0.59	0.75	15	1.17	0.69	3	0.65	0.33
Leukemia	28	5.02	3.80	50	3.83	4.07	75	5.49	7.05	104	8.13	4.80	32	6.97	3.50
Chronic															
Myeloproliferative disorders	1	0.18	0.14	114	8.74	9.27	18	1.32	1.69	6	0.47	0.28	3	0.65	0.33
C42 / Reticulo endothelial& Hematopoietic System	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
Immunoproliferative diseases															
mast cell tumor	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
Plasma cell tumor	7	1.25	0.95	39	2.99	3.17	19	1.39	1.79	7	0.55	0.32	2	0.44	0.22
Myelodysplastic syndromes	1	0.18	0.14	6	0.46	0.49	2	0.15	0.19	0	0.00	0.00	0	0.00	0.00
C44 / Skin, other	39	6.99	5.30	40	3.07	3.25	143	10.47	13.44	52	4.06	2.40	18	3.92	1.97
C47 /Nerves system	0	0.00	0.00	0	0.00	0.00	1	0.07	0.09	0	0.00	0.00	0	0.00	0.00
C48 / Peritoneum	2	0.36	0.27	2	0.15	0.16	3	0.22	0.28	0	0.00	0.00	0	0.00	0.00
C49 / soft tissues	7	1.25	0.95	11	0.84	0.89	22	1.61	2.07	24	1.88	1.11	3	0.65	0.33
C50 / Breast	2	0.36	0.27	5	0.38	0.41	19	1.39	1.79	8	0.63	0.37	5	1.09	0.55
C60 / Penis	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C61 / Prostate	53	9.50	7.20	152	11.65	12.37	158	11.57	14.85	118	9.22	5.45	41	8.93	4.49
C62 / Testis	13	2.33	1.77	24	1.84	1.95	24	1.76	2.26	27	2.11	1.25	6	1.31	0.66
C63 / Male genital - other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00

ICDO/Site	Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C64 / Kidney	16	2.87	2.17	41	3.14	3.34	55	4.03	5.17	64	5.00	2.96	26	5.66	2.84
C65 / Pelvis	2	0.36	0.27	15	1.15	1.22	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C66 / Ureter	0	0.00	0.00	0	0.00	0.00	1	0.07	0.09	1	0.08	0.05	0	0.00	0.00
C67 / Urinary bladder	39	6.99	5.30	89	6.82	7.24	104	7.61	9.77	98	7.66	4.53	42	9.15	4.59
C68 / Urinary organs, other	0	0.00	0.00	1	0.08	0.08	0	0.00	0.00	0	0.00	0.00	1	0.22	0.11
C69 / Eye & adnexa	1	0.18	0.14	2	0.15	0.16	6	0.44	0.56	3	0.23	0.14	2	0.44	0.22
C70 / Meninges	2	0.36	0.27	4	0.31	0.33	1	0.07	0.09	5	0.39	0.23	4	0.87	0.44
C71 / Brain	29	5.20	3.94	61	4.67	4.96	45	3.29	4.23	74	5.78	3.42	26	5.66	2.84
C72 / Nervous system, other	0	0.00	0.00	4	0.31	0.33	5	0.37	0.47	1	0.08	0.05	1	0.22	0.11
C73 / Thyroid gland	12	2.15	1.63	36	2.76	2.93	30	2.20	2.82	22	1.72	1.02	10	2.18	1.09
C74 / Adrenal gland	1	0.18	0.14	5	0.38	0.41	3	0.22	0.28	5	0.39	0.23	3	0.65	0.33
C75 / Endocrine gland, other	1	0.18	0.14	3	0.23	0.24	5	0.37	0.47	6	0.47	0.28	6	1.31	0.66
C76 / Unspecified site	2	0.36	0.27	6	0.46	0.49	2	0.15	0.19	0	0.00	0.00	1	0.22	0.11
C77/ Lymph node	16	2.87	2.17	25	1.92	2.03	21	1.54	1.97	34	2.66	1.57	5	1.09	0.55
C80 / Unknown primary site	31	5.56	4.21	67	5.13	5.45	61	4.47	5.73	52	4.06	2.40	17	3.70	1.86
All Sites Total	558	100%	75.8	1305	100%	106.2	1366	100%	128.4	1280	100%	59.1	459	100%	50.2

Table 75: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Males (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	6	0.14	0.13	0	0.00	0.00	0	0.00	0.00	1	0.16	0.10
C01 / Tongue, base	5	0.12	0.11	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C02 / Tongue, other	17	0.40	0.36	3	0.48	0.32	2	0.41	0.22	4	0.63	0.39
C03 / Gum	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C04 / Mouth - floor	7	0.16	0.15	1	0.16	0.11	0	0.00	0.00	0	0.00	0.00
C05 / Mouth - palate	1	0.02	0.02	1	0.16	0.11	0	0.00	0.00	0	0.00	0.00
C06 / Mouth - other	13	0.30	0.28	1	0.16	0.11	2	0.41	0.22	1	0.16	0.10
C07 / Parotid gland	15	0.35	0.32	1	0.16	0.11	0	0.00	0.00	2	0.32	0.19
C08 / Mouth glands	10	0.23	0.21	1	0.16	0.11	1	0.20	0.11	0	0.00	0.00
C09 / Tonsil	4	0.09	0.09	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C10 / Oropharynx	3	0.07	0.06	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C11 / Nasopharynx	37	0.87	0.79	0	0.00	0.00	6	1.22	0.66	7	1.11	0.68
C12 / Pyriform	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	1	0.02	0.02	0	0.00	0.00	1	0.20	0.11	0	0.00	0.00
C14 / Pharynx	2	0.05	0.04	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C15 / Oesophagus	31	0.73	0.66	5	0.79	0.54	2	0.41	0.22	4	0.63	0.39
C16 / Stomach	136	3.19	2.89	24	3.81	2.60	18	3.67	1.97	28	4.44	2.71
C17 / Small intestine	20	0.47	0.43	9	1.43	0.97	3	0.61	0.33	1	0.16	0.10
C18 / Colon	250	5.86	5.32	33	5.24	3.57	25	5.09	2.73	51	8.08	4.93
C19 / Recto sigmoid Junction	28	0.66	0.60	6	0.95	0.65	2	0.41	0.22	10	1.58	0.97
C20 / Rectum	130	3.05	2.77	12	1.90	1.30	14	2.85	1.53	19	3.01	1.84
C21 / Anus & anal canal	7	0.16	0.15	1	0.16	0.11	1	0.20	0.11	0	0.00	0.00
C22 / Liver & bile ducts	141	3.31	3.00	13	2.06	1.41	18	3.67	1.97	24	3.80	2.32
C23 / Gallbladder	24	0.56	0.51	1	0.16	0.11	5	1.02	0.55	3	0.48	0.29
C24 / Biliary tract, other	29	0.68	0.62	4	0.63	0.43	0	0.00	0.00	0	0.00	0.00
C25 / Pancreas	186	4.36	3.96	28	4.44	3.03	15	3.05	1.64	21	3.33	2.03

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C26 / Other digestive organs	8	0.19	0.17	0	0.00	0.00	2	0.41	0.22	4	0.63	0.39
C30 / Nasal cavity	11	0.26	0.23	2	0.32	0.22	1	0.20	0.11	1	0.16	0.10
C31 / Accessory sinus	4	0.09	0.09	1	0.16	0.11	0	0.00	0.00	1	0.16	0.10
C32 / Larynx	91	2.13	1.94	14	2.22	1.51	10	2.04	1.09	8	1.27	0.77
C33 / Trachea	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C34 / Bronchus & lung	432	10.13	9.19	92	14.60	9.95	61	12.42	6.66	61	9.67	5.90
C37 / Thymus	5	0.12	0.11	1	0.16	0.11	2	0.41	0.22	0	0.00	0.00
C38 / Heart, Mediastinum, pleura	14	0.33	0.30	2	0.32	0.22	1	0.20	0.11	2	0.32	0.19
C39 / Other respiratory & thoracic	1	0.02	0.02	0	0.00	0.00	0	0.00	0.00	1	0.16	0.10
C40 / Bone & cartilage, limbs	37	0.87	0.79	7	1.11	0.76	7	1.43	0.76	15	2.38	1.45
C41 / Bones & cartilage, other	38	0.89	0.81	1	0.16	0.11	5	1.02	0.55	6	0.95	0.58
Leukemia	206	4.83	4.38	30	4.76	3.24	20	4.07	2.18	31	4.91	3.00
Chronic												
Myeloproliferative disorders	3	0.07	0.06	1	0.16	0.11	0	0.00	0.00	1	0.16	0.10
C42 / Reticulo endothelial& Hematopoietic System	1	0.02	0.02	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
Immunoproliferative diseases												
mast cell tumor	1	0.02	0.02	0	0.00	0.00	0	0.00	0.00	1	0.16	0.10
Plasma cell tumor	38	0.89	0.81	4	0.63	0.43	2	0.41	0.22	11	1.74	1.06
Myelodysplastic syndromes	3	0.07	0.06	0	0.00	0.00	0	0.00	0.00	1	0.16	0.10
C44 / Skin, other	185	4.34	3.94	42	6.67	4.54	25	5.09	2.73	9	1.43	0.87
C47 /Nerves system	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C48 / Peritoneum	8	0.19	0.17	0	0.00	0.00	0	0.00	0.00	2	0.32	0.19
C49 / soft tissues	104	2.44	2.21	14	2.22	1.51	6	1.22	0.66	4	0.63	0.39
C50 / Breast	34	0.80	0.72	3	0.48	0.32	2	0.41	0.22	4	0.63	0.39
C60 / Penis	1	0.02	0.02	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C61 / Prostate	408	9.57	8.68	78	12.38	8.44	48	9.78	5.24	68	10.78	6.57
C62 / Testis	55	1.29	1.17	18	2.86	1.95	3	0.61	0.33	6	0.95	0.58
C63 / Male genital - other	1	0.02	0.02	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C64 / Kidney	224	5.25	4.76	24	3.81	2.60	28	5.70	3.06	19	3.01	1.84
C65 / Pelvis	1	0.02	0.02	0	0.00	0.00	3	0.61	0.33	1	0.16	0.10
C66 / Ureter	4	0.09	0.09	0	0.00	0.00	2	0.41	0.22	0	0.00	0.00
C67 / Urinary bladder	332	7.79	7.06	42	6.67	4.54	39	7.94	4.26	40	6.34	3.87
C68 / Urinary organs, other	4	0.09	0.09	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C69 / Eye & adnexa	18	0.42	0.38	2	0.32	0.22	4	0.81	0.44	3	0.48	0.29
C70 / Meninges	56	1.31	1.19	7	1.11	0.76	2	0.41	0.22	2	0.32	0.19
C71 / Brain	256	6.00	5.45	34	5.40	3.68	33	6.72	3.60	49	7.77	4.74
C72 / Nervous system, other	5	0.12	0.11	1	0.16	0.11	0	0.00	0.00	0	0.00	0.00
C73 / Thyroid gland	146	3.42	3.11	16	2.54	1.73	23	4.68	2.51	31	4.91	3.00
C74 / Adrenal gland	17	0.40	0.36	1	0.16	0.11	1	0.20	0.11	2	0.32	0.19
C75 / Endocrine gland, other	25	0.59	0.53	4	0.63	0.43	2	0.41	0.22	3	0.48	0.29
C76 / Unspecified site	23	0.54	0.49	1	0.16	0.11	0	0.00	0.00	4	0.63	0.39
C77/ Lymph node	70	1.64	1.49	12	1.90	1.30	13	2.65	1.42	27	4.28	2.61
	165	3.87	3.51	18	2.86	1.95	24	4.89	2.62	27	4.28	2.61
C80 / Unknown primary site	126	2.95	2.68	14	2.22	1.51	7	1.43	0.76	10	1.58	0.97
All Sites Total	4264	100%	90.7	630	100%	68.1	491	100%	53.6	631	100%	61.0

Table 76: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Males (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	1	0.12	0.12	1	0.14	0.14	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00
C01 / Tongue, base	0	0.00	0.00	0	0.00	0.00	3	0.34	0.25	0	0.00	0.00	0	0.00	0.00
C02 / Tongue, other	3	0.35	0.36	5	0.72	0.72	0	0.00	0.00	3	0.50	0.38	2	0.34	0.27
C03 / Gum	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.17	0.13	0	0.00	0.00
C04 / Mouth - floor	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C05 / Mouth - palate	1	0.12	0.12	0	0.00	0.00	1	0.11	0.08	0	0.00	0.00	1	0.17	0.14
C06 / Mouth - other	2	0.23	0.24	0	0.00	0.00	1	0.11	0.08	2	0.34	0.25	3	0.50	0.41
C07 / Parotid gland	2	0.23	0.24	1	0.14	0.14	1	0.11	0.08	1	0.17	0.13	1	0.17	0.14
C08 / Mouth glands	4	0.46	0.48	3	0.43	0.43	1	0.11	0.08	3	0.50	0.38	0	0.00	0.00
C09 / Tonsil	0	0.00	0.00	0	0.00	0.00	1	0.11	0.08	1	0.17	0.13	0	0.00	0.00
C10 / Oropharynx	0	0.00	0.00	1	0.14	0.14	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C11 / Nasopharynx	7	0.81	0.83	8	1.15	1.15	7	0.79	0.59	4	0.67	0.51	4	0.67	0.54
C12 / Pyriform	1	0.12	0.12	0	0.00	0.00	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	0	0.00	0.00	0	0.00	0.00	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00
C14 / Pharynx	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.17	0.13	0	0.00	0.00
C15 / Oesophagus	4	0.46	0.48	2	0.29	0.29	8	0.90	0.67	4	0.67	0.51	4	0.67	0.54
C16 / Stomach	27	3.11	3.22	17	2.44	2.43	21	2.36	1.77	14	2.35	1.77	12	2.01	1.62
C17 / Small intestine	2	0.23	0.24	4	0.57	0.57	3	0.34	0.25	4	0.67	0.51	3	0.50	0.41
C18 / Colon	32	3.68	3.82	52	7.45	7.44	46	5.16	3.88	31	5.19	3.92	35	5.87	4.73
C19 / Recto sigmoid Junction	6	0.69	0.72	1	0.14	0.14	0	0.00	0.00	2	0.34	0.25	4	0.67	0.54
C20 / Rectum	15	1.73	1.79	9	1.29	1.29	15	1.68	1.27	14	2.35	1.77	9	1.51	1.22
C21 / Anus & anal canal	2	0.23	0.24	2	0.29	0.29	3	0.34	0.25	0	0.00	0.00	0	0.00	0.00
C22 / Liver & bile ducts	21	2.42	2.50	18	2.58	2.58	25	2.81	2.11	21	3.52	2.65	18	3.02	2.43
C23 / Gallbladder	2	0.23	0.24	1	0.14	0.14	1	0.11	0.08	5	0.84	0.63	1	0.17	0.14
C24 / Biliary tract, other	1	0.12	0.12	3	0.43	0.43	1	0.11	0.08	5	0.84	0.63	6	1.01	0.81

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C25 / Pancreas	39	4.49	4.65	35	5.01	5.01	32	3.59	2.70	26	4.36	3.29	14	2.35	1.89
C26 / Other digestive organs	4	0.46	0.48	0	0.00	0.00	0	0.00	0.00	1	0.17	0.13	2	0.34	0.27
C30 / Nasal cavity	1	0.12	0.12	0	0.00	0.00	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00
C31 / Accessory sinus	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C32 / Larynx	23	2.65	2.74	10	1.43	1.43	22	2.47	1.86	12	2.01	1.52	10	1.68	1.35
C33 / Trachea	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.17	0.13	0	0.00	0.00
C34 / Bronchus & lung	113	13.00	13.48	93	13.32	13.31	96	10.77	8.10	65	10.89	8.22	82	13.76	11.09
C37 / Thymus	1	0.12	0.12	2	0.29	0.29	0	0.00	0.00	0	0.00	0.00	3	0.50	0.41
C38 / Heart, Mediastinum, pleura	4	0.46	0.48	2	0.29	0.29	1	0.11	0.08	0	0.00	0.00	2	0.34	0.27
C39 / Other respiratory & thoracic	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C40 / Bone & cartilage, limbs	5	0.58	0.60	6	0.86	0.86	10	1.12	0.84	3	0.50	0.38	4	0.67	0.54
C41 / Bones & cartilage, other	5	0.58	0.60	11	1.58	1.57	6	0.67	0.51	9	1.51	1.14	7	1.17	0.95
C42 / Reticulo endothelial& Hematopoietic System	66	7.59	7.87	43	6.16	6.15	53	5.95	4.47	24	4.02	3.03	49	8.22	6.63
	Leukemia														
	Immunoproliferative diseases														
	Immunoproliferative diseases														
	mast cell tumor														
C44 / Skin, other	Plasma cell tumor														
	Myelodysplastic syndromes														
	0	0.00	0.00	1	0.14	0.14	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00
C47 /Nerves system	47	5.41	5.61	24	3.44	3.44	36	4.04	3.04	37	6.20	4.68	19	3.19	2.57
C48 / Peritoneum	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C49 / soft tissues	2	0.23	0.24	1	0.14	0.14	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00
C50 / Breast	12	1.38	1.43	10	1.43	1.43	16	1.80	1.35	4	0.67	0.51	6	1.01	0.81
C60 / Penis	9	1.04	1.07	8	1.15	1.15	10	1.12	0.84	4	0.67	0.51	5	0.84	0.68
C61 / Prostate	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	2	0.34	0.27
C62 / Testis	61	7.02	7.28	54	7.74	7.73	79	8.87	6.66	45	7.54	5.69	57	9.56	7.71
	12	1.38	1.43	10	1.43	1.43	13	1.46	1.10	17	2.85	2.15	8	1.34	1.08

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C63 / Male genital - other	0	0.00	0.00	2	0.29	0.29	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C64 / Kidney	46	5.29	5.49	36	5.16	5.15	52	5.84	4.39	32	5.36	4.05	33	5.54	4.46
C65 / Pelvis	1	0.12	0.12	1	0.14	0.14	0	0.00	0.00	1	0.17	0.13	0	0.00	0.00
C66 / Ureter	0	0.00	0.00	1	0.14	0.14	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C67 / Urinary bladder	94	10.82	11.21	71	10.17	10.16	94	10.55	7.93	69	11.56	8.72	71	11.91	9.60
C68 / Urinary organs, other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.17	0.13	0	0.00	0.00
C69 / Eye & adnexa	5	0.58	0.60	1	0.14	0.14	1	0.11	0.08	2	0.34	0.25	2	0.34	0.27
C70 / Meninges	2	0.23	0.24	4	0.57	0.57	6	0.67	0.51	5	0.84	0.63	1	0.17	0.14
C71 / Brain	54	6.21	6.44	40	5.73	5.73	57	6.40	4.81	34	5.70	4.30	35	5.87	4.73
C72 / Nervous system, other	2	0.23	0.24	2	0.29	0.29	2	0.22	0.17	0	0.00	0.00	2	0.34	0.27
C73 / Thyroid gland	31	3.57	3.70	27	3.87	3.86	36	4.04	3.04	33	5.53	4.17	17	2.85	2.30
C74 / Adrenal gland	1	0.12	0.12	4	0.57	0.57	2	0.22	0.17	3	0.50	0.38	4	0.67	0.54
C75 / Endocrine gland, other	3	0.35	0.36	3	0.43	0.43	3	0.34	0.25	1	0.17	0.13	2	0.34	0.27
C76 / Unspecified site	10	1.15	1.19	1	0.14	0.14	1	0.11	0.08	0	0.00	0.00	7	1.17	0.95
C77/ Lymph node	23	2.65	2.74	21	3.01	3.01	19	2.13	1.60	11	1.84	1.39	10	1.68	1.35
Hodgkin Lymphoma															
Non-Hodgkin Lymphoma	44	5.06	5.25	38	5.44	5.44	46	5.16	3.88	32	5.36	4.05	27	4.53	3.65
C80 / Unknown primary site	7	0.81	0.83	0	0.00	0.00	34	3.82	2.87	5	0.84	0.63	3	0.50	0.41
All Sites Total	869	100%	103.6	698	100%	99.9	891	100%	75.1	597	100%	75.5	596	100%	80.6

Table 77: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Males (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	0	0.00	0.00	1	0.13	0.08	1	0.20	0.16	0	0.00	0.00
C01 / Tongue, base	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C02 / Tongue, other	1	0.27	0.22	2	0.26	0.17	2	0.40	0.32	7	0.47	0.42
C03 / Gum	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C04 / Mouth - floor	0	0.00	0.00	1	0.13	0.08	0	0.00	0.00	0	0.00	0.00
C05 / Mouth - palate	0	0.00	0.00	3	0.39	0.25	0	0.00	0.00	0	0.00	0.00
C06 / Mouth - other	0	0.00	0.00	3	0.39	0.25	0	0.00	0.00	4	0.27	0.24
C07 / Parotid gland	0	0.00	0.00	1	0.13	0.08	0	0.00	0.00	4	0.27	0.24
C08 / Mouth glands	0	0.00	0.00	0	0.00	0.00	1	0.20	0.16	1	0.07	0.06
C09 / Tonsil	0	0.00	0.00	1	0.13	0.08	1	0.20	0.16	0	0.00	0.00
C10 / Oropharynx	0	0.00	0.00	0	0.00	0.00	2	0.40	0.32	1	0.07	0.06
C11 / Nasopharynx	1	0.27	0.22	14	1.81	1.17	3	0.60	0.48	17	1.13	1.02
C12 / Pyriform	1	0.27	0.22	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	1	0.27	0.22	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C14 / Pharynx	0	0.00	0.00	2	0.26	0.17	0	0.00	0.00	2	0.13	0.12
C15 / Oesophagus	6	1.63	1.29	5	0.65	0.42	3	0.60	0.48	14	0.93	0.84
C16 / Stomach	16	4.35	3.44	18	2.33	1.51	19	3.82	3.02	48	3.19	2.89
C17 / Small intestine	2	0.54	0.43	4	0.52	0.33	5	1.01	0.79	9	0.60	0.54
C18 / Colon	13	3.53	2.80	30	3.88	2.51	26	5.23	4.13	77	5.12	4.64
C19 / Recto sigmoid Junction	3	0.82	0.65	1	0.13	0.08	4	0.80	0.64	11	0.73	0.66
C20 / Rectum	7	1.90	1.51	16	2.07	1.34	10	2.01	1.59	52	3.46	3.13
C21 / Anus & anal canal	1	0.27	0.22	2	0.26	0.17	0	0.00	0.00	4	0.27	0.24
C22 / Liver & bile ducts	7	1.90	1.51	25	3.23	2.09	9	1.81	1.43	20	1.33	1.20
C23 / Gallbladder	4	1.09	0.86	6	0.78	0.50	2	0.40	0.32	7	0.47	0.42
C24 / Biliary tract, other	1	0.27	0.22	5	0.65	0.42	0	0.00	0.00	12	0.80	0.72
C25 / Pancreas	13	3.53	2.80	40	5.17	3.35	18	3.62	2.86	67	4.45	4.04

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C26 / Other digestive organs	1	0.27	0.22	0	0.00	0.00	1	0.20	0.16	0	0.00	0.00
C30 / Nasal cavity	0	0.00	0.00	1	0.13	0.08	1	0.20	0.16	5	0.33	0.30
C31 / Accessory sinus	0	0.00	0.00	2	0.26	0.17	0	0.00	0.00	2	0.13	0.12
C32 / Larynx	8	2.17	1.72	15	1.94	1.26	10	2.01	1.59	37	2.46	2.23
C33 / Trachea	0	0.00	0.00	0	0.00	0.00	1	0.20	0.16	1	0.07	0.06
C34 / Bronchus & lung	59	16.03	12.69	122	15.78	10.21	54	10.87	8.57	147	9.77	8.85
C37 / Thymus	0	0.00	0.00	0	0.00	0.00	1	0.20	0.16	8	0.53	0.48
C38 / Heart, Mediastinum, pleura	4	1.09	0.86	2	0.26	0.17	4	0.80	0.64	4	0.27	0.24
C39 / Other respiratory & thoracic	0	0.00	0.00	1	0.13	0.08	0	0.00	0.00	0	0.00	0.00
C40 / Bone & cartilage, limbs	3	0.82	0.65	5	0.65	0.42	4	0.80	0.64	16	1.06	0.96
C41 / Bones & cartilage, other	6	1.63	1.29	5	0.65	0.42	4	0.80	0.64	5	0.33	0.30
Leukemia	23	6.25	4.95	50	6.47	4.18	30	6.04	4.76	86	5.72	5.18
Chronic Myeloproliferative disorders	1	0.27	0.22	1	0.13	0.08	4	0.80	0.64	20	1.33	1.20
C42 / Reticulo endothelial& Hematopoietic System	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.07	0.06
Immunoproliferative diseases	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
mast cell tumor	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
Plasma cell tumor	4	1.09	0.86	10	1.29	0.84	7	1.41	1.11	23	1.53	1.39
Myelodysplastic syndromes	1	0.27	0.22	0	0.00	0.00	4	0.80	0.64	11	0.73	0.66
C44 / Skin, other	15	4.08	3.23	11	1.42	0.92	10	2.01	1.59	51	3.39	3.07
C47 /Nerves system	0	0.00	0.00	1	0.13	0.08	0	0.00	0.00	0	0.00	0.00
C48 / Peritoneum	0	0.00	0.00	1	0.13	0.08	0	0.00	0.00	6	0.40	0.36
C49 / soft tissues	4	1.09	0.86	15	1.94	1.26	10	2.01	1.59	14	0.93	0.84
C50 / Breast	2	0.54	0.43	12	1.55	1.00	2	0.40	0.32	5	0.33	0.30
C60 / Penis	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.07	0.06
C61 / Prostate	22	5.98	4.73	32	4.14	2.68	38	7.65	6.03	130	8.64	7.83
C62 / Testis	1	0.27	0.22	8	1.03	0.67	6	1.21	0.95	21	1.40	1.26
C63 / Male genital - other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C64 / Kidney	13	3.53	2.80	32	4.14	2.68	18	3.62	2.86	72	4.79	4.34
C65 / Pelvis	1	0.27	0.22	0	0.00	0.00	2	0.40	0.32	2	0.13	0.12

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C66 / Ureter	0	0.00	0.00	0	0.00	0.00	2	0.40	0.32	0	0.00	0.00
C67 / Urinary bladder	34	9.24	7.31	89	11.51	7.45	68	13.68	10.80	157	10.44	9.46
C68 / Urinary organs, other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.07	0.06
C69 / Eye & adnexa	1	0.27	0.22	1	0.13	0.08	3	0.60	0.48	4	0.27	0.24
C70 / Meninges	5	1.36	1.08	4	0.52	0.33	4	0.80	0.64	2	0.13	0.12
C71 / Brain	31	8.42	6.67	69	8.93	5.77	37	7.44	5.87	102	6.78	6.14
C72 / Nervous system, other	1	0.27	0.22	3	0.39	0.25	3	0.60	0.48	8	0.53	0.48
C73 / Thyroid gland	12	3.26	2.58	22	2.85	1.84	14	2.82	2.22	35	2.33	2.11
C74 / Adrenal gland	1	0.27	0.22	10	1.29	0.84	1	0.20	0.16	8	0.53	0.48
C75 / Endocrine gland, other	2	0.54	0.43	3	0.39	0.25	0	0.00	0.00	9	0.60	0.54
C76 / Unspecified site	1	0.27	0.22	4	0.52	0.33	0	0.00	0.00	8	0.53	0.48
C77/ Lymph node	18	4.89	3.87	12	1.55	1.00	16	3.22	2.54	45	2.99	2.71
	16	4.35	3.44	34	4.40	2.85	19	3.82	3.02	72	4.79	4.34
C80 / Unknown primary site	1	0.27	0.22	16	2.07	1.34	13	2.62	2.06	28	1.86	1.69
All Sites Total	368	100%	79.1	773	100%	64.7	497	100%	78.9	1504	100%	90.6

Table 78: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Females (per 100,000) by Primary Site and Governorates,2023

ICDO/Site	Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	1	0.16	0.14	1	0.07	0.08	1	0.06	0.10	0	0.00	0.00	0	0.00	0.00
C01 / Tongue, base	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C02 / Tongue, other	5	0.80	0.68	1	0.07	0.08	6	0.36	0.57	8	0.45	0.39	1	0.15	0.11
C03 / Gum	0	0.00	0.00	0	0.00	0.00	2	0.12	0.19	0	0.00	0.00	0	0.00	0.00
C04 / Mouth - floor	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C05 / Mouth - palate	0	0.00	0.00	2	0.13	0.16	2	0.12	0.19	0	0.00	0.00	1	0.15	0.11
C06 / Mouth - other	0	0.00	0.00	1	0.07	0.08	1	0.06	0.10	1	0.06	0.05	1	0.15	0.11
C07 / Parotid gland	0	0.00	0.00	0	0.00	0.00	3	0.18	0.29	4	0.22	0.19	0	0.00	0.00
C08 / Mouth glands	2	0.32	0.27	1	0.07	0.08	1	0.06	0.10	1	0.06	0.05	1	0.15	0.11
C09 / Tonsil	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C10 / Oropharynx	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C11 / Nasopharynx	0	0.00	0.00	1	0.07	0.08	4	0.24	0.38	6	0.34	0.29	1	0.15	0.11
C12 / Pyriform	0	0.00	0.00	1	0.07	0.08	0	0.00	0.00	1	0.06	0.05	0	0.00	0.00
C13 / Hypopharynx	0	0.00	0.00	1	0.07	0.08	1	0.06	0.10	1	0.06	0.05	1	0.15	0.11
C14 / Pharynx	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	2	0.11	0.10	0	0.00	0.00
C15 / Oesophagus	4	0.64	0.55	17	1.14	1.38	9	0.54	0.86	7	0.39	0.34	7	1.03	0.78
C16 / Stomach	15	2.39	2.05	38	2.55	3.09	36	2.16	3.45	44	2.47	2.12	25	3.69	2.77
C17 / Small intestine	2	0.32	0.27	0	0.00	0.00	4	0.24	0.38	7	0.39	0.34	3	0.44	0.33
C18 / Colon	30	4.78	4.09	92	6.17	7.49	64	3.85	6.13	82	4.61	3.95	32	4.73	3.55
C19 / Recto sigmoid Junction	1	0.16	0.14	4	0.27	0.33	10	0.60	0.96	4	0.22	0.19	3	0.44	0.33
C20 / Rectum	19	3.03	2.59	26	1.74	2.12	24	1.44	2.30	35	1.97	1.69	18	2.66	2.00

ICDO/Site	Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C21 / Anus & anal canal	0	0.00	0.00	0	0.00	0.00	2	0.12	0.19	1	0.06	0.05	0	0.00	0.00
C22 / Liver & bile ducts	8	1.27	1.09	16	1.07	1.30	8	0.48	0.77	15	0.84	0.72	17	2.51	1.89
C23 / Gallbladder	9	1.43	1.23	18	1.21	1.47	12	0.72	1.15	7	0.39	0.34	9	1.33	1.00
C24 / Biliary tract, other	2	0.32	0.27	4	0.27	0.33	5	0.30	0.48	3	0.17	0.14	2	0.30	0.22
C25 / Pancreas	8	1.27	1.09	25	1.68	2.04	29	1.74	2.78	40	2.25	1.93	15	2.22	1.66
C26 / Other digestive organs	0	0.00	0.00	0	0.00	0.00	1	0.06	0.10	1	0.06	0.05	1	0.15	0.11
C30 / Nasal cavity	1	0.16	0.14	0	0.00	0.00	0	0.00	0.00	1	0.06	0.05	0	0.00	0.00
C31 / Accessory sinus	0	0.00	0.00	0	0.00	0.00	2	0.12	0.19	0	0.00	0.00	0	0.00	0.00
C32 / Larynx	0	0.00	0.00	0	0.00	0.00	8	0.48	0.77	11	0.62	0.53	3	0.44	0.33
C33 / Trachea	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C34 / Bronchus & lung	12	1.91	1.64	44	2.95	3.58	52	3.13	4.98	58	3.26	2.80	30	4.43	3.33
C37 / Thymus	1	0.16	0.14	0	0.00	0.00	2	0.12	0.19	2	0.11	0.10	0	0.00	0.00
C38 / Heart, Mediastinum, pleura	1	0.16	0.14	2	0.13	0.16	3	0.18	0.29	3	0.17	0.14	2	0.30	0.22
C39 / Other respiratory & thoracic	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C40 / Bone & cartilage, limbs	4	0.64	0.55	11	0.74	0.90	5	0.30	0.48	9	0.51	0.43	5	0.74	0.55
C41 / Bones & cartilage, other	3	0.48	0.41	7	0.47	0.57	3	0.18	0.29	10	0.56	0.48	1	0.15	0.11
C42 / Reticulo endothelial& Hematopoietic System	38	6.05	5.19	44	2.95	3.58	52	3.13	4.98	85	4.78	4.10	23	3.40	2.55
	Leukemia														
	Chronic														
	Myeloproliferative disorders	0	0.00	0.00	54	3.62	4.40	11	0.66	1.05	6	0.34	0.29	0	0.00
	Immunoproliferative diseases	0	0.00	0.00	0	0.00	0.00	1	0.06	0.10	0	0.00	0.00	0	0.00
Plasma cell tumor	mast cell tumor	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00
	Plasma cell tumor	5	0.80	0.68	29	1.95	2.36	23	1.38	2.20	14	0.79	0.68	3	0.44

ICDO/Site		Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
		No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
	Myelodysplastic syndromes	1	0.16	0.14	13	0.87	1.06	4	0.24	0.38	0	0.00	0.00	0	0.00	0.00
C44 / Skin, other		36	5.73	4.91	36	2.41	2.93	127	7.63	12.17	40	2.25	1.93	11	1.62	1.22
C47 /Nerves system		0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C48 / Peritoneum		0	0.00	0.00	4	0.27	0.33	6	0.36	0.57	2	0.11	0.10	1	0.15	0.11
C49 / soft tissues		2	0.32	0.27	13	0.87	1.06	11	0.66	1.05	26	1.46	1.25	4	0.59	0.44
C50 / Breast		248	39.49	33.84	528	35.41	43.00	650	39.06	62.28	644	36.22	31.06	304	44.90	33.71
C51 / Vulva		0	0.00	0.00	0	0.00	0.00	3	0.18	0.29	1	0.06	0.05	1	0.15	0.11
C52 / Vagina		0	0.00	0.00	2	0.13	0.16	2	0.12	0.19	2	0.11	0.10	1	0.15	0.11
C53 / Cervix uteri		8	1.27	1.09	13	0.87	1.06	24	1.44	2.30	19	1.07	0.92	5	0.74	0.55
C54 / Corpus uteri		7	1.11	0.96	43	2.88	3.50	44	2.64	4.22	40	2.25	1.93	6	0.89	0.67
C55 / Uterus unspecified		17	2.71	2.32	7	0.47	0.57	38	2.28	3.64	58	3.26	2.80	15	2.22	1.66
C56 / Ovary		24	3.82	3.28	66	4.43	5.37	68	4.09	6.52	89	5.01	4.29	29	4.28	3.22
C57 / Female genital - other		1	0.16	0.14	1	0.07	0.08	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C58 / Placenta		2	0.32	0.27	1	0.07	0.08	4	0.24	0.38	2	0.11	0.10	0	0.00	0.00
C64 / Kidney		13	2.07	1.77	19	1.27	1.55	44	2.64	4.22	37	2.08	1.78	11	1.62	1.22
C65 / Pelvis		1	0.16	0.14	8	0.54	0.65	2	0.12	0.19	0	0.00	0.00	0	0.00	0.00
C66 / Ureter		0	0.00	0.00	1	0.07	0.08	2	0.12	0.19	0	0.00	0.00	0	0.00	0.00
C67 / Urinary bladder		6	0.96	0.82	18	1.21	1.47	17	1.02	1.63	20	1.12	0.96	8	1.18	0.89
C69 / Eye & adnexa		0	0.00	0.00	2	0.13	0.16	4	0.24	0.38	4	0.22	0.19	4	0.59	0.44
C70 / Meninges		2	0.32	0.27	9	0.60	0.73	4	0.24	0.38	11	0.62	0.53	10	1.48	1.11
C71 / Brain		14	2.23	1.91	53	3.55	4.32	49	2.94	4.70	82	4.61	3.95	10	1.48	1.11
C72 / Nervous system, other		1	0.16	0.14	2	0.13	0.16	2	0.12	0.19	7	0.39	0.34	1	0.15	0.11
C73 / Thyroid gland		38	6.05	5.19	89	5.97	7.25	94	5.65	9.01	97	5.46	4.68	26	3.84	2.88

ICDO/Site	Duhok			Al-Sulaimaniyah			Erbil			Nineveh			Kirkuk		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C74 / Adrenal gland	2	0.32	0.27	8	0.54	0.65	5	0.30	0.48	5	0.28	0.24	3	0.44	0.33
C75 / Endocrine gland, other	3	0.48	0.41	6	0.40	0.49	4	0.24	0.38	3	0.17	0.14	3	0.44	0.33
C76 / Unspecified site	0	0.00	0.00	2	0.13	0.16	2	0.12	0.19	2	0.11	0.10	1	0.15	0.11
C77// Lymph Node	8	1.27	1.09	24	1.61	1.95	15	0.90	1.44	25	1.41	1.21	5	0.74	0.55
C77// Lymph Node	17	2.71	2.32	44	2.95	3.58	36	2.16	3.45	49	2.76	2.36	8	1.18	0.89
C80 / Unknown primary site	6	0.96	0.82	39	2.62	3.18	16	0.96	1.53	44	2.47	2.12	5	0.74	0.55
All Sites Total	628	100%	85.7	1491	100%	121.4	1664	100%	159.4	1778	10	85.8	677	100%	75.1

Table 79: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Females (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	2	0.03	0.04	0	0.00	0.00	1	0.12	0.11	0	0.00	0.00
C01 / Tongue, base	3	0.04	0.07	0	0.00	0.00	2	0.25	0.22	0	0.00	0.00
C02 / Tongue, other	20	0.29	0.44	1	0.10	0.11	2	0.25	0.22	4	0.45	0.41
C03 / Gum	1	0.01	0.02	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C04 / Mouth - floor	2	0.03	0.04	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C05 / Mouth - palate	2	0.03	0.04	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C06 / Mouth - other	6	0.09	0.13	1	0.10	0.11	0	0.00	0.00	0	0.00	0.00
C07 / Parotid gland	5	0.07	0.11	0	0.00	0.00	1	0.12	0.11	1	0.11	0.10
C08 / Mouth glands	10	0.15	0.22	2	0.19	0.22	1	0.12	0.11	3	0.34	0.31
C09 / Tonsil	1	0.01	0.02	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C10 / Oropharynx	1	0.01	0.02	0	0.00	0.00	1	0.12	0.11	0	0.00	0.00
C11 / Nasopharynx	16	0.24	0.35	2	0.19	0.22	2	0.25	0.22	3	0.34	0.31
C12 / Pyriform	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	2	0.03	0.04	1	0.10	0.11	1	0.12	0.11	0	0.00	0.00
C14 / Pharynx	3	0.04	0.07	0	0.00	0.00	1	0.12	0.11	1	0.11	0.10
C15 / Oesophagus	21	0.31	0.46	1	0.10	0.11	4	0.49	0.45	3	0.34	0.31
C16 / Stomach	132	1.94	2.89	38	3.65	4.19	15	1.85	1.67	19	2.15	1.94
C17 / Small intestine	21	0.31	0.46	5	0.48	0.55	2	0.25	0.22	2	0.23	0.20
C18 / Colon	273	4.01	5.98	41	3.93	4.53	33	4.06	3.68	30	3.40	3.06
C19 / Recto sigmoid Junction	24	0.35	0.53	2	0.19	0.22	3	0.37	0.33	2	0.23	0.20
C20 / Rectum	125	1.84	2.74	15	1.44	1.66	4	0.49	0.45	25	2.83	2.55
C21 / Anus & anal canal	4	0.06	0.09	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C22 / Liver & bile ducts	99	1.45	2.17	19	1.82	2.10	13	1.60	1.45	17	1.93	1.74
C23 / Gallbladder	34	0.50	0.74	2	0.19	0.22	3	0.37	0.33	3	0.34	0.31
C24 / Biliary tract, other	21	0.31	0.46	4	0.38	0.44	2	0.25	0.22	1	0.11	0.10

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C25 / Pancreas	149	2.19	3.26	25	2.40	2.76	21	2.58	2.34	17	1.93	1.74
C26 / Other digestive organs	8	0.12	0.18	1	0.10	0.11	0	0.00	0.00	3	0.34	0.31
C30 / Nasal cavity	11	0.16	0.24	1	0.10	0.11	0	0.00	0.00	1	0.11	0.10
C31 / Accessory sinus	4	0.06	0.09	0	0.00	0.00	1	0.12	0.11	0	0.00	0.00
C32 / Larynx	15	0.22	0.33	6	0.58	0.66	5	0.62	0.56	2	0.23	0.20
C33 / Trachea	1	0.01	0.02	0	0.00	0.00	1	0.12	0.11	0	0.00	0.00
C34 / Bronchus & lung	205	3.01	4.49	32	3.07	3.53	34	4.18	3.79	28	3.17	2.86
C37 / Thymus	17	0.25	0.37	1	0.10	0.11	0	0.00	0.00	0	0.00	0.00
C38 / Heart, Mediastinum, pleura	14	0.21	0.31	3	0.29	0.33	1	0.12	0.11	3	0.34	0.31
C39 / Other respiratory & thoracic	1	0.01	0.02	0	0.00	0.00	1	0.12	0.11	0	0.00	0.00
C40 / Bone & cartilage, limbs	28	0.41	0.61	3	0.29	0.33	2	0.25	0.22	4	0.45	0.41
C41 / Bones & cartilage, other	28	0.41	0.61	5	0.48	0.55	2	0.25	0.22	3	0.34	0.31
Leukemia	147	2.16	3.22	37	3.55	4.08	30	3.69	3.34	30	3.40	3.06
Chronic												
Myeloproliferative disorders	2	0.03	0.04	3	0.29	0.33	0	0.00	0.00	1	0.11	0.10
Immunoproliferative diseases	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
mast cell tumor	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
Plasma cell tumor	23	0.34	0.50	3	0.29	0.33	3	0.37	0.33	9	1.02	0.92
Myelodysplastic syndromes	2	0.03	0.04	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C44 / Skin, other	134	1.97	2.94	38	3.65	4.19	18	2.21	2.01	10	1.13	1.02
C47 /Nerves system	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C48 / Peritoneum	9	0.13	0.20	1	0.10	0.11	1	0.12	0.11	3	0.34	0.31
C49 / soft tissues	77	1.13	1.69	15	1.44	1.66	10	1.23	1.11	5	0.57	0.51
C50 / Breast	2675	39.30	58.61	366	35.12	40.40	269	33.09	29.99	274	31.03	27.99
C51 / Vulva	11	0.16	0.24	3	0.29	0.33	1	0.12	0.11	1	0.11	0.10
C52 / Vagina	2	0.03	0.04	0	0.00	0.00	1	0.12	0.11	1	0.11	0.10

ICDO/Site	Baghdad			Diyala			Salah Al-Deen			Al-Anbar		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C53 / Cervix uteri	89	1.31	1.95	12	1.15	1.32	10	1.23	1.11	16	1.81	1.63
C54 / Corpus uteri	233	3.42	5.11	19	1.82	2.10	3	0.37	0.33	15	1.70	1.53
C55 / Uterus unspecified	202	2.97	4.43	31	2.98	3.42	28	3.44	3.12	21	2.38	2.15
C56 / Ovary	271	3.98	5.94	50	4.80	5.52	25	3.08	2.79	41	4.64	4.19
C57 / Female genital - other	3	0.04	0.07	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C58 / Placenta	9	0.13	0.20	0	0.00	0.00	3	0.37	0.33	0	0.00	0.00
C64 / Kidney	111	1.63	2.43	22	2.11	2.43	11	1.35	1.23	13	1.47	1.33
C65 / Pelvis	0	0.00	0.00	3	0.29	0.33	1	0.12	0.11	0	0.00	0.00
C66 / Ureter	1	0.01	0.02	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C67 / Urinary bladder	105	1.54	2.30	12	1.15	1.32	13	1.60	1.45	14	1.59	1.43
C69 / Eye & adnexa	8	0.12	0.18	4	0.38	0.44	1	0.12	0.11	2	0.23	0.20
C70 / Meninges	146	2.14	3.20	17	1.63	1.88	11	1.35	1.23	13	1.47	1.33
C71 / Brain	231	3.39	5.06	49	4.70	5.41	38	4.67	4.24	36	4.08	3.68
C72 / Nervous system, other	9	0.13	0.20	2	0.19	0.22	1	0.12	0.11	0	0.00	0.00
C73 / Thyroid gland	610	8.96	13.37	83	7.97	9.16	133	16.36	14.83	144	16.31	14.71
C74 / Adrenal gland	18	0.26	0.39	2	0.19	0.22	8	0.98	0.89	2	0.23	0.20
C75 / Endocrine gland, other	35	0.51	0.77	4	0.38	0.44	3	0.37	0.33	2	0.23	0.20
C76 / Unspecified site	36	0.53	0.79	3	0.29	0.33	3	0.37	0.33	1	0.11	0.10
C77/ Lymph Node	55	0.81	1.21	8	0.77	0.88	11	1.35	1.23	15	1.70	1.53
Non-Hodgkin Lymphoma	134	1.97	2.94	23	2.21	2.54	13	1.60	1.45	30	3.40	3.06
C80 / Unknown primary site	110	1.62	2.41	21	2.02	2.32	5	0.62	0.56	9	1.02	0.92
All Sites Total	6807	100%	149.1	1042	100%	115.0	813	100%	90.6	883	100%	90.2

Table 80: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Females (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	0	0.00	0.00	0	0.00	0.00	1	0.08	0.09	1	0.12	0.13	1	0.14	0.14
C01 / Tongue, base	0	0.00	0.00	0	0.00	0.00	2	0.16	0.17	0	0.00	0.00	0	0.00	0.00
C02 / Tongue, other	6	0.53	0.72	5	0.48	0.73	2	0.16	0.17	2	0.24	0.26	1	0.14	0.14
C03 / Gum	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C04 / Mouth – floor	0	0.00	0.00	0	0.00	0.00	1	0.08	0.09	0	0.00	0.00	0	0.00	0.00
C05 / Mouth – palate	0	0.00	0.00	0	0.00	0.00	2	0.16	0.17	0	0.00	0.00	0	0.00	0.00
C06 / Mouth - other	1	0.09	0.12	5	0.48	0.73	3	0.24	0.26	0	0.00	0.00	0	0.00	0.00
C07 / Parotid gland	4	0.35	0.48	2	0.19	0.29	0	0.00	0.00	0	0.00	0.00	2	0.28	0.27
C08 / Mouth glands	0	0.00	0.00	0	0.00	0.00	2	0.16	0.17	0	0.00	0.00	3	0.41	0.41
C09 / Tonsil	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C10 / Oropharynx	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C11 / Nasopharynx	3	0.26	0.36	5	0.48	0.73	4	0.32	0.34	3	0.36	0.39	0	0.00	0.00
C12 / Pyriform	0	0.00	0.00	1	0.10	0.15	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	1	0.09	0.12	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C14 / Pharynx	0	0.00	0.00	1	0.10	0.15	1	0.08	0.09	0	0.00	0.00	1	0.14	0.14
C15 / Oesophagus	1	0.09	0.12	1	0.10	0.15	14	1.12	1.21	1	0.12	0.13	2	0.28	0.27
C16 / Stomach	29	2.55	3.48	23	2.21	3.35	26	2.07	2.24	18	2.18	2.32	18	2.49	2.47
C17 / Small intestine	3	0.26	0.36	7	0.67	1.02	8	0.64	0.69	2	0.24	0.26	2	0.28	0.27
C18 / Colon	43	3.78	5.16	55	5.29	8.01	36	2.87	3.10	36	4.36	4.64	26	3.59	3.57
C19 / Recto sigmoid Junction	3	0.26	0.36	1	0.10	0.15	1	0.08	0.09	3	0.36	0.39	3	0.41	0.41
C20 / Rectum	6	0.53	0.72	9	0.87	1.31	10	0.80	0.86	6	0.73	0.77	12	1.66	1.65
C21 / Anus & anal canal	3	0.26	0.36	2	0.19	0.29	0	0.00	0.00	1	0.12	0.13	1	0.14	0.14
C22 / Liver & bile ducts	25	2.20	3.00	16	1.54	2.33	24	1.91	2.07	18	2.18	2.32	14	1.93	1.92

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C23 / Gallbladder	5	0.44	0.60	9	0.87	1.31	7	0.56	0.60	3	0.36	0.39	4	0.55	0.55
C24 / Biliary tract, other	2	0.18	0.24	1	0.10	0.15	2	0.16	0.17	1	0.12	0.13	8	1.10	1.10
C25 / Pancreas	33	2.90	3.96	29	2.79	4.23	28	2.23	2.41	17	2.06	2.19	17	2.35	2.34
C26 / Other digestive organs	2	0.18	0.24	0	0.00	0.00	2	0.16	0.17	0	0.00	0.00	1	0.14	0.14
C30 / Nasal cavity	0	0.00	0.00	0	0.00	0.00	1	0.08	0.09	1	0.12	0.13	1	0.14	0.14
C31 / Accessory sinus	0	0.00	0.00	0	0.00	0.00	1	0.08	0.09	0	0.00	0.00	0	0.00	0.00
C32 / Larynx	2	0.18	0.24	7	0.67	1.02	8	0.64	0.69	5	0.61	0.64	3	0.41	0.41
C33 / Trachea	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C34 / Bronchus & lung	51	4.48	6.12	45	4.33	6.56	70	5.58	6.03	28	3.39	3.61	45	6.22	6.18
C37 / Thymus	2	0.18	0.24	0	0.00	0.00	0	0.00	0.00	1	0.12	0.13	0	0.00	0.00
C38 / Heart, Mediastinum, pleura	4	0.35	0.48	0	0.00	0.00	2	0.16	0.17	1	0.12	0.13	0	0.00	0.00
C39 / Other respiratory & thoracic	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C40 / Bone & cartilage, limbs	2	0.18	0.24	8	0.77	1.17	5	0.40	0.43	5	0.61	0.64	4	0.55	0.55
C41 / Bones & cartilage, other	6	0.53	0.72	4	0.38	0.58	2	0.16	0.17	3	0.36	0.39	5	0.69	0.69
C42 / Reticulo endothelial& Hematopoietic System	68	5.98	8.15	42	4.04	6.12	40	3.19	3.45	30	3.63	3.87	23	3.18	3.16
	Leukemia														
	Chronic														
	Myeloproliferative disorders			1	0.10	0.15	1	0.08	0.09	1	0.12	0.13	0	0.00	0.00
	Immunoproliferative diseases			0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C44 / Skin, other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
	0	0.00	0.00	1	0.10	0.15	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
	3	0.26	0.36	5	0.48	0.73	13	1.04	1.12	3	0.36	0.39	4	0.55	0.55
C47 /Nerves system	0	0.00	0.00	2	0.19	0.29	1	0.08	0.09	0	0.00	0.00	1	0.14	0.14
	31	2.72	3.72	30	2.89	4.37	18	1.44	1.55	43	5.21	5.54	26	3.59	3.57
	1	0.09	0.12	1	0.10	0.15	1	0.08	0.09	0	0.00	0.00	1	0.14	0.14
C48 / Peritoneum	0	0.00	0.00	2	0.19	0.29	2	0.16	0.17	0	0.00	0.00	0	0.00	0.00

ICDO/Site	Al-Najaf			Karbala			Babil			Wasit			Al-Qadisiya		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C49 / soft tissues	11	0.97	1.32	10	0.96	1.46	12	0.96	1.03	6	0.73	0.77	3	0.41	0.41
C50 / Breast	346	30.40	41.49	334	32.15	48.67	392	31.26	33.77	257	31.11	33.13	194	26.80	26.66
C51 / Vulva	2	0.18	0.24	2	0.19	0.29	1	0.08	0.09	1	0.12	0.13	1	0.14	0.14
C52 / Vagina	1	0.09	0.12	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.14	0.14
C53 / Cervix uteri	13	1.14	1.56	23	2.21	3.35	13	1.04	1.12	7	0.85	0.90	6	0.83	0.82
C54 / Corpus uteri	25	2.20	3.00	4	0.38	0.58	7	0.56	0.60	1	0.12	0.13	6	0.83	0.82
C55 / Uterus unspecified	24	2.11	2.88	46	4.43	6.70	56	4.47	4.82	28	3.39	3.61	39	5.39	5.36
C56 / Ovary	55	4.83	6.60	30	2.89	4.37	46	3.67	3.96	36	4.36	4.64	19	2.62	2.61
C57 / Female genital - other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.12	0.13	0	0.00	0.00
C58 / Placenta	3	0.26	0.36	3	0.29	0.44	1	0.08	0.09	0	0.00	0.00	0	0.00	0.00
C64 / Kidney	33	2.90	3.96	22	2.12	3.21	16	1.28	1.38	24	2.91	3.09	23	3.18	3.16
C65 / Pelvis	0	0.00	0.00	0	0.00	0.00	1	0.08	0.09	0	0.00	0.00	0	0.00	0.00
C66 / Ureter	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C67 / Urinary bladder	24	2.11	2.88	28	2.69	4.08	32	2.55	2.76	21	2.54	2.71	13	1.80	1.79
C69 / Eye & adnexa	1	0.09	0.12	0	0.00	0.00	1	0.08	0.09	0	0.00	0.00	1	0.14	0.14
C70 / Meninges	10	0.88	1.20	19	1.83	2.77	24	1.91	2.07	14	1.69	1.80	8	1.10	1.10
C71 / Brain	41	3.60	4.92	37	3.56	5.39	63	5.02	5.43	24	2.91	3.09	36	4.97	4.95
C72 / Nervous system, other	2	0.18	0.24	1	0.10	0.15	4	0.32	0.34	1	0.12	0.13	0	0.00	0.00
C73 / Thyroid gland	127	11.16	15.23	104	10.01	15.15	145	11.56	12.49	121	14.65	15.60	100	13.81	13.74
C74 / Adrenal gland	1	0.09	0.12	2	0.19	0.29	6	0.48	0.52	0	0.00	0.00	5	0.69	0.69
C75 / Endocrine gland, other	5	0.44	0.60	7	0.67	1.02	3	0.24	0.26	7	0.85	0.90	4	0.55	0.55
C76 / Unspecified site	9	0.79	1.08	0	0.00	0.00	2	0.16	0.17	4	0.48	0.52	6	0.83	0.82
C77/ Lymph Node	26	2.28	3.12	15	1.44	2.19	24	1.91	2.07	11	1.33	1.42	2	0.28	0.27
C80 / Unknown primary site	29	2.55	3.48	27	2.60	3.93	37	2.95	3.19	17	2.06	2.19	25	3.45	3.44
All Sites Total	1138	100%	136.5	1039	100%	151.4	1254	100%	108.0	826	100%	106.5	724	100%	99.5

Table 81: Number of Cases, Percentage and Crude Incidence Rate (CIR) Among Iraqi Females (per 100,000) by Primary Site and Governorates,2023.

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C00 / lip	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.05	0.06
C01 / Tongue, base	1	0.24	0.22	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C02 / Tongue, other	0	0.00	0.00	1	0.11	0.08	1	0.17	0.16	12	0.60	0.73
C03 / Gum	0	0.00	0.00	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00
C04 / Mouth - floor	2	0.48	0.43	1	0.11	0.08	0	0.00	0.00	2	0.10	0.12
C05 / Mouth - palate	1	0.24	0.22	1	0.11	0.08	0	0.00	0.00	1	0.05	0.06
C06 / Mouth - other	1	0.24	0.22	1	0.11	0.08	1	0.17	0.16	6	0.30	0.36
C07 / Parotid gland	1	0.24	0.22	1	0.11	0.08	2	0.34	0.32	1	0.05	0.06
C08 / Mouth glands	0	0.00	0.00	0	0.00	0.00	1	0.17	0.16	2	0.10	0.12
C09 / Tonsil	0	0.00	0.00	1	0.11	0.08	0	0.00	0.00	1	0.05	0.06
C10 / Oropharynx	1	0.24	0.22	1	0.11	0.08	0	0.00	0.00	1	0.05	0.06
C11 / Nasopharynx	3	0.72	0.65	7	0.77	0.59	1	0.17	0.16	5	0.25	0.30
C12 / Pyriform	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C13 / Hypopharynx	2	0.48	0.43	1	0.11	0.08	2	0.34	0.32	0	0.00	0.00
C14 / Pharynx	2	0.48	0.43	0	0.00	0.00	1	0.17	0.16	1	0.05	0.06
C15 / Oesophagus	2	0.48	0.43	1	0.11	0.08	7	1.18	1.10	6	0.30	0.36
C16 / Stomach	10	2.41	2.17	19	2.09	1.60	18	3.05	2.84	59	2.96	3.59
C17 / Small intestine	3	0.72	0.65	7	0.77	0.59	2	0.34	0.32	5	0.25	0.30
C18 / Colon	9	2.17	1.95	32	3.53	2.70	21	3.55	3.31	78	3.92	4.74
C19 / Recto sigmoid Junction	0	0.00	0.00	2	0.22	0.17	4	0.68	0.63	5	0.25	0.30
C20 / Rectum	7	1.69	1.52	14	1.54	1.18	9	1.52	1.42	34	1.71	2.07
C21 / Anus & anal canal	2	0.48	0.43	1	0.11	0.08	0	0.00	0.00	1	0.05	0.06
C22 / Liver & bile ducts	14	3.37	3.04	26	2.87	2.19	10	1.69	1.58	18	0.90	1.09
C23 / Gallbladder	0	0.00	0.00	2	0.22	0.17	3	0.51	0.47	20	1.00	1.22
C24 / Biliary tract, other	1	0.24	0.22	5	0.55	0.42	3	0.51	0.47	9	0.45	0.55
C25 / Pancreas	19	4.58	4.13	27	2.98	2.28	13	2.20	2.05	48	2.41	2.92

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah			
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR	
C26 / Other digestive organs	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.05	0.06	
C30 / Nasal cavity	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	
C31 / Accessory sinus	1	0.24	0.22	0	0.00	0.00	0	0.00	0.00	2	0.10	0.12	
C32 / Larynx	2	0.48	0.43	3	0.33	0.25	2	0.34	0.32	4	0.20	0.24	
C33 / Trachea	0	0.00	0.00	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00	
C34 / Bronchus & lung	34	8.19	7.38	49	5.40	4.13	19	3.21	2.99	48	2.41	2.92	
C37 / Thymus	0	0.00	0.00	1	0.11	0.08	1	0.17	0.16	5	0.25	0.30	
C38 / Heart, Mediastinum, pleura	0	0.00	0.00	2	0.22	0.17	1	0.17	0.16	1	0.05	0.06	
C39 / Other respiratory & thoracic	1	0.24	0.22	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	
C40 / Bone & cartilage, limbs	2	0.48	0.43	8	0.88	0.67	5	0.85	0.79	5	0.25	0.30	
C41 / Bones & cartilage, other	2	0.48	0.43	4	0.44	0.34	1	0.17	0.16	5	0.25	0.30	
Leukemia	25	6.02	5.43	50	5.51	4.22	25	4.23	3.94	64	3.21	3.89	
C42 / Reticulo endothelial& Hematopoietic System	Chronic Myeloproliferative disorders	0	0.00	0.00	1	0.11	0.08	4	0.68	0.63	15	0.75	0.91
	Immunoproliferative diseases	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
	mast cell tumor	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
	Plasma cell tumor	4	0.96	0.87	10	1.10	0.84	10	1.69	1.58	23	1.16	1.40
	Myelodysplastic syndromes	0	0.00	0.00	0	0.00	0.00	1	0.17	0.16	6	0.30	0.36
	C44 / Skin, other	5	1.20	1.09	20	2.21	1.69	8	1.35	1.26	46	2.31	2.80
C47 /Nerves system	2	0.48	0.43	0	0.00	0.00	1	0.17	0.16	2	0.10	0.12	
C48 / Peritoneum	3	0.72	0.65	2	0.22	0.17	1	0.17	0.16	6	0.30	0.36	
C49 / soft tissues	3	0.72	0.65	11	1.21	0.93	3	0.51	0.47	23	1.16	1.40	
C50 / Breast	106	25.54	23.02	248	27.34	20.91	173	29.27	27.27	631	31.69	38.36	
C51 / Vulva	0	0.00	0.00	1	0.11	0.08	2	0.34	0.32	8	0.40	0.49	
C52 / Vagina	1	0.24	0.22	1	0.11	0.08	0	0.00	0.00	0	0.00	0.00	

ICDO/Site	Al-Muthana			ThiQar			Misan			Al-Basrah		
	No.	%	IR	No.	%	IR	No.	%	IR	No.	%	IR
C53 / Cervix uteri	3	0.72	0.65	11	1.21	0.93	3	0.51	0.47	42	2.11	2.55
C54 / Corpus uteri	9	2.17	1.95	3	0.33	0.25	1	0.17	0.16	25	1.26	1.52
C55 / Uterus unspecified	3	0.72	0.65	36	3.97	3.04	28	4.74	4.41	108	5.42	6.57
C56 / Ovary	15	3.61	3.26	25	2.76	2.11	21	3.55	3.31	108	5.42	6.57
C57 / Female genital - other	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00
C58 / Placenta	1	0.24	0.22	0	0.00	0.00	1	0.17	0.16	5	0.25	0.30
C64 / Kidney	12	2.89	2.61	25	2.76	2.11	14	2.37	2.21	49	2.46	2.98
C65 / Pelvis	0	0.00	0.00	1	0.11	0.08	0	0.00	0.00	1	0.05	0.06
C66 / Ureter	0	0.00	0.00	0	0.00	0.00	0	0.00	0.00	1	0.05	0.06
C67 / Urinary bladder	12	2.89	2.61	25	2.76	2.11	14	2.37	2.21	25	1.26	1.52
C69 / Eye & adnexa	0	0.00	0.00	2	0.22	0.17	1	0.17	0.16	3	0.15	0.18
C70 / Meninges	5	1.20	1.09	10	1.10	0.84	14	2.37	2.21	6	0.30	0.36
C71 / Brain	20	4.82	4.34	58	6.39	4.89	34	5.75	5.36	101	5.07	6.14
C72 / Nervous system, other	1	0.24	0.22	4	0.44	0.34	1	0.17	0.16	10	0.50	0.61
C73 / Thyroid gland	35	8.43	7.60	79	8.71	6.66	61	10.32	9.61	131	6.58	7.96
C74 / Adrenal gland	2	0.48	0.43	2	0.22	0.17	1	0.17	0.16	4	0.20	0.24
C75 / Endocrine gland, other	1	0.24	0.22	4	0.44	0.34	4	0.68	0.63	12	0.60	0.73
C76 / Unspecified site	0	0.00	0.00	0	0.00	0.00	3	0.51	0.47	4	0.20	0.24
C77/ Lymph Node	7	1.69	1.52	14	1.54	1.18	9	1.52	1.42	40	2.01	2.43
	Hodgkin Lymphoma			2.87			3.21			3.31		
C80 / Unknown primary site	12	2.89	2.61	34	3.75	2.87	19	3.21	2.99	66	3.31	4.01
	Non-Hodgkin Lymphoma			1.10			1.02			1.96		
All Sites Total	415	100%	90.1	907	100%	76.5	591	100%	93.1	1991	100%	121.1

Table 82: Number and Percentage of Cancers in Both Genders by Age Group and Governorates, Iraq, 2023.

Governorate	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total	%
Baghdad	166	135	136	156	195	258	393	515	742	981	1,244	1,215	1,331	1,138	1,119	680	667	11,071	25.7
Al-Basrah	63	57	51	72	83	86	146	161	223	312	371	371	384	374	374	175	192	3,495	8.1
Nineveh	65	50	74	55	47	51	114	142	193	280	313	350	297	380	295	183	169	3,058	7.1
Erbil	43	27	34	40	62	60	117	169	240	229	355	303	310	350	324	155	212	3,030	7.0
Al-Sulaimaniyah	54	40	27	44	53	53	113	163	241	232	306	263	245	316	272	178	196	2,796	6.5
Babil	16	21	27	53	37	70	92	103	139	182	228	213	193	233	258	135	145	2,145	5.0
Al-Najaf	26	27	23	38	45	54	85	101	143	169	212	209	175	196	239	114	151	2,007	4.7
Karbala	19	23	27	25	27	68	84	79	123	137	185	196	177	180	178	112	97	1,737	4.0
ThiQar	38	38	26	32	41	50	66	80	117	153	144	179	135	156	186	120	119	1,680	3.9
Diyala	30	15	23	18	24	40	60	67	110	155	149	189	184	180	190	104	134	1,672	3.9
Al-Anbar	28	22	25	28	37	50	83	103	104	131	168	183	141	153	123	73	62	1,514	3.5
Wasit	30	15	16	22	33	41	57	73	87	130	153	153	135	130	157	94	97	1,423	3.3
Al-Qadisiya	18	18	26	23	29	36	42	74	90	111	148	150	128	126	134	77	90	1,320	3.1
Salah Al-Deen	25	19	18	20	29	51	64	66	98	109	136	146	109	140	136	77	61	1,304	3.0
Duhok	26	19	14	14	23	34	66	71	108	94	106	129	102	134	105	67	74	1,186	2.8
Kirkuk	29	17	17	10	21	20	51	48	73	101	122	127	126	139	105	73	57	1,136	2.6
Misan	25	9	18	20	19	34	51	57	89	92	85	113	111	103	110	78	74	1,088	2.5
Al-Muthana	28	24	16	13	17	12	27	33	57	61	83	72	58	82	98	52	50	783	1.8
Unknown	3	7	9	16	10	19	35	32	39	45	79	72	65	66	64	25	31	617	1.4
Total	732	583	607	699	832	1,087	1,746	2,137	3,016	3,704	4,587	4,633	4,406	4,576	4,467	2,572	2,678	43,062	100%

Table 83: Number and Percentage of Cancers Among Males by Governorates and Age Group, Iraq, 2023.

Governorate	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total	%
Baghdad	90	79	83	79	87	81	116	156	181	251	404	411	510	489	542	367	338	4,264	23.6
Al-Basrah	37	32	29	34	32	34	50	55	68	100	130	153	153	182	204	96	115	1,504	8.3
Erbil	21	17	20	21	33	30	45	48	60	83	148	113	139	186	190	95	117	1,366	7.6
Al-Sulaimaniyah	27	19	14	25	28	21	40	66	78	76	121	128	106	171	159	102	124	1,305	7.2
Nineveh	36	23	38	24	21	24	31	48	66	89	103	149	128	184	150	85	81	1,280	7.1
Babil	5	12	13	26	16	23	28	31	53	67	80	71	71	126	122	72	75	891	4.9
Al-Najaf	11	19	16	16	16	20	28	28	43	53	87	90	69	98	140	58	77	869	4.8
ThiQar	24	19	8	18	14	20	25	18	48	55	56	77	72	92	95	69	63	773	4.3
Karbala	13	14	13	8	12	21	30	20	32	43	69	80	69	84	91	54	45	698	3.9
Al-Anbar	17	16	17	20	15	19	21	36	23	38	58	67	60	88	62	42	32	631	3.5
Diyala	16	7	8	8	7	14	14	14	29	42	44	70	71	80	79	62	65	630	3.5
Wasit	14	11	10	10	15	17	15	19	20	43	48	48	55	73	83	59	57	597	3.3
Al-Qadisiya	9	14	18	10	11	14	16	21	28	44	55	55	65	71	74	40	51	596	3.3
Duhok	10	12	9	6	16	13	27	22	19	30	43	66	49	71	77	46	42	558	3.1
Misan	12	6	7	5	9	11	18	21	25	31	34	55	52	62	64	47	38	497	2.8
Salah Al-Deen	13	8	13	7	13	16	17	16	25	24	40	57	34	68	70	40	30	491	2.7
Kirkuk	15	10	9	7	12	6	21	12	23	25	42	44	48	72	48	35	30	459	2.5
Al-Muthana	15	12	10	5	8	5	10	14	18	29	38	25	29	40	51	32	27	368	2.0
Unknown	3	3	6	8	0	8	11	11	14	16	34	32	30	32	31	9	16	264	1.5
Total	388	333	341	337	365	397	563	656	853	1,139	1,634	1,791	1,810	2,269	2,332	1,410	1,423	18,041	100%

Table 84: Number and Percentage of Cancers Among Females by Governorates and Age Group, Iraq, 2023.

Governorate	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	Total	%
Baghdad	76	56	53	77	108	177	277	359	561	730	840	804	821	649	577	313	329	6,807	27.2
Al-Basrah	26	25	22	38	51	52	96	106	155	212	241	218	231	192	170	79	77	1,991	8.0
Nineveh	29	27	36	31	26	27	83	94	127	191	210	201	169	196	145	98	88	1,778	7.1
Erbil	22	10	14	19	29	30	72	121	180	146	207	190	171	164	134	60	95	1,664	6.7
Al-Sulaimaniyah	27	21	13	19	25	32	73	97	163	156	185	135	139	145	113	76	72	1,491	6.0
Babil	11	9	14	27	21	47	64	72	86	115	148	142	122	107	136	63	70	1,254	5.0
Al-Najaf	15	8	7	22	29	34	57	73	100	116	125	119	106	98	99	56	74	1,138	4.5
Diyala	14	8	15	10	17	26	46	53	81	113	105	119	113	100	111	42	69	1,042	4.2
Karbala	6	9	14	17	15	47	54	59	91	94	116	116	108	96	87	58	52	1,039	4.2
ThiQar	14	19	18	14	27	30	41	62	69	98	88	102	63	64	91	51	56	907	3.6
Al-Anbar	11	6	8	8	22	31	62	67	81	93	110	116	81	65	61	31	30	883	3.5
Wasit	16	4	6	12	18	24	42	54	67	87	105	105	80	57	74	35	40	826	3.3
Salah Al-Deen	12	11	5	13	16	35	47	50	73	85	96	89	75	72	66	37	31	813	3.2
Al-Qadisiya	9	4	8	13	18	22	26	53	62	67	93	95	63	55	60	37	39	724	2.9
Kirkuk	14	7	8	3	9	14	30	36	50	76	80	83	78	67	57	38	27	677	2.7
Duhok	16	7	5	8	7	21	39	49	89	64	63	63	53	63	28	21	32	628	2.5
Misan	13	3	11	15	10	23	33	36	64	61	51	58	59	41	46	31	36	591	2.4
Al-Muthana	13	12	6	8	9	7	17	19	39	32	45	47	29	42	47	20	23	415	1.7
Unknown	0	4	3	8	10	11	24	21	25	29	45	40	35	34	33	16	15	353	1.4
Total	344	250	266	362	467	690	1,183	1,481	2,163	2,565	2,953	2,842	2,596	2,307	2,135	1,162	1,255	25,021	100%

PART 8

CANCER AMONG

NON-IRAQIS IN

IRAQ

2023

Cancer Among Non-Iraqis in Iraq, 2023

Table 85: Number and Percentage of Cancer Among Non-Iraqis by Primary Site and Gender, Iraq, 2023.

ICD-O/Site		Male		Female		Both Genders	
		No.	%	No.	%	No.	%
C00 / lip		1	1.06	0	0.00	1	0.44
C02 / Tongue, other		1	1.06	0	0.00	1	0.44
C05 / Mouth - palate		1	1.06	0	0.00	1	0.44
C11 / Nasopharynx		2	2.13	2	1.50	4	1.76
C16 / Stomach		3	3.19	1	0.75	4	1.76
C18 / Colon		3	3.19	6	4.51	9	3.96
C19 / Recto sigmoid Junction		0	0.00	4	3.01	4	1.76
C20 / Rectum		3	3.19	5	3.76	8	3.52
C22 / Liver & bile ducts		2	2.13	0	0.00	2	0.88
C23 / Gallbladder		0	0.00	1	0.75	1	0.44
C25 / Pancreas		3	3.19	1	0.75	4	1.76
C26 / Other digestive organs		1	1.06	1	0.75	2	0.88
C31 / Accessory sinus		1	1.06	0	0.00	1	0.44
C32 / Larynx		2	2.13	0	0.00	2	0.88
C34 / Bronchus & lung		18	19.15	3	2.26	21	9.25
C40 / Bone & cartilage, limbs		0	0.00	1	0.75	1	0.44
C42/Reticulo endothelial& Hematopoietic System	Leukemia	2	2.13	4	3.01	6	2.64
	Plasma cell tumor	0	0.00	2	1.50	2	0.88
	Myelodysplastic syndromes	1	1.06	0	0.00	1	0.44
C44 / Skin, other		6	6.38	5	3.76	11	4.85
C48 / Peritoneum		1	1.06	0	0.00	1	0.44
C49 / soft tissues		1	1.06	0	0.00	1	0.44
C50 / Breast		1	1.06	58	43.61	59	25.99
C53 / Cervix uteri		0	0.00	1	0.75	1	0.44
C54 / Corpus uteri		0	0.00	2	1.50	2	0.88
C55 / Uterus unspecified		0	0.00	2	1.50	2	0.88
C56 / Ovary		0	0.00	7	5.26	7	3.08
C58 / Placenta		0	0.00	1	0.75	1	0.44
C61 / Prostate		10	10.64	0	0.00	10	4.41
C62 / Testis		4	4.26	0	0.00	4	1.76

ICD-O/Site		Male		Female		Both Genders	
		No.	%	No.	%	No.	%
C64 / Kidney		1	1.06	3	2.26	4	1.76
C66 / Ureter		1	1.06	0	0.00	1	0.44
C67 / Urinary bladder		8	8.51	2	1.50	10	4.41
C69 / Eye & adnexa		0	0.00	1	0.75	1	0.44
C71 / Brain		8	8.51	6	4.51	14	6.17
C72 / Nervous system, other		0	0.00	1	0.75	1	0.44
C73 / Thyroid gland		1	1.06	4	3.01	5	2.20
C75 / Endocrine gland, other		1	1.06	1	0.75	2	0.88
C76 / Unspecified site		0	0.00	1	0.75	1	0.44
C77/Lymph Node	Hodgkin Lymphoma	1	1.06	0	0.00	1	0.44
	Non-Hodgkin Lymphoma	4	4.26	7	5.26	11	4.85
C80 / Unknown primary site		2	2.13	0	0.00	2	0.88
All Site Total		94	100%	133	100%	227	100%

Table No. (86), shows that the most affected age group in male was 55-59 years, while in female the most affected age group was 60-64 year.

Table 86: Number and Percentage of Cancer Among Non-Iraqis by Age Group and Gender, Iraq, 2023.

Age Group	Male		Female		Both Genders	
	No.	%	No.	%	No.	%
0-4	3	3.2	3	2.3	6	2.6
5-9	0	0.0	1	0.8	1	0.4
10-14	2	2.1	0	0.0	2	0.9
15-19	2	2.1	2	1.5	4	1.8
20-24	2	2.1	5	3.8	7	3.1
25-29	2	2.1	2	1.5	4	1.8
30-34	4	4.3	8	6.0	12	5.3
35-39	3	3.2	9	6.8	12	5.3
40-44	4	4.3	17	12.8	21	9.3
45-49	10	10.6	14	10.5	24	10.6
50-54	7	7.4	17	12.8	24	10.6
55-59	15	16.0	10	7.5	25	11.0
60-64	10	10.6	18	13.5	28	12.3
65-69	14	14.9	13	9.8	27	11.9
70-74	9	9.6	5	3.8	14	6.2
75-79	4	4.3	6	4.5	10	4.4
80+	3	3.2	3	2.3	6	2.6
All Ages	94	100%	133	100%	227	100%

Number and Percentage of Cancer Among Non-Iraqis by Governorates and Gender, Iraq, 2023:

Table No.; (87) shows that the highest number and percentage of cases in male and female was reported in Erbil governorate.

Table 87: Number and Percentage of Cancer Among Non-Iraqi by Governorates and Gender, Iraq, 2023.

Governorates	Male		Female		Both Genders	
	No.	%	No.	%	No.	%
Erbil	45	47.9	67	50.4	112	49.3
Duhok	30	31.9	40	30.1	70	30.8
Al-Sulaimaniyah	3	3.2	9	6.8	12	5.3
Baghdad	6	6.4	4	3.0	10	4.4
Al-Anbar	3	3.2	2	1.5	5	2.2
Nineveh	3	3.2	2	1.5	5	2.2
Al-Najaf	2	2.1	0	0.0	2	0.9
ThiQar	1	1.1	1	0.8	2	0.9
Al-Basrah	0	0.0	1	0.8	1	0.4
Al-Qadisiya	1	1.1	0	0.0	1	0.4
Babil	0	0.0	1	0.8	1	0.4
Karbala	0	0.0	1	0.8	1	0.4
Salah Al-Deen	0	0.0	1	0.8	1	0.4
Unknown	0	0.0	4	3.0	4	1.8
Total	94	100%	133	100%	227	100%

Number And Percentage of Cancer Mortality Among Non-Iraqis by ICD-O Code, Site of Tumor, Age Group, Gender, And Governorates, Iraq, 2023:

Table No.; (88) shows that the highest number of cases were reported among females.

Table 88: Number and Percentage of Cancer Mortality Among Non-Iraqi by Primary Site and Gender, Iraq, 2023.

ICD-O/ Site	Male		Female		Total	
	No.	%	No.	%	No.	%
C00 / lip	1	8.3	0	0.0	1	3.7
C11 / Nasopharynx	0	0.0	1	6.7	1	3.7
C18 / Colon	1	8.3	4	26.7	5	18.5
C22 / Liver & bile ducts	1	8.3	0	0.0	1	3.7
C23 / Gallbladder	0	0.0	1	6.7	1	3.7
C25 / Pancreas	1	8.3	0	0.0	1	3.7
C26 / Other digestive organs	0	0.0	1	6.7	1	3.7
C32 / Larynx	1	8.3	0	0.0	1	3.7
C34 / Bronchus & lung	1	8.3	0	0.0	1	3.7
C42 / Leukemia	0	0.0	1	6.7	1	3.7
C42 / Plasma cell tumor	1	8.3	0	0.0	1	3.7
C49 / soft tissues	0	0.0	1	6.7	1	3.7
C50 / Breast	0	0.0	3	20.0	3	11.1
C55 / Uterus unspecified	0	0.0	1	6.7	1	3.7
C56 / Ovary	0	0.0	1	6.7	1	3.7
C61 / Prostate	1	8.3	0	0.0	1	3.7
C67 / Urinary bladder	2	16.7	0	0.0	2	7.4
C72 / Nervous system, other	0	0.0	1	6.7	1	3.7
C77 / Non-Hodgkin Lymphoma	2	16.7	0	0.0	2	7.4
All Sites Total	12	100%	15	100%	27	100%

Table No.; (89) shows that the highest number, percentage of cancer mortality was reported in Duhok governorate.

Table 89: Number and Percentage of Cancer Mortality Among Non-Iraqi by Primary Site and Governorates, Iraq, 2023.

ICD-O/ Site		Duhok	Baghdad	Al-Sulaimanyia	Al-Basrah	Diyala	Erbil	Nineveh	ThiQar	Unknown	Total
C00 / lip		1	0	0	0	0	0	0	0	0	1
C11 / Nasopharynx		1	0	0	0	0	0	0	0	0	1
C18 / Colon		2	0	0	0	0	1	0	1	1	5
C22 / Liver & bile ducts		0	1	0	0	0	0	0	0	0	1
C23 / Gallbladder		0	0	1	0	0	0	0	0	0	1
C25 / Pancreas		0	1	0	0	0	0	0	0	0	1
C26 / Other digestive organs		0	0	0	0	0	0	0	0	1	1
C32 / Larynx		0	0	0	1	0	0	0	0	0	1
C34 / Bronchus & lung		1	0	0	0	0	0	0	0	0	1
C42/Reticulo endothelial& Hematopoietic System	Leukemia	0	0	1	0	0	0	0	0	0	1
	Plasma cell tumor	0	0	1	0	0	0	0	0	0	1
C49 / soft tissues		1	0	0	0	0	0	0	0	0	1
C50 / Breast		1	0	0	0	1	0	1	0	0	3
C55 / Uterus unspecified		1	0	0	0	0	0	0	0	0	1
C56 / Ovary		1	0	0	0	0	0	0	0	0	1
C61 / Prostate		0	0	0	0	0	0	0	0	1	1
C67 / Urinary bladder		1	1	0	0	0	0	0	0	0	2
C72 / Nervous system, other		0	1	0	0	0	0	0	0	0	1
C77 / Non-Hodgkin Lymphoma		2	0	0	0	0	0	0	0	0	2
All Sites Total		12	4	3	1	1	1	1	1	3	27

أكثر عشرة أنواع للسرطان شيوعاً عند النساء تتمثل بسرطان الثدي (34.8%) (40.6 لكل مئة ألف من السكان من فئة النساء) وسرطان الغدة الدرقية (9.1%) (10.6 لكل مئة ألف من السكان من فئة النساء) وسرطان القولون والمستقيم (6%) (7.0 لكل مئة ألف من السكان من فئة النساء) وأورام الدماغ والجهاز العصبي المركزي (6%) (7 لكل مئة ألف من السكان من فئة النساء) وسرطان المبيض (4.1%) (4.8 لكل مئة ألف من السكان من فئة النساء) وسرطان القصبات والرئة (3.6%) (4.2 لكل مئة ألف من السكان من فئة النساء) وسرطان الدم (اللوكيميا) (3.5%) (4.1 لكل مئة ألف من السكان من فئة النساء) سرطان الرحم دون تحديد الجزء المصاب (3.2%) (3.7 لكل مئة ألف من السكان من فئة النساء) وسرطان الجلد (2.8%) (3.3 لكل مئة ألف من السكان من فئة النساء) وسرطان الغدة اللمفاوية اللاهودجكيني (2.5%) (3.0 لكل مئة ألف من السكان من فئة النساء) و كان العدد الكلي للحالات السرطانية الجديدة المسجلة بين الأطفال (0-14 سنة) هو 1922 من مجموع 43062 (العدد الكلي للإصابات السرطانية ولكافة الفئات العمرية) وتمثل 4.5% من العدد الكلي للإصابات ولكافة الفئات العمرية، وان التقدير السنوي للإصابة هو 11 لكل مئة ألف من السكان/ فئة الأعمار 0-14 سنة كما ان أقل الفئات العمرية تعرضاً للإصابة ضمن الأكثر عشرة أنواع للسرطان شيوعاً عند الأطفال كان ضمن الفئة العمرية 5-9 ويمثل 9.9 لكل مئة ألف من السكان/ فئة الأعمار 0-14 سنة. وأن أعلى تقدير سنوي للإصابات بين الأطفال هو بسبب سرطان الدم (اللوكيميا) (3.1 لكل مئة ألف من السكان/ فئة الأعمار 0-14 سنة. أما فيما يتعلق بالتقدير السنوي للإصابة في المحافظات فقد لوحظ ان أعلى تقدير سنوي للإصابات ضمن الأكثر عشرة أنواع للسرطان شيوعاً عند الأطفال كان في محافظة المثنى (17.1 لكل مئة ألف من السكان/ فئة الأعمار 0-14 سنة)، وان أدنى تقدير سنوي للإصابات كان في محافظة بابل (6.5 لكل مئة ألف من السكان/ فئة الأعمار 0-14 سنة). وكان العدد الكلي للوفيات بسبب السرطان خلال عام 2023 هو 12982 وبتقدير سنوي للعشر اسباب الاولى للوفيات بسبب السرطان حسب عدد السكان للفئات العمرية المعتمد من قبل منظمة الصحة العالمية 56 لكل مئة ألف من السكان وقد لوحظ أن أعلى تقدير سنوي للوفاة هو بسبب سرطان القصبات والرئة (15.7%) (4.7 لكل مئة ألف من السكان) كما ان أعلى تقدير سنوي للوفاة عند الرجال هو ايضا بسبب سرطان القصبات والرئة (21.8%) (6.3 لكل مئة ألف من السكان من فئة الرجال) وان أعلى تقدير سنوي للوفاة عند النساء هو بسبب سرطان الثدي (24.2%) (7.5 لكل مئة ألف من السكان من فئة النساء). وأن أعلى الفئات العمرية تعرضاً للوفاة ضمن الأكثر عشرة أنواع للسرطان هو 75-79 سنة. كما أن أعلى تقدير سنوي للوفاة سجل في محافظة النجف (45.4 لكل مئة ألف من السكان).

وبلغ عدد حالات الإصابة بالسرطان بين غير العراقيين خلال العام 2023 (227 حالة)، وكانت الفئة العمرية الأكثر تضرراً لدى الذكور 55-59 سنة، في حين كانت الفئة العمرية الأكثر تضرراً لدى الإناث 60-64 سنة. كانت أعلى نسبة من السرطان لدى الذكور هي الرئة (19.1%) يليها سرطان البروستاتا (10.6%)، بينما كانت أعلى نسبة من السرطان عند الإناث هي سرطان الثدي (43.6%) تليها سرطان الغدة الليمفاوية اللاهودجكيني (5.3%). وسجلت محافظة أربيل أعلى نسبة من الحالات السرطانية في كلا الجنسين (49.3%). وبلغ العدد الإجمالي لوفيات السرطان بين غير العراقيين 27 (12 من الذكور و15 من الإناث). وكانت أعلى نسبة وفيات في محافظة دهوك (44.4%).

ملخص التقرير السنوي

يعطي التقرير السنوي للتسجيل السرطاني في العراق معلومات عن الحالات السرطانية الجديدة المشخصة خلال السنة بالإضافة إلى حالات الوفاة المسجلة بسبب السرطان، عن طريق جمع البيانات من المستشفيات والمختبرات (الحكومية والأهلية) في جميع دوائر الصحة في العراق بواسطة برنامج 5 CanReg. العدد الكلي للحالات السرطانية الجديدة المسجلة خلال عام 2023 هو 43062. وان التقدير السنوي للإصابات حسب عدد السكان للفئات العمرية المعتمد من قبل منظمة الصحة العالمية هو 171.6 لكل مئة ألف من السكان وقد لوحظ أن أعلى الفئات العمرية تأثرا للإصابة بمرض السرطان هو 70-74 سنة. وفيما يتعلق بالمحافظات، لوحظ أن أعلى تقدير سنوي للإصابة في العراق كان في محافظة اربيل (143.8 لكل مئة ألف من السكان). وكذلك بالنسبة لفئة الرجال فإن أعلى تقدير سنوي للإصابة كان في محافظة اربيل (128.4 لكل مئة ألف من السكان فئة الرجال)، أما بالنسبة لفئة النساء فإن أعلى تقدير سنوي للإصابة كان في محافظة اربيل أيضا (159.4 لكل مئة ألف من السكان فئة النساء) وأن أقل تقدير سنوي للإصابة في العراق كان في كركوك (62.6 لكل مئة ألف من السكان) وان أقل تقدير سنوي للإصابة بين الرجال كان في محافظة كركوك (50.2 لكل مئة ألف من السكان من فئة الرجال) وكذلك بالنسبة للنساء فإن أقل تقدير سنوي للإصابة كان في محافظة كركوك (75.1 لكل مئة ألف من السكان من فئة النساء). وقد ازدادت نسبة الاصابات الجديدة بالمرض في التقدير السنوي لمرض السرطان في العراق من عام 1976 (31.5 لكل مئة ألف من السكان) الى عام 2023 (99.4 لكل مئة ألف من السكان). وقد ظهر أن أكثر عشرة انواع شيوعا لمرض السرطان لكلا الجنسين كانت سرطان الثدي (20.5%) (20.4 لكل مئة ألف من السكان) وسرطان القولون والمستقيم (7.2%) (7.2 لكل مئة ألف من السكان) وسرطان القصبات والرئة (7.0%) (7.0 لكل مئة ألف من السكان) وسرطان الغدة الدرقية (6.6%) (6.5 لكل مئة ألف من السكان) وأورام الدماغ والجهاز العصبي المركزي (6.5%) (6.5 لكل مئة ألف من السكان) وسرطان المثانة (4.7%) (4.7 لكل مئة ألف من السكان) وسرطان الدم (اللوكيميا) (4.4%) (4.4 لكل مئة ألف من السكان) وسرطان البروستات (3.8%) (7.6 لكل مئة ألف من فئة الرجال) وسرطان الجلد (3.5%) (3.5 لكل مئة ألف من السكان) وسرطان الغدد اللمفاوية اللاهودجكيني (3.3%) (3.3 لكل مئة ألف من السكان). وكانت أكثر عشرة انواع شيوعا للسرطان عند الرجال تتمثل بسرطان القصبات والرئة (11.8%) (9.7 لكل مئة ألف من السكان من فئة الرجال) وسرطان البروستات (9.2%) (7.6 لكل مئة ألف من السكان من فئة الرجال) وسرطان القولون والمستقيم (8.9%) (7.3 لكل مئة ألف من السكان من فئة الرجال) وسرطان المثانة (8.9%) (7.3 لكل مئة ألف من السكان من فئة الرجال) وأورام الدماغ والجهاز العصبي المركزي (7.4%) (6.1 لكل مئة ألف من السكان من فئة الرجال) وسرطان الدم (اللوكيميا) (5.6%) (4.6 لكل مئة ألف من السكان من فئة الرجال) وسرطان الكلى (4.7%) (3.9 لكل مئة ألف من السكان من فئة الرجال) وسرطان الجلد (4.6%) (3.8 لكل مئة ألف من السكان من فئة الرجال) وسرطان الغدد اللمفاوية اللاهودجكيني (4.5%) (3.7 لكل مئة ألف من السكان من فئة الرجال) وسرطان البنكرياس (3.7%) (3.0 لكل مئة ألف من السكان من فئة الرجال)

المعلومات المرضية (Tumor)

Family History	(0) No	(1) Yes	(9) Unknown
----------------	--------	---------	-------------

Affected members	
------------------	--

Diagnosis date	Day/	Month/	Year/
----------------	------	--------	-------

Basis of diagnosis	(0) Death certificate only	(1) Clinical only	(2) Clinical investigation	(3) Surgery/ Autopsy
	(4) Laboratory test	(5) Cytology/ Hematological	(6) History of metastases	(7) History of primary
	(8) Autopsy with histology	(9) Unknown		

Topography		Morphology	
------------	--	------------	--

Behavior	(0) Benign	(1) Uncertain	(2) In situ	(3) Malignant
----------	------------	---------------	-------------	---------------

Grade	(1) Grad I	(2) Grad II	(3) Grad III	(4) Grad IV
	(5) T-Cell	(6) B-Cell	(7) Null Cell	(8) Killer Cell
	(9) Unknown			

Extent	(0) In situ	(1) Localized	(2) Regional by direct extension	(3) Regional lymph nodes
	(4) Regional direct extension and lymph nodes	(7) Distant metastasis	(8) Not applicable	(9) Unknown

Laterality	(1) Right	Left (2)	(4) Not applicable	(9) Unknown
------------	-----------	----------	--------------------	-------------

T	(0) In situ	(1) T 1	(2) T 2	(3) T 3	(4) T 4	(X) Not assessed
---	-------------	---------	---------	---------	---------	------------------

N	(0) N 0	(1) N 1	(2) N 2	(3) N 3	(X) Not assessed
---	---------	---------	---------	---------	------------------

M	(0) M 0	(1) M 1	(X) Not assessed
---	---------	---------	------------------

Surgery	(1) Yes	(2) No	(3) Suggested	(9) Unknown
---------	---------	--------	---------------	-------------

Chemotherapy	(1) Yes	(2) No	(3) Suggested	(9) Unknown
--------------	---------	--------	---------------	-------------

Radiotherapy	(1) Yes	(2) No	(3) Suggested	(9) Unknown
--------------	---------	--------	---------------	-------------

Hormonal therapy	(1) Yes	(2) No	(3) Suggested	(9) Unknown
------------------	---------	--------	---------------	-------------

Isotope	(1) Yes	(2) No	(3) Suggested	(9) Unknown
---------	---------	--------	---------------	-------------

Target therapy	(1) Yes	(2) No	(3) Suggested	(9) Unknown
----------------	---------	--------	---------------	-------------

اسم وتوقيع الطبيب

ملاحظة: تملأ من قبل الطبيب حصراً.



وزارة الصحة Ministry of Health



استمارة التسجيل السرطاني في العراق Iraqi Cancer Registry Form

CanReg5

رقم المريض Patient record

معلومات المريض الشخصية (Patient)

أسم المريض أسم الأب أسم الجد

أسم الأم الثلاثي

الجنس (1) ذكر (2) أنثى (9) غير معروف

تاريخ التولد اليوم/ الشهر/ السنة

الجنسية (1) عراقي (2) عربي (3) أجنبي (9) غير معروف

العنوان المحافظة/ القضاء/ الناحية/ غير معروف

المهنة (1) ربة بيت (2) عامل (3) مزارع (4) موظف (5) كاسب (6) طفل (7) متقاعد (8) أخرى (9) غير معروف

رقم هاتف المريض رقم هاتف المرافق

مصدر المعلومات (Source) (المستشفيات والمختبرات)

تاريخ دخول المستشفى اليوم/ الشهر/ السنة

أسم المستشفى رقم الطبلة

أسم المستشفى 2 رقم الطبلة 2

أسم المختبر رقم الشريحة

أسم المختبر 2 رقم الشريحة 2

متابعة المريض (Follow up)

تاريخ آخر تواصل مع المريض اليوم/ الشهر/ السنة

حالة المريض (1) على قيد الحياة (2) متوفي

تاريخ الوفاة اليوم/ الشهر/ السنة

سبب الوفاة (1) السرطان (2) أسباب أخرى (9) غير معروف

ملاحظة: يتم رفع نسخة من هوية الأحوال المدنية ونسخة من الفحص التشخيصي للمرض مع الاستمارة. اسم وتوقيع الإحصائي



جمهورية العراق
وزارة الصحة
مجلس السرطان في العراق



التقرير السنوي للتسجيل السرطاني في العراق ٢٠٢٣

